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Abstract 
The role of β-synuclein in the pathological mechanisms of Dementia with Lewy 
bodies 
Dementia with Lewy bodies (DLB) is the second most prevalent neurodegenerative 
dementia following Alzheimer’s disease (AD). DLB neuropathology is characterised 
by Lewy bodies (LBs) and Lewy neurites (LNs) resulting from the modification and 
aggregation of α-synuclein. The presence of small pre-synaptic accumulations of α-
synuclein lead to structural synaptic alterations that may precede neuronal demise. 
Family member β-synuclein does not readily aggregate and has been shown to 
prevent α-synuclein aggregation in vitro and in vivo and regional changes in β-
synuclein levels has been observed in the brains of DLB patients.  
α-synuclein pathology is found in the limbic and cortical regions of the DLB brain 
producing fluctuating cognitive impairment, visual hallucinations and extrapyramidal 
motor disturbances. In order to examine whether regional changes in β-synuclein 
influence the course of DLB, examination of protein levels of α-synuclein and β-
synuclein in the frontal cortex, occipital cortex and hippocampus of patients with DLB 
and age-matched controls was performed.  
Evidence is provided here for a neuronal increase of β-synuclein within the frontal 
cortex and a decrease in occipital cortex of DLB patients, both regions see similar 
levels of oligomeric α-synuclein. Further examination of key pre-synaptic SNARE 
proteins reveal an increase of VAMP2 in the frontal cortex and a decrease of VAMP2 
and SNAP25 in the occipital cortex. Autophagy markers LC3-II and p62 were also 
increased in the frontal cortex where an increase in β-synuclein was identified in DLB 
brains and in vitro overexpression of β-synuclein attenuates the autophagy flux. 
9 
 
Collectively, this data suggests that β-synuclein changes in the DLB cortex are 
regionally distinct and the possibility that β-synuclein may exacerbate neuronal 
dysfunction by influencing protein degradation pathways, cannot be excluded. This 
data highlights the possibility of a dual role for β-synuclein that may be both 
protective and antagonistic, advocating caution when considering the use of β-
synuclein as a potential therapeutic. 
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CHAPTER 1: INTRODUCTION 
1.1. Dementia with Lewy bodies 
Neurodegenerative conditions are predicted by the World Health Organisation 
(WHO) to become the world’s leading cause of death by 2040 [1]. This class of 
disease constitutes a group of progressively debilitating conditions with unique 
disease-specific profiles, united by the selective loss of distinctive neuronal groups.  
1.1.1. Neurodegenerative Dementias Epidemiology 
Neurodegenerative Dementias represent a class of pathologies characterised by 
varying degrees of, but inexorably, the progressive decline in cognitive functions 
such that there is interference in an individual’s ability to perform everyday duties, 
impacting on their social function and/or their capacity to perform usual occupational 
tasks [2]. 
Dementia has emerged as an epidemic with aging being the predominant risk factor. 
By 2050, the number of people aged ≥60 years will have increased by 1.25 billion, 
accounting for approximately 22% of the total global population, with 79% living in 
less developed regions [3]. Whilst the observed and projected increase in the 
number of people affected by dementia has largely been explained by the increase 
in population longevity, specifically in the developing world, dementia per se is not a 
natural part of the aging process. 
Those affected by neurodegenerative dementias are principally aged 65 years and 
over with early-onset dementia accounting for only 2-5% of all cases, furthermore the 
prevalence nearly doubles with every additional 5 years of age following the age of 
23 
 
65 [4] underscoring an increase in an age-related risk of developing 
neurodegeneration, in parallel with an increase in longevity. 
The most common forms of dementia include Alzheimer’s disease (AD), Lewy body 
dementia (DLB), frontotemporal dementia (FTD) and vascular dementia [5]. Both AD 
and DLB continue to be the leading cause of degenerative dementia in the elderly 
population (Figure 1).  
 
 
Figure 1 - Dementia subtypes and prevalence  
Representative data from the Alzheimer’s society’s (UK) envisaged proportions of the 
subtypes of dementia and their prevalence in the UK alone. Adapted from 
(https://www.alzheimers.org.uk/info/20091/position_statements/93/demography), published 
September 2014. 
62%
17%
10%
4%
3%
2% 2%
Types and prevalence of dementia
Alzheimer's disease
Vascular dementia
Mixed dementia
Lewy-body dementia
Other
Parkinson's with dementia
Fronto-temporal dementia
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In 2015 WHO reported 47.5 million people were afflicted worldwide by dementia, 
increasing from 35.6 million people in 2012 (WHO April 2012) and cases are 
predicted to rise by 7.7 million each year. It has been forecast that by 2050 the 
worldwide prevalence of dementia will reach 137.5 million [6]. In the UK alone, 
850,000 people are affected, this bestows a substantial burden on the economy with 
the cost of health care in the region of £26 billion, annually. 
(https://www.mrc.ac.uk/research/spotlights/neurodegenerative-diseases-dementia/).  
The broad-spectrum of dementia produces a gender bias with a predisposition 
towards females, 61% of dementia cases are seen in the female population when 
compared to 39% of males. This is a consistent observation that could be explained 
by the protracted longevity in females when compared to males.  
(http://www.dementiaconsortium.org/dementia-facts/). 
A systematic review by Prince et al. [5] contemplates the global prevalence of 
dementia and identifies a higher incidence in Latin-America and lowest in Sub-
Saharan Africa with the greater proportion of dementia cases being affiliated with 
low-middle range incomes. To corroborate this, more recent population based 
studies on “high-income” countries have contradicted previous projections regarding 
dementia prevalence, indicating a decline in the age-associated risk of dementia. 
This has been attributed to various factors, largely surrounding the fact that higher 
levels of education and advances in treatment and diagnostics may lead to the early 
intervention of dementia indicators; these include cardiovascular risk factors such as 
obesity and diabetes [7]. A recent UK based study on dementia has reported a 20% 
decrease in dementia incidence over the last two decades in males [8]. If the 
previous projections are proving variable, then it is possible that the predicted figures 
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may be regionally modulated in accordance with the scope of social health care 
support available and attainable by the general population. 
1.1.2. Dementia with Lewy bodies  
Population based studies show that Dementia with Lewy bodies  (DLB) accounts for 
approximately 4% of all dementias [9]. DLB is the second most common form of 
neurodegenerative dementia after AD [10]. In contrast to general dementia 
demographics, DLB predominantly affects the male population [11] and symptom 
onset is usually after the 5th decade of life [12]. Diagnostically, DLB is associated 
with three predominant clinical presentations: cognitive fluctuation, extra pyramidal 
motor symptoms that present as parkinsonism [13] and visual hallucinations [14]. A 
single identified core symptom provides a possible diagnosis of DLB (Table 1) [15]  
whilst two of these presentations provide a probable diagnosis of DLB - it is possible 
to have two core features or one core characteristic in addition to suggestive 
features. 
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Central 
Characteristic of 
DLB 
 The progressive cognitive decline such that an 
individual is no longer able to undertake 
conventional social or occupational functions 
 
Core 
characteristic 
 Fluctuating cognitive impairments  
o Likely, prominent alterations in alertness and 
attention & visual-spatial awareness 
 Visual hallucinations 
 Spontaneous Parkinsonism features 
 REM sleep behaviour disorder 
Suggestive or 
supportive 
characteristics 
 Unexplained transient loss of consciousness 
 Falls 
 Autonomic dysfunction 
 Depression 
 Delusions 
 Hallucinations in other modes 
Table 1 - Characteristics to support a DLB diagnosis:  
Table of central, core and suggestive characteristics that support a diagnosis of DLB (adapted 
from [15] [16] & The Lewy Body Dementia Association (LBA) (http://www.lbda.org/content/dlb-
and-pdd-diagnostic-criteria).  
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1.1.3. DLB symptoms 
1.1.3.1. DLB Core Symptoms – Cognitive 
The underlying progressive cognitive decline in DLB may initiate as early as 55 years 
and be undetected for many years. The decline in cognitive functions is not dissimilar 
to those observed in AD although the deterioration of these events can proceed 
more rapidly in DLB (reviewed by [17]). An abating memory may be one of the earlier 
features of DLB with an impairment in the ability to encode new memories and a 
decline in the capacity to retrieve long term memories [18]; however, dementia is not 
a requisite for DLB diagnosis in the early stages. Attention and alertness are primary 
features that often represent changes in cognition and fluctuations [19] and may be 
identified initially by family members or colleagues. Visual-spatial awareness can 
also be disturbed in DLB [20] the manifestation of which include the inability to 
navigate otherwise familiar locations. Further, executive functions, including 
problem-solving and reasoning are affected, as is language and judgment [21]. 
These cognitive manifestations can vary dramatically, fluctuating between little 
evidence of cognitive dysfunction to incomprehension and confusion in a short 
duration; it is this fluctuating pattern of changes that is the defining feature of a DLB 
diagnosis. 
1.1.3.2. DLB Core Symptoms – Hallucinations 
Symptoms of DLB vary between patients although often early dementia will present 
in association with visual hallucinations [22]. Tiraboschi et al. [22] indicated that 
visual hallucinations were the most efficient predictor of a clinical diagnosis of DLB in 
contrast to AD. The visual hallucinations are typically well formed, recurring and 
complex in detail. They will involve the incorrect visual awareness of moving objects 
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and complex scenarios of people and objects that are non-existent [23]. It is 
noteworthy that hallucinations in DLB may also be audible although, this is relatively 
rare.  
1.1.3.3. DLB Core Symptoms - Parkinsonism motor syndrome 
The extrapyramidal symptoms seen in PD are also common in DLB with 25% of 
patients displaying Parkinsonism at disease onset, consistent with the loss of 
dopaminergic neurons in the substantia nigra [24]. Conversely, 25% of DLB patients 
will not develop Parkinsonism features during the pathological course, reflected by 
significantly less dopaminergic neuronal loss in these patients [25]. Bradykinesia, 
postural instability, rigidity and a resting tremor are representative of the predominant 
features of PD. These characteristics may appear in DLB though the resting tremor 
exists to a lesser extent than is observed in PD. Typically, in DLB, dementia will 
present prior to the advancement of motor symptoms, but motor symptoms could 
follow the disease progression within 1 year [2]. In view of the symptom similarity 
between DLB and PD/PDD, correct diagnosis requires the employment of The 
Unified PD Rating Scale (UPDRS), an assessment of the motor features in DLB. It is 
universally accepted that a DLB diagnosis acquiesces when cognitive dysfunction 
precedes parkinsonism or appears within a year [26]. A PDD diagnosis required 
dementia symptom to present >1year following motor dysfunction, [27]. In this 
regard, PDD differs only from DLB in the temporal course of the pathology.  In DLB 
dementia precedes Parkinsonism features and in PDD Parkinsonism precedes 
dementia.  
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1.1.3.3. DLB Core Symptoms – Rapid-eye-movement (REM) sleep behaviour 
disorder (RBD) 
REM-RBD is associated with vivid dreams with often simple or complex motor 
behaviour during the REM sleep [28] such that injuries may occur from the 
enactment of dreams, leading to kicking or punching. 
1.1.3.4. DLB Supportive features 
Supportive features include unexplained transient loss of consciousness and falls, 
delirium and depression, in addition to a decreased sense of smell, increased saliva 
production and intestinal changes (reviewed in [26]). Non-specific non-cognitive 
symptoms may precede the appearance of memory and other cognitive DLB related 
characteristics, by some years. Rapid eye movement sleep behaviour disorder 
(RBD) may be clinically representative of PD Braak stage 2 as RBD cases are 
known to progress and develop DLB or other α-synucleinopathies [29]. (Figure 3: 
Diagram of Braak staging). Whilst these symptoms alone would not necessarily be 
an immediate indicator of Lewy body disease; they could be suggestive of prodromal 
Lewy body disease and therefore, an early method of detection. 
The variable symptoms between patients frequently leads to the mis-diagnosis of 
DLB. There presently is not an identified biomarker to enable dementia-specific 
diagnosis, so it is not unexpected that final clinical diagnosis will be made post-
mortem.  
1.1.4. The neuropathology of DLB 
The neuropathology associated with DLB is characterised by α-synuclein protein 
accumulations that present in the form of Lewy bodies (LBs) and Lewy neurites 
(LNs) [30]. Whilst LBs were first observed over a century ago, the main component 
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of these structures was not identified as α-synuclein until 1997 [31]. These insoluble 
α-synuclein aggregates are found extensively distributed throughout the brain in the 
form of intracytoplasmic neuronal inclusions, in the neurite processes as LNs or as 
smaller aggregates located at pre-synaptic terminals; a defining pathological feature 
that is also exhibited in PD and PDD [32]. Furthermore, multiple system atrophy 
(MSA) is characterised by α-synuclein deposits located in glial cells [33]. The 
temporal expression and distribution patterns of these diseases are unique to each 
disease. Regardless of the differential expression pattern of the α-synuclein 
pathological spread, due to the common representation of LBs and LNs, these 
neurodegenerative pathologies are considered α-synucleinopathies, by virtue of the 
predominance of the α-synuclein aggregating protein in the form of LBs and LNs.  
Dr. Fritz Jakob Heinrich Lewy (1885 – 1950, Friedrich Lewy) first described 
proteinaceous aggregates in 1912 when he published his initial findings from the 
postmortem brain examination of PD patients [34]. Lewy described these insoluble 
structures in the dorsal motor nucleus of the vagus nerve, the basal nucleus of 
Meynert and the lateral and periventricular nucleus of the thalamus. In 1919 similar 
inclusions were identified in the substantia nigra of PD patients by Tretiakoff and 
subsequently named as Lewy bodies [35]. It is well established that the substania 
nigra pars compacta of the basal ganglia is significantly affected by LB pathology in 
PD [36], with the specific and selective targeting of the dopamine producing neurons 
in this region [24]. Studies of PD and the substantia nigra pars compacta has 
enabled the advancement of the understanding of pathology in α-synucleinopathies. 
In combination with the findings of Lewy and the subsequent evidence, presence of 
inclusions that develop into “thread-like” LNs in the neuronal processes and neuronal 
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intracytoplasmic LBs underpin a clinic-pathological post mortem diagnosis of DLB or 
PD.  
Those patients with PD follow a more specific pattern of LB distribution, as described 
above [37], in DLB, LBs are diffusely distributed throughout the neocortical regions  
[38] including the frontal, parietal, occipital and temporal cortex and in subcortical 
regions such as the substania nigra, the locus coeruleus [39] and the paralimbic 
regions [40]. 
Additional neuropathological characteristics of DLB include spongiform changes that 
are representative of fine neuropil microvacuolations  [41]. It is observed that this 
spongiosis-effect is more severe in AD with concurrent LB pathology than in pure AD 
[42] and that the spongiosis distribution pattern corresponds to the LBs that are 
present, in particular in relation to the superior and inferior temporal cortex, 
amygdala and entorhinal cortex [43]. 
1.1.4.1. Lewy body structure 
Lewy bodies are intracytoplasmic, eosinophilic structures, characteristically between 
8μM and 30μM in diameter [44]. The morphology of the LBs is location dependent, 
presenting as classical or cortical LB depending on whether they are identified in the 
brainstem region or cortex, respectively [45]. Classical LBs typically are located in 
the brainstem and diencephalon regions, including frequently the substantia nigra, 
locus coeruleus, hypothalamus, dorsal motor nucleus of the vagus nerve and median 
raphe nucleus [46]. Spherical and uniform in shape, classical LBs have a dense core 
and an outer halo-like formation [47]; the dense core is encircled by radially 
positioned filaments [48]. Cortical LBs are more irregular and unstructured in 
appearance, the core of which is less distinctive with the absence of a peripheral 
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halo. Frequently it has been shown that cortical LBs will displace the nucleus of the 
cell [31, 49] however, from an ultrastructural perspective, cortical LBs have a similar 
filamentous morphology to those LBs seen in the brain stem. Insoluble α-synuclein 
filaments exhibit either a straight or a twisted conformation of approximately 5-10nm 
in diameter  [49], they are 200-600nm in length with the core of the filament covering 
over 70 amino acids (reviewed in [50]; this conformation drives a typical beta-sheet 
formation [51], frequently associated with protein aggregate formations in 
neurodegenerative diseases. 
1.1.4.2. Lewy body and Lewy neurite composition 
LNs are dystrophic processes with an identical immunostaining profile as LBs [31]. 
The structural arrangement of both LBs and LNs is a complex formation, composed 
largely of the aggregated and fibrillary form of insoluble α-synuclein. These 
aggregates can be identified by α-synuclein immuno-staining, in addition there are 
over 70 other components of Lewy bodies [47] that can be further categorised to 
include: structural proteins, degradation pathway associated proteins and cell 
signalling molecules, providing evidence of multiple pathways potentially involved in 
the complexities of LB formation. The ubiquitin protein (UB), related to the ubiquitin-
proteasome system (UPS), is readily used as a positive immuno-staining marker for 
the presence of LBs; its functional involvement with protein degradation pathways 
indicates defects in aggregate clearance in LB diseases.  
1.1.4.3. Pale bodies 
The presence of pale bodies is also associated with LB pathology; these cytoplasmic 
structures often co-occur in neurons with LBs. Ultra-structural examination shows 
that they contain vesicular and granular matter, dispersed amongst disorganised 
filamentous structures. The filamentous structures present in pale bodies are 
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identical to those observed in true Lewy bodies [47]. There is a strong correlation 
between the number of pale bodies and the UB-positive LBs in PD and DLB [52]. 
This correlation may indicate the possibility that pale bodies may represent pre-LB 
structures. 
1.1.4.4. The process of Lewy body formation 
Lewy bodies are critical to the neuropathology of DLB, whether this function is 
accountable for the pathological drive of neurodegeneration or whether the formation 
of Lewy bodies is a neuroprotective mechanism in the face of toxic insults, is still 
debatable. In contrast to its presence in LBs, under normal physiological conditions, 
α-synuclein is a soluble protein abundantly distributed throughout the brain with the 
predisposition for pre-synaptic terminals; where it is also associated with synaptic 
vesicles [53]. The cytoplasmic appearance of α-synuclein points to an early indicator 
of the erroneous behaviour of the protein. Increasing evidence suggests that the 
oligomeric form of α-synuclein is the toxic intermediate [54] and it is possible that 
these formations are occurring pre-synaptically. A common hypothesis for the 
formation of Lewy bodies is that monomeric α-synuclein merges to form oligomeric 
species of the protein, protofibrils [55] (To be discussed – Figure 8). In the 
monomeric or protofibril state, α-synuclein may still be soluble [56], although 
protofibrils can act as a template for nucleation, enabling the multimerisation of 
further protofibrils that proceed to larger fibril formations. The development  of 
classical LBs has been described using α-synuclein immunoreactivity to map the 
aggregation process in the cytoplasm [47, 57] (Figure 2).  Stage 1 presents as a 
diffuse, speckled pattern of α-synuclein staining in the neuronal cytoplasm (A). Stage 
2 is more moderately intense but displays an irregular pattern (B). A pale body 
appears in stage 3, α-synuclein immunoreactivity detected a darker outer layer and a 
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less intensely stained core, the shape is still irregular (C). By stage 4 a ring like 
structure with the distinct halo and core associated with classical Lewy bodies is 
evident (D). Together, this demonstrated the temporal pattern of intraneuronal 
cytoplasmic α-synuclein aggregation leading to Lewy body formation and maturation. 
  
Figure 2 - LB formation and maturation  
Hand drawn representations of LB formation and maturation stages (by Tracey Evans), as 
described by Wakabayashi, 1998. α-synuclein immunoreactivity of classical LB formation 
stage 1 (A): diffuse cytoplasmic staining; stage 2 (B): irregular pattern of staining; stage 3 (C): 
more discrete staining corresponding with a pale body and stage 4 (D). Cortical LB 
representation of the different stages (E – F, respectively). Immunoreactivity detected by 5G4 
for oligomeric α-synuclein in the DLB brain. 
 
The cytoplasmic and diffuse presence of α-synuclein that precedes the arrival of a 
pale body structure [57] and the subsequent LB formation is suggestive of an 
organised pathway in LB formation. Whether all Lewy bodies descend from pale 
bodies is not fully established, but they appear in some cases to provide the material 
on the basis of which the larger and more structured Lewy body may derive [58]. 
One considers the concept that all Lewy bodies may derive from pale bodies, pale 
bodies have a disorganised arrangement of α-synuclein, this is a stark contrast to the 
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concluding phase of LB formation; a structure that appears to be well structured  
[48]. This points to the possibility that the pale body is representative of early, 
potentially non-specific methods and attempts by multiple pathways to remove α-
synuclein. This may provide the appearance of a more dis-organised structure, 
which all the same has sought to segregate and localise the aggregating proteins. In 
the event that these attempts are defeated, Lewy bodies may represent the structure 
that envelops the pathological species and bind the protein complexes into a more 
orderly structure to prevent further toxicity.  
1.1.5. The temporal progression of Lewy body pathology - Braak staging 
Lewy bodies in the midbrain are usually associated with idiopathic PD and are 
essential for a clinical-pathological diagnosis of PD. In DLB patients however the LB 
pattern of accumulation involves cortical regions [27] with pathology in the cerebral 
cortex affecting layers V-VI initially, advancement continues into layer III and 
ultimately layer II. This distribution pattern has been correlated with symptom 
severity [59]. In an attempt to provide a unifying pathological description of LB 
pathology in the brains of PD patients Braak & Braak, [37] proposed a stage scoring 
system. According to the proposed model for LB pathology in PD, specific neuronal 
phenotypes and regions of the brain are affected by deposits of α-synuclein in a 
predictable and temporal manner. The direction of the pathology is caudo-rostral 
over six stages from the lower brain stem to the neocortical structures (Figure 3), 
each stage refers to the anatomical location and progression of the pathology. 
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Figure 3 - Lewy body Braak staging  
The image has been adapted from [60], the original is available under common creative 
license. 
 
Stage 1 LB and LN appearance in the brain stem regions: the dorsal motor nucleus 
of the medulla oblongata and on occasions the intermediate reticular zone.  
Stage 2: LBs and LNs in the caudal raphe nuclei, gigantocellular reticular nucleus 
and the melanin rich cells of the coeruleus-subcoeruleus complex. 
Stage 3: LBs present in the midbrain especially, the melanin-rich neurons of the 
substantia nigra pars compacta. The magnocellular nuclei of the basal forebrain are 
also affected. Subcortical and cortical regions associated with the anterior olfactory 
bulb may see mild LB and LN pathology, but there are no LBs in the non-olfactory 
cortical areas in stage 3. Although there is a predilection for melano-neurons of the 
substantia nigra to be affected by pathology in stage 3, depigmentation is not yet 
detectable by the human eye. 
Stage 4: There is a devastating loss of the melanin rich projecting neurons which 
may now be observed macroscopically. Projection neurons in the pedunculopontine 
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tegmental nucleus are severely affected and there is pathological spread into the 
basal forebrain, the paralimbic cortex and the allocortex. Stage 4 also sees the 
involvement of the temporal mesocortex, providing a point of access to the 
neocortex.   
Stage 5 and 6 exhibits a further increase in the extent of LB and LN pathology in 
already affected regions. 
Stage 5: The olfactory regions are severely afflicted and via the temporal 
mesocortex, the connecting sensory association region of the neocortex sees the 
involvement of the higher order sensory neurons. At this stage, the inclusion of some 
pre-frontal regions may be established 
Stage 6: The progression at this stage will involve almost the entire neocortex.  
 
Autopsy examination will confirm a definitive diagnosis between DLB, PD, PDD or 
AD based on the clinical picture of the patient, neuropathological observations 
correlated with the Braak staging and the presence of aggregating protein in target 
areas of the brain [61]. Whilst the Braak hypothesis is a powerful tool that enables 
the precise clinical diagnosis post-mortem, it is not universally accepted. α-synuclein 
deposits have been described in healthy elderly patients with no α-synucleinopathy-
like symptoms or other neurodegenerative features [62]. Further, a peripheral 
rostrocaudal gradient of phosphorylation α-synuclein has been observed in PD 
patients [63] in contrast to the caudo-rostral pathway determined. Whilst a robust 
and reproducible diagnostic tool is required, inter-patient variability may see differing 
clinical and post-mortem outcomes, this is largely unavoidable until the precise 
mechanisms that initiate the pathological spread are understood. 
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1.1.6. DLB with concurrent AD-related pathology 
The challenges facing a clinical diagnosis of DLB relate to the great crossover in 
pathology between DLB and AD.  The neuronal presence of Lewy bodies supports a 
diagnosis of DLB and AD is characterised by neuritic amyloid beta plaques and 
neurofibrillary tangles (NFTs) although, DLB and AD may share neuropathological 
features such as Lewy bodies, amyloid plaques and NFTs collectively. DLB occurs in 
isolation as pure DLB (pDLB) and more commonly it presents with concurrent AD-
type pathology [64]. There are conflicting reports on the prevalence of these 
conditions, although it is accepted that pDLB is less frequent in occurrence 
(reviewed by [65]). 
Amyloid plaques are frequent in DLB and PDD; the incidence is lower in PDD and as 
many as 80% of DLB patients may exhibit amyloid pathology. Moreover, in up to 
30% of AD cases Lewy bodies are present [66]. The mixed pathology associated 
with these neurodegenerative conditions leads to discrepancies in accurate clinical 
diagnoses which are not corroborated until an autopsy is undertaken; in this regard, 
it is reported that there is an astounding error rate of between 34% - 65% in correct 
diagnosis of DLB [67].  
The knowledge that DLB and AD arise in the pure form and concurrently with 
amyloid-β plaques, α-synuclein and tau pathology (Figure 4) further complicates the 
multiplex field of dementia and fosters the questions of the driving force behind the 
neuropathology. Knowledge of the primary proteins in the initiation of the 
pathological process may expose the more toxic aggregates. The toxicity of these 
aggregating proteins may be revealed by life expectancy from diagnosis: the life 
expectancy in DLB is approximately 8 years from onset and approximately 8-12 
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years in AD [68]. It could potentially be argued that the presence of aggregating α-
synuclein may lead to neuronal demise more rapidly. 
 
Figure 4 - α-synucleinopathies and AD share neuropathological characteristics  
DLB, AD, LBvAD (Lewy body variant of AD) and PDD share Aβ, Tau and α-synuclein pathology. 
Adapted from [69].  
 
The symptomatic similarities between DLB and AD relate to cognitive function and 
memory although, DLB have more pronounced attentional deficits, mild memory 
visual-spatial deficits [70] and executive function disparities [71] early in the disease 
course. Extrapyramidal signs and the psychiatric symptoms: hallucinations, 
depression, delusions & behavioural symptoms are also more pronounced in DLB 
when compared to AD, in the early stages, later in the disease course the disparity 
between the two diseases is less defined [71]. 
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1.1.7. Treatment 
There is no known cure for DLB although medications are prescribed to alleviate 
some of the symptoms. The management of DLB appears to be more complex than 
many other neurodegenerative diseases due to the convolution of symptoms that 
include: cognitive, neuropsychiatric, movement, autonomic, and sleep disparities 
(reviewed in [72]). Individual symptom categories require unique and specific 
treatments. DLB patients can have a high responsiveness to cholinesterase inhibitor 
(CHEI) treatment; these may be used to treat fluctuating cognitive functions, 
neuropsychiatric symptoms and visual hallucinations [2]. Neuroleptic drugs are 
prescribed to address some of the psychiatric symptoms present in DLB such as 
depression, however, due to DLB patients exhibiting an increase in sensitivity to 
neuroleptics, they are administered with caution [73]. Levodopa (L-Dopa ) is used to 
treat the motor features associated with Parkinsonism in PD, this is the most 
successful treatment for extrapyramidal features although only one-third of DLB 
patients are as responsive to the treatment [74].   
Collectively, DLB is a multifaceted, complex disease that reaches multiple brain 
regions. Symptoms may vary from patient-to-patient and a conclusive diagnosis is 
not able to be provided until post-mortem. The identification of disease specific bio-
markers would enable a rapid diagnosis and the administration of therapeutics, early 
in the course of the pathology in order to manage disease symptoms. 
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1.2.  The Synucleins 
The synuclein family comprise of α-synuclein [75], β-synuclein [76] and γ-synuclein 
[77], they are small natively unfolded monomeric proteins associated with 
neurodegenerative conditions and cancer. α-synuclein and β-synuclein are primarily 
found in the pre-synaptic nerve terminals of the central nervous system (CNS) [78]. 
Conversely, γ-synuclein, although found in the CNS, is mainly associated with the 
peripheral nervous system (PNS) [79] and is linked to ovarian [80] and breast cancer 
[81]. For the purpose of this study, γ-synuclein will not be described in relation to 
DLB. 
1.2.1. The history of α-synuclein and β-synuclein protein identification 
The synuclein protein sequence was originally identified in the Torpedo California 
[82] with proteins of different molecular weights revealed. The regional distribution 
was limited to the nervous system only, found predominantly localised to the nuclear 
envelope and at pre-synaptic terminals. 
Subsequently, the entire sequence of an amyloid preparation isolated from AD 
patients was analysed. In addition to the presence of amyloid-β, a 140-amino acid 
sequence was characterised and tentatively named the non-amyloid-β component 
precursor (NACP) and a fragment, of the full 140-amino acid sequence was named 
the non-amyloid-β component (NAC) [83]. The NAC region was predisposed to form 
β-sheet structures that associated with amyloid plaques in AD patients and the 
NACP was re-named α-synuclein. The protein previously known as phospho- 
neuroprotein 14 (PNP14) was renamed β-synuclein [76] [78]. 
 
43 
 
1.2.2. The synuclein genes 
1.2.2.1. SNCA  
The α-synuclein gene is located on the long arm of chromosome 4: 4q21.3 – 4q22 
[84]. There are five coding exons for the full-length α-synuclein protein [85], total 
transcript length is 3041base pairs (bp)  [86] with at least three further splice variants 
of the gene: SNCA-98 [87], SNCA112 and SNCA-126 [88]. Transcript variants 
SNCA-112 and SNCA-126 have “in-frame deletions” of exon 3 and 5 respectively, in 
contrast, SNCA-98 lacks exon 3 and 5 [87]. The SNCA-126 transcript has an 
interruption in the N terminal domain (NTD) and it is thought this isoform reduces 
inherent aggregation propensity; conversely, SNCA-122 has a shorter C-terminal 
domain (CTD) than the full-length transcript and is more aggregation prone. The 
shortest transcript SNCA-98 has lower levels of expression when compared to the 
other isoforms [87].  The differential α-synuclein isoforms have been implicated in the 
pathogenesis of DLB with increased expression of SNCA-112 in the prefrontal 
cortices of DLB patients in parallel to a reduction in SNCA-140 [89] and SNCA-126 
transcript [90]. The SNCA-112 transcript with a shortened, disordered CTD appears 
to favour aggregation propensity. Alternative splicing provides the platform for 
regulating transcriptional diversity, however, the physiological drive behind changes 
in the α-synuclein isoforms are not understood.  
Transcription factors mediating the SNCA gene expression have not been fully 
elucidated. Inhibition of poly-(ADP-ribose) transferase/polymerase-1 (PARP1) via the 
REP1 region, a polymorphic microsatellite region situated approximately 10 kb 
upstream of the SNCA gene, leads to an increase in endogenous levels of α-
synuclein [91]. Variations in the size of a dinucleotide repeat region in REP1 has 
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been linked to increased risk of PD [92], the increased risk was in parallel to an 
expansion of the repeat region. Furthermore, in vitro analysis has shown that a 
greater length of the repeat region can lead to a three-fold increase in expression of 
the SNCA gene [93]. This may in part be responsible for driving the over expression 
of α-synuclein leading in effect to an increase in gene-dosage and increase in the 
risk of protein aggregation. Promoter regions within the SNCA gene have been 
identified as potential transcriptional factors binding sites such as GATA [94] and 
zinc finger-and scan domain containing (ZSCAN) [95]; α-synuclein transcriptional 
regulatory factors are still under investigation. Not surprisingly, a GWAS study 
identified association at the SNCA locus in DLB, PD and PDD [96] [97]. 
1.2.2.2. SNCB 
The β-synuclein gene (SNCB) is encoded by 7 exons and localised to the long arm 
of chromosome 5 (5q35.2) [98]. Two mRNA transcript variants of the SNCB gene are 
known; transcript 1 (SNCBtv1) includes exon 2 and the mRNA is 1594bp in length; 
the second transcript variant (SNCBtv2) lacks exon 2 and the mRNA size is 1437bp. 
Exon 2 is located within the untranslated 5’ region producing an identical translation 
of the protein [98]. The SNCBtv2 transcript appears to be the predominant form and 
is expressed primarily in the frontal and temporal cortex and the caudate nucleus 
[89]. Transcriptional control of β-synuclein expression is not established, MTF-1, 
NRF2 and ZSCAN21 may regulate β-synuclein in vitro [99] although, supporting 
evidence for transcriptional regulation by these factors has not yet been established 
in the human brain. Other regulatory mechanisms may involve α-synuclein, this is 
based on of a potential inverse relationship present between β-synuclein and α-
synuclein; supported by the findings that transcription factor, ZSCAN21, induces an 
increase in the levels of β-synuclein while repressing levels of α-synuclein [99]; thus, 
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indicative of a potential reciprocal synuclein relationship between the synuclein; in 
contrast, MTF-1 drives the expression of β-synuclein but does not affect the levels of 
α-synuclein [1].  
Co-operative regulatory mechanisms are further corroborated by the finding that β-
synuclein may act in a compensatory anti-apoptotic manner in relation to the loss of 
wild type α-synuclein. In vitro, both α-synuclein [100] and β-synuclein [101] have 
been shown to have anti-apoptotic properties. Wild type, α-synuclein is able to 
prevent apoptosis in response to toxic insults, and is associated with a reduction of 
caspase 3 [102] and p53 [100]; in contrast, this inhibitory effect of apoptosis is lost in 
the presence of PD associated mutant α-synuclein, A53T and in response to 
dopamine derivative 6-hydroxydopamine. Importantly, β-synuclein has been shown 
to reduce caspase 3 activity and p53 expression levels; furthermore, a reduction in 
p53 transcriptional activity in the presence of 6-hydroxydopamine is observed [101]. 
This provides evidence for a functional compensatory role such that the loss of 
function of α-synuclein in PD-type models can be compensated for by β-synuclein 
expression; thus, leading to the concept that there is inter-protein cross talk under 
toxic conditions.  
1.2.3. Synuclein protein structure 
1.2.3.1. α-synuclein  
α-synuclein is a protein of 140 amino acids [82] (Figure 5)  with a molecular weight of 
14460 Da. The N-terminal domain (NTD) region of α-synuclein is crucial for 
membrane interactions with a partiality for alpha-helical conformations when 
interacting with lipids [103], mirroring the behaviour of apolipoproteins [104] and 
suggesting a role for α-synuclein as a lipid-binding protein. The NTD region contains 
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seven 11 amino acid imperfect repeats, each of which contains a highly conserved 
hexameric consensus sequence: KTKEGV [105]. The size of the repeats in the N 
terminal domain enables the protein to make three turns of a helix, conferring 
membrane binding capacity through multiple repeats (reviewed in [106]). These 
amphipathic regions confer binding properties to highly curved membranes [107]. 
The central NAC region sets α-synuclein apart from the other synuclein family 
members, it is highly hydrophobic [25] and this region is thought to enable the 
oligomerisation and fibrillisation of the α-synuclein protein producing, a “face-to-face” 
β-sheet formation [108]. Deletion of this region or inhibition decreases the 
aggregation propensity of α-synuclein [109].  
The C-terminal domain (CTD) of α-synuclein is acidic, unfolded and disorderly when 
compared to the NTD and is subject to multiple post translational modifications that 
are found associated with α-synuclein in aggregates and Lewy bodies [110]. The 
CTD of α-synuclein has been implicated in the regulation of the nuclear location of 
the protein and has been shown to interact with histones [111] and double stranded 
DNA [112]. In addition, the CTD interacts with metal ions [113] and proteins including 
tau [114]. The CTD region may be able to directly or indirectly interact with the NAC 
region thereby inhibiting fibrillisation [115] with truncation of the CTD region leading 
to increased neurotoxicity and the number of α-synuclein inclusion bodies [116]. It is 
possible that the physiological conformation of the protein is such that the NAC is 
masked by the CTD region and that occupation of the CTD by other biomolecules 
alters the conformation exposing part of or all of the NAC region. Under stressful or 
dis-equilibrated conditions, this may effect a chain of events that leads to the 
fibrillisation of α-synuclein. 
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Figure 5 - α-synuclein protein structure  
Schematic is based on reviews of the α-synuclein protein structure [117] & [118] 
 
The natively unfolded conformation of α-synuclein protein [119] adopts an α-helical 
secondary structure associated with the membranes in vitro [120], once dissociated 
from the membrane the helical conformation is lost and the protein reverts to its 
native state [121]. It is possible that under normal physiological conditions, α-
synuclein transitions between states of being monomeric and unfolded to an α-
helical conformation when in association with lipid membranes. 
1.2.3.2. β-synuclein 
β-synuclein is 134 amino acids in length and under physiological conditions, is a 
monomeric natively unfolded protein (Figure 6). Like α-synuclein, β-synuclein has 
seven well conserved imperfect, eleven amino acid repeats, each containing the 
consensus sequence KTKEGV in the NTD domain, enabling the interaction between 
β-synuclein and synaptic membranes [122] and acidic phospholipids [123]. 
 β-synuclein has a central hydrophobic region that does not confer fibrillisation 
propensity like α-synuclein [124] and as with the synuclein family, the CTD is rich in 
acidic residues [125]   
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Figure 6 - β-synuclein protein structure  
Schematic is based on reviews of the β-synuclein protein structure [118]. 
 
1.2.4. Structural similarities of β-synuclein to α-synuclein 
α-synuclein and β-synuclein share 78% amino acid sequence homology [126] 
(Figure 7). 84% homology is seen in the NTD, a highly-conserved region in the 
synuclein family. It comprises almost half of the synuclein protein’s sequence 
indicating a common biological mechanism among all of the synucleins such as lipid 
binding [127]. The absence of 11 amino acids in the central domain of β-synuclein 
that are present in α-synuclein [128] result in an interruption in the alpha-helical 
region of the β-synuclein protein that may contribute to the reduced ability of β-
synuclein to self-aggregate and form fibrils [124]. It is the CTD of β-synuclein sees a 
greater divergence in homology from α-synuclein [129]. Despite, such similarities in 
the protein structure, it is thought that the differences that do occur in the amino acid 
configuration of β-synuclein, enables greater conformation outcomes in its native 
state when compared to α-synuclein [118].   
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Figure 7 - Synuclein protein structure similarities  
Structural similarities between the α-synuclein and β-synuclein protein. (A) region absent in β-
synuclein that is present in α-synuclein. (B) Region absent in α-synuclein that is present in β-
synuclein. 
 
1.2.5. Regional distribution of the synucleins 
1.2.5.1. α-synuclein 
α-synuclein is an abundant protein accounting for between 0.5% and 1% of the 
cytosolic fraction  [130] of the human brain and has only been identified in 
vertebrates [127]. α-synuclein is broadly expressed throughout the CNS but is 
present in the PNS, including intestinal tissue and the CSF (reviewed by, [131]). The 
highest regional levels of α-synuclein mRNA expression are observed in the 
neocortex, hippocampus, thalamus, striatum and cerebellum [130] and in 
pathological conditions such as MSA (multiple system atrophy), in glia cells [132]. 
Although α-synuclein was originally identified in association with the nuclear 
envelope, it has since been shown to be primarily located at pre-synaptic nerve 
terminals in close proximity to synaptic vesicles [82], with little evidence of dendritic 
or somata staining or along extra-synaptic sites.  
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1.2.5.2. β-synuclein 
β-synuclein shows a strikingly similar pattern of regional distribution to α-synuclein 
throughout the human brain, high levels of expression are observed in the 
hippocampus, amygdala, substantia nigra, caudate nucleus and thalamus (Reviewed 
by [85]).  β-synuclein mRNA is revealed in the neocortex, hippocampus, cerebellum, 
basal ganglia and substantia nigra; it is the most abundant synuclein in the 
neocortex and cerebellum; comprising approximately 75-80% of the total synuclein 
mRNA [133]. β-synuclein also presents with a limited peripheral expression 
including, in olfactory receptor neurons of olfactory epithelium [134].   
In healthy controls, β-synuclein is present in astrocytes [135], α-synuclein is 
expressed in astrocytes and oligodendrocytes in relation to PD [136], DLB brains 
[137] and oligodendrocytes in MSA [33] but not the control brains. This relationship is 
redolent of β-synuclein supporting a possible physiological function in glial cells 
whilst α-synuclein may be more representative of a pathological presence only.  
1.2.6. Physiological role for the synucleins 
1.2.6.1. α-synuclein 
Despite the abundant presence of α-synuclein in the central nervous system and its 
predominant feature in neurodegenerative α-synucleinopathies, the role of α-
synuclein still remains elusive. Its physiological and pathological roles have been 
extensively scrutinised providing a plethora of possible functions and although the 
lipid-binding features go uncontested, there are distinct gaps in the scientific 
knowledge surrounding the role of α-synuclein at the pre-synaptic terminal.  
In development, α-synuclein is one of the last pre-synaptic proteins to localise at 
developing synapses [138]. α-synuclein has been shown to be expressed after 
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synaptophysin and localised exclusively to the presynaptic terminals of mature 
neurons. [139] indicating it does not have a role in synaptogenesis. Moreover, early 
observations of α-synuclein in zebra finch pointed to a potential role for α-synuclein 
in regulating synaptic plasticity [104], however, no further evidence to support a role 
in synaptic plasticity has been identified. 
The membrane binding properties of α-synuclein have been identified both in vitro 
and in vivo. The association of α-synuclein with synaptic vesicles was observed as 
early as 1991 when it was detected in the presence of cholinergic vesicles of the 
Torpedo electric organ [122]. Examination of its role at the synapse, in relation to 
vesicle trafficking, SNARE complex formation and neurotransmitter release has been 
undertaken to elucidate its physiological role. The knockdown of α-synuclein in 
hippocampal neurons leads to a reduction in the vesicular pools at the synapse [139] 
pointing to a role for α-synuclein in maintenance of the pool of vesicles. Human wild 
type α-synuclein expressed in mice has been shown to negatively affect 
neurogenesis, by reducing the survival rate of neuronal-committed progenitors in the 
olfactory bulb and dentate gyrus [140]. Furthermore, a role has been established 
supporting a chaperoning role for α-synuclein in the formation of the SNARE-
complex [141], (this will be discussed at length in Chapter 3). The different 
conformations that α-synuclein is able to adapt may suggest multiple roles at the pre-
synaptic terminal that have yet to be determined.  
1.2.6.2. β-synuclein 
The abundance and pattern of expression of β-synuclein throughout the human brain 
[98] and its synapse rich presence [82] does not reveal a physiological role for β-
synuclein. β-synuclein expression is observed in the brain [142] and the testes [143] 
is significantly increased 2-3 weeks postnatally and is located within axonal growth 
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cones during axonal regeneration following damage [144] indicating a potential role 
in cellular proliferation. The knockout of the β-synuclein gene in murine models does 
not lead to any defining changes when compared to the wild type, life span is 
unchanged, neurotransmitter release is normal, including the size of the pool of 
vesicles and no abnormalities in long term potentiation [145]. In contrast, triple 
synuclein knock out mouse models do display changes, the absence of α-synuclein, 
β-synuclein and γ-synuclein leads to synaptic alterations, age-related neuronal 
dysfunction in addition to a decreased survival rate [146]. Whilst synaptic density is 
unchanged in the triple knockout model, the area of the pre-synaptic terminals is 
reduced in size, rescued by re-introducing α-synuclein alone. The age-related 
changes and survival may predispose some role for the synucleins that is more 
relevant in more advanced years as opposed to early in life. 
The rescue effect by α-synuclein in the triple knock out model and the lack of 
obvious phenotype in the β-synuclein or α-synuclein knock out model is reinforcing 
the possibility of redundancy between the synucleins. It is possible that interplay 
between the synucleins is responsible for the lack of phenotype observed in a single 
knockout model, with this compensatory effect lost with deletion of all three 
synucleins. One must also consider the possibility of a hierarchy effect suggesting an 
existence of a delicate balance of the synuclein proteins whereby modifications in 
one may lead to the upregulation/downregulation of another producing a functional 
compensatory effect under physiological or pathological conditions.  
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1.2.7. Aggregation of synuclein proteins 
1.2.7.1. α-synuclein  
The aggregating process of α-synuclein that results in a neurodegenerative 
phenotype is complex; the triggering factor is usually indeterminable although gene 
[147] and pathological post translational modifications have been implicated in the 
initiation of protein fibrillisation such as  phosphorylation [110], oxidation [148] and 
nitration [149]. Protein homeostasis and folding efficiency as forms of quality control 
in the normal physiological cellular environment are critical and these systems are 
progressively dysregulated in the pathogenesis of neurodegenerative disease 
(reviewed in [150]). Once cellular mechanisms that are in place to ensure correct 
folding and/or removal of the offending protein are breached, the protein creates a 
neurotoxic environment that can lead to dysfunction of routine cellular functions. The 
consequence of misfolding proteins that bring about protein aggregation is the 
potential for these proteins to fibrillise and to provide a “seed” [151] for the further 
propagation of pathology (Figure 8).  
 
. 
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Figure 8 - Protein aggregation process:  
α-synuclein mRNA (1); Newly translated monomeric α-synuclein (2); Misfolded α-synuclein 
protein (3), degraded by the UPS or autophagy pathway. 3(a). Misfolded α-synuclein can form 
aggregates 3(b) produce an antiparallel beta sheet formation (3c). Post-translational 
modifications (4) may lead to aggregated (3(b) or fibrillar form 3(c) of α-synuclein. 5. 
Aggregated or fibrillar α-synuclein can lead to Lewy neurites or Lewy bodies. 
 
The process of aggregation may occur at various steps, during mRNA transcription 
(Figure 8-1) the polypeptide chain will predictably fold into its unique active 3D 
conformation determined by the sequence of hydrophobic and hydrophilic amino 
acids (Figure 8-2). The formation of a hydrophobic core induces a globular structure 
that limits the available conformational space [152] reducing the risk of a misfolded 
protein (Figure 8-3). Exposure of this region to the cytoplasm could induce a 
conformation change that is not conducive to the proteins final structure. In the event 
that α-synuclein is misfolded, the UPS or autophagy system will attempt to degrade 
the protein (Figure 8-3a). PTMs of α-synuclein (Figure 8-4) have been shown to 
55 
 
encourage protein aggregation (Figure 8-3b) or fibrils (Figure 8-3c), these species of 
α-synuclein may lead to LB or LN formation (Figure 8-5). Fibrils form interactions of 
variable strength and morphological associations but are often resistant to rigorous 
degradation processes [153]. The prevention of degradation leads to the formation of 
larger aggregates, LB formation, maturation and pathological spread. 
1.2.7.2. β-synuclein  
β-synuclein is not found in Lewy bodies [31] and wild type β-synuclein has 
significantly less intrinsic, fibrillogenic properties in comparison to α-synuclein [154]. 
β-synuclein is typically found in a soluble monomeric state, extensive periods of 
protein incubation see no changes to the protein conformation [155]. Isolation of the 
NAC fragment from α-synuclein leads to the rapid and efficient formation of 
proteolytic-digestion resistant, amyloid fibrils [154] although, when introduced into 
the central region of β-synuclein, it only marginally increases the protein fibrillisation 
propensity [129]. The fibrillogenic conferring properties of the NAC fragment, 
therefore, despite protein homology of the synuclein, does not predispose the same 
aggregating properties in the chimeric β-synuclein protein. It is possible that local or 
distal properties in the existing sequence of β-synuclein negate the aggregating 
effects of the amyloid fragment. 
Enforced harsh conditions have been shown to induce the aggregation of β-
synuclein, the presence of SDS led to a fibril-like morphology and protofilament 
structures [129], this multimerisation process is not conferred in the absence of the 
NTD. Metal copper, zinc and lead have been shown to induce structural changes 
and aggregation features in β-synuclein [156]. Following incubation with the metals 
the protein changed from a disorganised unfolded protein to a more structurally 
organised fibrillated β-synuclein, corresponding to a β-sheet formation.  
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Collectively, this evidence suggests that under certain enforced, artificial and harsh 
conditions, β-synuclein has the ability to form fibrils and to aggregate in much the 
same way that α-synuclein can. It can be argued that any polypeptide has capacity 
to aggregate under enforced conditions that do not represent the physiological 
environment.  
1.2.8. Synuclein gene mutations 
1.2.8.1. SNCA 
The E46K mutation is the only mutation in the SNCA gene that has been associated 
with familial DLB [157] and there is presently no genetic marker for idiopathic DLB. In 
contrast, a genome wide association study (GWAS) identified that an increase in 
susceptibility to sporadic PD was linked to single nucleotide polymorphisms in the 
SNCA gene [158]. In PD, point mutations have been identified, including but not 
limited to: A53T [159],  E46K [157], A30P [160], G51D [161], and H50Q  [162]. 
Furthermore, duplications [163] and triplications [164] of the SNCA gene have been 
identified in families with autosomal-dominant PD. Point mutations in the SNCA gene 
and gene triplication lead to high penetrance, whilst duplication has incomplete 
penetrance [165]. Multiple gene copies see an increase in the wild-type expression 
of α-synuclein that is sufficient enough to cause early on-set PD [166]; the age of 
onset following duplication of SNCA induces clinical symptoms in the 50s and 
triplication as soon as the thirties (reviewed in [167]). The age of PD onset in those 
with gene duplication is similar to that observed with point mutations and thus, the 
argument is presented that increased gene dosage increases the propensity of α-
synuclein to aggregate. 
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The point mutations A53T, A30P, E46K, H50Q and G51D in the SNCA gene, 
implicated in PD/DLB are all positioned in the NTD of the protein (Figure 9). This 
finding may suggest that alterations in the region of the protein associated with the 
formation of alpha-helices, leads to a change in a conformation such that favours 
oligomerisation/aggregation.  
 
Figure 9 - SNCA mutations  
Diagrammatic of mutations associated with α-synuclein. They are all located in the NTD. 
 
1.2.8.2. SNCB  
Missense mutations in SNCB gene have been associated with DLB [168]. The 
challenge is the lack of multi-generational-families with DLB, leading to the absence 
of the genetic power required for linkage analysis and positional cloning strategies. 
The ability to study families with a DLB history would enable the research into the 
molecular genetics of the disease, increasing the capacity to identify novel genes. A 
relatively large study screened sporadic DLB and familial DLB patients and found 
only two patients with two different two amino acid substitutions that occurred at 
conserved sites in the SNCB gene [169]. The sporadic DLB patient had a 
substitution in exon 4, at codon 70 of valine to methionine: the V70M mutation. The 
second patient they identified as an extended pedigree, with a substitution at codon 
123 in exon 5 from proline to histidine: the P123H mutation. Immunohistochemical 
examination of the patient with the P123H mutation did not detect β-synuclein in 
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Lewy bodies, there were no β-synuclein positive aggregation or inclusions, although, 
a diffuse β-synuclein staining was observed in the hilus of the hippocampus and 
amygdala.  
 
Figure 10 - SNCB mutations:  
Diagrammatic of mutations associated with β-synuclein. Mutations are linked to the central 
domain and the CTD. 
 
1.2.9. Pathological role of synucleins  
1.2.9.1. α-synuclein 
Lack of wild type α-synuclein does not produce a phenotype with severe 
neuropathological effects [170] but an increase in α-synuclein gene dosage leads to 
LB formation [164]. PTMs to α-synuclein can give rise to a toxic gain of function - α-
synuclein is constituently phosphorylated occurring under both normal physiological 
conditions [171] and pathological [110]. It is not ascertained whether PTMs occur as 
a method of protein regulation or further propagates the disease. Extensive 
phosphorylation at serine 129 (PS129) of protein aggregates is associated with α-
synucleinopathies and evidence suggests that phosphorylation at this site is 
promoting fibrillogenesis in vitro [110], contrasting reports suggest that PS129 may 
inhibit fibrillisation [172] Moreover, phosphorylation of α-synuclein at serine 87 
(PS87) is increased in DLB brains, but is thought to inhibit fibrillisation and reduce 
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the ability of α-synuclein to bind to membranes [173]. Nitration of tyrosine residues in 
α-synuclein is a common feature in LBs in PD, DLB and LB variant of AD brains 
(LBVAD). It is proposed that nitration is a direct link to oxidation induced-cross 
linking of the protein that further encourages fibrillisation [148], nitration of α-
synuclein is expressly neurotoxic for dopaminergic neurons [174].  
Pre-fibrillar, soluble oligomeric α-synuclein is increasingly considered the 
predominant toxic species of the protein [54]. By inducing various mutations, 
associated with α-synucleinopathies, it was shown that the fibrillisation properties of 
the α-synuclein protein were reduced, but the propensity to form soluble oligomeric 
species was increased, correlating with increased neurotoxicity, neuritic defects, loss 
of dopaminergic neurons and behavioural deficits in multiple system models [175]. 
Moreover, examination of the DLB brain reveals at least ten times smaller α-
synuclein aggregates when compared to the amount of Lewy bodies, 90% of these 
were outside of Lewy bodies and present at the pre-synapse in the DLB frontal 
cortex [176]. 
1.2.9.2. β-synuclein 
In order to assess the functional effect of the P123H mutation, Fujita et al., [177] 
developed a mouse model overexpressing the human P123H transgene. 
Accumulations immuno-positive for β-synuclein were identified in hippocampal axons 
and apical dendrites in cortical regions. The aggregates were not Lewy-body-like and 
increased in insolubility with age. In the basal ganglia, small spheroidal axonal 
swellings composed of membranous components were observed that were non-
functional as a pre-synapse and spatial learning and memory were affected. 
Although endogenous α-synuclein did not alter the pathology associated with P123H 
β-synuclein, the double transgenic mice over expressing α-synuclein in conjunction 
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with P123H saw augmented neurodegenerative pathology. Thus, a toxic gain of 
function for P123H- β-synuclein, requires overexpression of wild type α-synuclein to 
rescue the pathological phenotype. Furthermore, lysosomal dysfunction, 
representative of lysosomal storage disorders in the presence of both V70M and 
P123H SNCB mutations have been observed [168]. P123H overexpression 
produces various types and sizes of lysosomal structures including macro-
lysosomes and giant autophagosomes. 
1.2.10. Protective function of β-synuclein 
Despite the lack of studies of β-synuclein, there are significant indications that the 
protein may bestow protective properties in the presence of increased levels of/or 
the modified structure of α-synuclein. Hashimoto et al., [178] developed a mouse 
model expressing human wild-type α-synuclein that develop intraneuronal inclusions, 
dopaminergic impairments and motor deficits. Co-expression of human β-synuclein 
and α-synuclein ameliorated the motor deficit in concurrence with significantly less 
intraneuronal inclusions. Co-incubation of α-synuclein with β-synuclein reduces the 
rate of α-synuclein fibrillation [124] and β-synuclein significantly reduces the 
generation of the mutant form of α-synuclein, A53T protofibrils and fibrils [179]. 
Finally, transient overexpression of β-synuclein is shown to enhance cell survival 
when exposed to potential toxins, such as α-synuclein-fibrillisation inducer, rotenone 
[180]. Indicative of direct or indirect neuroprotective responses by β-synuclein in 
toxic cellular conditions. 
The evidence suggest that direct binding to α-synuclein by β-synuclein occurs, its 
regulation of α-synuclein aggregation and the fact that β-synuclein is not present in 
Lewy bodies [49] demonstrates that the protein is able to avoid being caught up in 
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the aggregating process. It could be argued that the neuropathological features of 
DLB in the patient become clinical when there is a loss of equilibrium between 
modification to α-synuclein and its aggregating properties and the presence of β-
synuclein. It is important that levels of β-synuclein protein are examined in DLB 
neuropathological regions in relation to α-synuclein levels in order to establish the 
course of change in protein levels that may be occurring in the DLB brain. 
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1.3. Interaction between SNARE proteins and synucleins at the pre-synapse 
Intercellular signaling, mediated at the synapse in the central nervous system, is 
highly organised. Neurotransmitters are packaged into synaptic vesicles, transported 
to the reserve pool of readily releasable pool of synaptic vesicles in anticipation of an 
action potential resulting in exocytosis. These constitutive and universal processes 
provide the foundation for many of the biological processes [181], the modulation of 
which can change the efficiency of the synapse such that it can impact on synaptic 
activity. 
1.3.1. SNAREs at the pre-synaptic terminal 
The soluble N-ethylmaleimide sensitive fusion attachment protein receptor (SNARE) 
proteins are a family of membrane bound proteins that facilitate the association of 
intracellular membranes with target membranes [182]. The exchange of materials 
between organelles or other cellular membranes such as the plasma membrane or 
pre-synapse requires the fusion of two phospholipid membranes [183]. The 
formation of the trans-SNARE complex and the association between SNAREs on 
independent membranes underpins the subsequent fusion of the membranes 
leading to the cis-SNARE complex formation, a conformation that sees the SNAREs 
associated with the same membrane [184]. Crucially, neurotransmitter release at the 
synapse relies on the efficiency of synaptic vesicles binding to the target membrane 
in order to release the neurotransmitter into the synaptic cleft. Each pre-synaptic 
portion of an axon includes hundreds of synaptic vesicles that contain 
neurotransmitter [185] and from the arrival of an action potential to the release of 
neurotransmitter can take as little as 100µs [186].The regulation of neurotransmitter 
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release underpins most functions of the nervous system, including those that 
mediate cognition and memory processes that are dysfunctional in DLB. 
Depending on the pre-determined location for the SNAREs, they are either V-
SNAREs, that are assembled onto the vesicle, such as VAMP2 (vesicle-associated 
membrane protein 2) or t-SNAREs that characterise the SNARE proteins that 
associate with the target membrane, such as syntaxin and SNAP25 [187]. 
1.3.2. The SNARE complex  
VAMP2, syntaxin, and SNAP25 form the SNARE complex [188] at the pre-synapse 
(Figure 11). The SNAREs have a region of 70 amino acids [189] that is an extended 
coiled-coil motif. Most SNAREs including syntaxin and VAMP2, have a short linker 
that associated the SNARE motif to the carboxyl-terminal transmembrane region 
(TMR). SNAP25 deviates from this structure with the SNARE motifs being connected 
by a palmitoylated linker and the absence of the TMR [190]. 
 The characteristics of these three SNARE proteins are unique in that they assemble 
into a ternary complex with 1:1:1 stoichiometry [187] forming a tight-SDS resistant 
complex [191]. The principal regions within each of the SNAREs that are important to 
ensure cooperative binding in the SNARE complex formation has been determined 
[191]  - in VAMP2 this was identified in the central domain (residues 27-96); syntaxin 
relies on an H3 helix domain in the C-terminal region (194-261) and SNAP requires 
both the C-terminal and N-terminal regions (180-208 and 26-82, respectively). Each 
of these areas have a high predisposition towards alpha-helical coil-coiled formations 
[192] leading to a four-helix bundle as a result of the complex, two of the helices 
belonging to SNAP25 [193].  
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Figure 11 - SNARE proteins at the pre-synapse 
Diagrammatic illustration of V-SNARE, VAMP2 in association with the vesicle. T-SNAREs 
syntaxin and SNAP25 are in association with the pre-synaptic plasma membrane. N denotes 
NTD and C denotes CTD. The arrow represents the region of the SNARE protein that is critical 
for producing the ternary structured SNARE complex. 
 
A plethora of other proteins complement and support the role of the SNAREs 
ensuring efficient docking, priming and fusion of synaptic vesicle including, but not 
limited to, SM proteins [194] the N-ethylmaleimide-sensitive-factor (NSF), the soluble 
NSF attachment proteins (SNAPs), complexins, synaptotagmins [195] and Rabs 
[196]. This is an expansive area with much research and for the purpose of the 
thesis will remain limited. 
1.3.2.1. SNARE complex assembly, priming, fusion and exocytosis 
At the presynaptic terminal, vesicles cycle through a succession of trafficking phases 
including docking, priming, fusion, exocytosis, endocytosis and recycling (reviewed 
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in [197]). Some of these vesicles can be found already docked at specific regions of 
the plasma membrane, so-called “the active zone” [198]. At the active zone, this 
readily releasable pool (RRP) of vesicles is joined by multiple proteins that act in the 
manner of a scaffold to allow docking of the vesicle in preparation for an action 
potential, calcium flux and subsequent release of neurotransmitter.  
Further co-operative components are required: SM protein, Munc 18-1, is a negative 
regulator of SNARE complex formation by its binding to syntaxin 1A, disassociation 
of syntaxin and Munc18 binding exposes syntaxin residues that are available for 
SNAP25 binding [194]. Tethering factors are important for bringing the vesicle into 
close proximity to the target site [199]. Subsequent assembly of the SNARE complex 
requires the contact of v-SNARE and t-SNAREs by associating in trans, starting from 
the NTD of the SNAREs and advancing towards the CTD, in a “zippering” effect 
anchoring the SNAREs [192].  
Priming is the phase that sees docked vesicles transition into an exocytosis-
proficient state, waiting for the calcium influx following an action potential that will 
induce fusion pore formation [200]. In the final stages of exocytosis, fusion of the 
vesicle membrane and the plasma membrane occurs. The development of a fusion 
pore ensues whilst maintaining the integrity of the hydrophobic components of the 
membranes. The precise mechanisms surrounding this process is still under 
investigation with one hypothesis focusing on the stalk hypothesis [201] once the 
fusion pore ruptures exocytosis of neurotransmitter at the synaptic cleft will occur. 
1.3.2.3. Snare complex disassembly and endocytosis 
Following fusion with the plasma membrane, the SNARE complex is released in a 
“spring-loaded” manner and unwinding of the four bundle helices arises [202]. Fast 
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neurotransmission in the human brain requires the efficient and rapid recycling of 
synaptic vesicles at the presynaptic terminals; this relies on competent endocytic 
processes that are relevant to the physiological requirements. There is only a little 
evidence suggesting a role for the SNAREs in endocytosis and reports are 
contradictory. Knock down of VAMP2 leads to a diminished response in the 
replenishment of readily releasable vesicles although, the overall number of pre-
synaptic vesicles is unchanged [203]. A role for SNAP25 and VAMP2 in slow 
clathrin-mediated endocytosis is suggested [204] although, the role for SNAP25 is 
contradicted in other studies [205].  
 
1.3.3. α-synuclein, SNAREs and neurodegeneration 
1.3.3.1. SNAREs and α-synuclein in vesicle pool maintenance 
α-synuclein is thought to play a role in synaptic transmission by the tempering of 
neurotransmission release through the supervision of SNARE complex assembly 
[141] and a role for α-synuclein is proposed in the maintenance of vesicle numbers 
[206, 207].  
Partial α-synuclein knock down shows a reduction in the resting pool of vesicles but 
the number of docked vesicles is unchanged [139]. A mouse null α-synuclein model, 
had a significant decrease in the number of vesicles, in the resting pool of the 
hippocampus and vesicle replenishment was not readily available following repeated 
stimulation, leading to synaptic depression [206]. Thus, presenting a role for α-
synuclein in the maintenance of the pool of resting synaptic vesicles. 
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1.3.3.2. α-synuclein in SNARE complex assembly and exocytosis 
Age-dependent re-distribution of SNAP25, syntaxin and VAMP2 in a mouse model 
with C-terminal truncated α-synuclein is observed [208]. Triple-synuclein knock down 
sees a VAMP2 decrease in an age-dependent manner [141] but not when α-
synuclein knockdown occurs alone [139]. Pre-synaptic accumulations of α-synuclein 
in addition to re-distributed SNARE proteins lead to synaptic failure associated with a 
decline in exocytosis and reduced dopamine release. Importantly, α-synuclein also 
chaperones the assembly of the SNARE complex by both binding to phospholipids 
by its NTD and via it’s CTD binding to the NTD of VAMP2 [141] (Figure 12, A-D). 
 
Figure 12 – An overview of SNARE complex formation 
α-synuclein NTD anchors to the vesicle and its CTD binds to the VAMP2 NTD (A-B), this 
interaction stabilises the SNARE complex enabling VAMP2 to bind to syntaxin and SNAP25 
(C). Fusion of the vesicle with the plasma membrane enables neurotransmitter exocytosis (D).  
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1.3.3.3. SNARES, α-synuclein and neurodegeneration: 
The pre-synaptic terminal is increasingly linked to the initial location for the onset of 
neurodegeneration. Much focus has been given to examining the roles of pre-
synaptic proteins to help elucidate the mechanisms that lead to synaptic de-
regulation. VAMP2 has been shown to be decreased in DLB but increased in PDD 
[209]. The authors correlated the changes with the duration of dementia suggesting 
that an increase in VAMP2 may be an early compensatory mechanism at the 
synapse to overcome the toxic insults of α-synuclein. This is interesting as VAMP2 
has been associated with replenishment of the pool of vesicles [203], a role also 
suggested for α-synuclein, indicating a compensatory effect. 
α-synuclein pathology that occurs at the distal axon can proceed to cause retrograde 
degeneration [210]. In a rat model of PD, the levels of α-synuclein pathology reflect 
the dopaminergic terminal loss in the basal ganglia which parallels the reduced 
levels of dopamine available in the region, indicating a possible retrograde dying-
back process [211]. α-synuclein may have multiple roles at the pre-synapse that 
include chaperoning and maintaining the integrity of the distal pool of vesicles. 
Dysregulation in these functions may underlie or contribute to neurodegenerative 
processes in an age-dependent manner. The knowledge that triple knock out models 
has a greater impact on the SNARE proteins than single knockout models requires 
further exploration, examining the potential of synuclein and family protein 
redundancy behaviours. 
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1.4. Synuclein regulation of Autophagy and neurodegeneration 
Eukaryotic cells have two main pathways for degradation, lysosomal proteolysis and 
the ubiquitin-proteasome system (UPS). The UPS system is primarily responsible for 
the degradation of short-lived proteins that have been tagged with UB [212]. 
Lysosomal proteolysis incorporates several pathways including endocytic pathway, 
whereby extracellular components and plasma membrane are delivered directly to 
the lysosome and the autophagy pathway (reviewed by [213]). 
Autophagy per se embodies three individual processes: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA).  Microautophagy refers 
to the invagination of the endosomal or lysosomal membrane, enabling direct 
engulfment of the target substrate from the cytoplasm, which is then degraded by 
lysosomal proteases  [214]. CMA is mediated by chaperone proteins enabling the 
passage of proteins into the lysosomal lumen [215]. Macroautophagy sees the 
sequestering of components targeted for degradation by an autophagosome, this 
fuses with a lysosome, containing proteases that lead to the degradation of the 
autophagosome contents  [216]. Macroautophagy is a bulk process that is able to 
degrade cytoplasmic proteins that have served a long-life in addition to aged and 
superfluous cellular organelles such as the mitochondria  [217] and endoplasmic 
reticulum [218]. The mechanisms described in this chapter will predominantly focus 
on macroautophagy, from here on in, described only as autophagy.  
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1.4.1. The autophagy process 
Saccharomyces cerevisiae is a model that has been extensively manipulated in 
order to elucidate the mechanisms surrounding autophagy. Over 30 ‘autophagy 
related genes’ (ATG) have been identified and are thought to be involved in the 
process, each regulating a different phase of the autophagosome formation [219]. 
The process of capturing cytoplasmic components for degradation occurs by the 
elongation of isolation membranes (phagophores), into doubled-membraned 
autophagosomes that encapsulate the material targeted for degradation [216]. 
Autophagosomes are shuttled to the microtubule-organising centre of the cell via the 
dynein machinery where it will be in close proximity to enzyme containing lysosomes 
[220] for fusion between the lysosome and autophagosome to ensue. Lysosomal 
proteases act on the sequestered cargo and break it down into down into smaller 
components that may be reused by the cell or in the case of protein aggregates, 
degraded in an attempt to prevent cellular dysfunction (Figure 13). 
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Figure 13 - An overview of the autophagy process 
Substrate is tagged by UB (1) and recognised by p62 (2). mTOR is inactivated, dis-inhibiting 
ULK 1/2 (3) which is free to form the ULK complex on the phagophore (4). The ULK, Atg and 
Beclin complexes enable initiation and nucleation of the phagophore that will encapsulate the 
cargo destined for degradation. PE is conjugated to LC3-I (5), LC3-II binds the autophagosome 
and participates in the elongation process. The autophagosome is shuttled close to the 
lysosome (6) and autophagosome-lysosome formation occurs via fusion (7); thus, enabling 
enzymes access to the cargo for degradation. 
 
1.4.1.1. Cargo delivery 
Autophagosomes can non-selectively (in the case of starvation) and selectively 
sequester cytosolic components. The selection process is not fully understood 
although it is thought that cargo destined for degradation is tagged with UB. Protein 
aggregates are recognised by UB-binding receptors (UBR)  such as p62, a 
multimodal adapter able to non-covalently bind to UB [221]. Concurrent binding of 
p62 to UB and ubiquitin-like (UBL) proteins associated with the autophagosome, will 
effectively deliver the cargo to the nascent autophagosome [222].  
73 
 
1.4.1.2. Autophagy regulation and initiation 
The upstream modulator of autophagy, the (mammalian) target of rapamycin 
(mTOR) is a negative regulator of autophagosome formation by inhibiting UNC51-
like kinase (ULK) 1 and 2 [223]. mTOR inactivation and resulting suppression are 
induced by various stress signals (reviewed by [224]). Once mTOR is inactivated, 
activation of ULK 1 and ULK2 occurs proceeding in the direction of autophagy; 
ULK1/2 is free to form the ULK complex initiating the extension of the phagophore 
that sequesters portions of the cytoplasm associated with the target cargo, forming 
an autophagosome. The process of autophagosome biogenesis involves - initiation, 
nucleation and elongation of the membrane.  
The phagophore, a double membraned, small vesicular sac is destined to form the 
autophagosome [225]. The Atg proteins are crucial for initiating the formation of the 
autophagosome [226] this elaborate formation occurs at the phagophore assembly 
site, here the ULK complex gathers in order to begin the formation of the 
autophagosome. This complex comprises of ULK1/2, Atg13, FAK family kinase 
interacting protein of 200kDa (FIP200) and Atg10 ) and transmembrane At99 
(reviewed by [227]). The activated ULK1 complex translocates to a region within the 
ER where it proceeds to activate a class III PI3K complex that consists of Beclin 1, 
vacuolar protein sorting 15 (VPS15), VPS34, AMBRA1 and ATG14 [227].  
1.4.1.3. Nucleation 
Activation of the ULK1 complex and the class III PI3K complex stimulates 
phosphatidyl-inositol 3-phosphate (PI(3)P) production, essential for phagophore 
elongation and the recruitment of other Atg proteins. Beclin 1 is necessary for the 
localisation of proteins involved in autophagy to couple with the phagophore and is 
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dependent on PI3KC (Vsp34) to form the complex that is composed of Beclin 1-
Vsp34-Vsp15 [228].  
1.4.1.4. Elongation 
Membrane elongation requires the recruitment of complex Atg12-Atg5-Atg16 [229]. 
This enables the lipidation of microtubule-associated protein 1 light chain 3 
(LC3B/Atg8) with phosphatidylethanolamine. Atg7 is an important facilitator in 
autophagosome formation; it acts as an E1-like activating enzyme [230] for UBL 
proteins, Atg12 and LC3; activation of the UBLs by Atg7 ensures their transfer to an 
E2 enzyme to support their final destination. Early in autophagosome formation, Atg7 
will bind to Atg12 thus ensuring its transfer to Atg5, where a complex is formed 
between Atg12- Atg5. The complex forms a larger complex with Atg16 and is 
localised to the elongating phagophore where it acts as an E3 enzyme during the 
process of LC3-I lipidation [231]. 
LC3B is expressed as a full-length protein, however, upon stimulation of autophagy, 
the CTD of the LC3 precursor is proteolytically cleaved by Atg4, to form LC3-I [232]. 
LC3-I requires lipidation in order to become the active form of LC3 that is known as 
LC3-II. The Atg12- Atg5- Atg16 complex facilitates the transfer and conjugation of 
LC3-I to phosphatidylethanolamine (PE) [231]; during lipidation, Atg7 activates LC3. 
LC3-I-PE is then localised into the phagophore double membrane where it will be 
responsible for the recruitment of essential components of autophagy [233] including 
the proteins that associate with the cargo destined for degradation.  
The Atg12-Atg5-Atg16 complex dissociates from the membrane once the 
autophagosome is formed  [234]. A role for LC3 has been implicated in the closure of 
the autophagosome [177], creating a possible role for LC3-II in the later stages of 
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elongation and development of mature autophagosomes. The making of a fully 
enclosed autophagosome with encapsulated cargo is essential to ensure isolation 
from the cytosol and efficient passage to the lysosome.  
1.4.1.5. Autophagosome-lysosome fusion 
Once the autophagosome has formed and sealed it is ready to be fused to the 
lysosome, it will be shuttled along microtubules to the microtubule-organising centre 
using the kinesin and dynein motor proteins.  A trans-SNARE complex, including 
members syntaxin 17 and SNAP29, enables the fusion of endosome or lysosomes 
with the autophagosome [235] leading to degradation of the cargo. 
This is a finely tuned process that is still being explored; efficiency is needed at each 
step in the pathway to ensure that autophagy proceeds to completion. 
1.4.2. Synucleins and autophagy-lysosomal degradation pathways 
1.4.2.1. α-synuclein  
The α-synuclein protein under normal physiological circumstances, is degraded by 
both the proteasomes and lysosomes [236] [237].  Pathological α-synuclein may 
impair all three of these degradation pathways leading to cellular accumulations.  
Monomeric α-synuclein can be degraded by the proteasome in a non-UB dependent 
manner [238] indicating that ubiquitination of the protein is potentially a pathological 
event [239]. In this regard, LBs are rich in UB [240] and UPS impairment is seen in 
PD brains [241]. Moreover, PTM species of α-synuclein obstruct the transition of 
PTM α-synuclein, into the lysosomal lumen [242] and mutant forms of α-synuclein, 
such as A30P and A53T, identified in familial PD, impair CMA and may also favour 
the autophagy pathway [237]. Ubiquitin-carboxy terminal hydrolase L1 (UCHL-1)  
[243] and Parkin [244] are both enzymes involved in the UPS, Parkin has been 
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associated with the early onset form of PD and although a UCH-L1 mutation was 
thought to have been implicated, this was in one family only and has not been further 
validated; interestingly however, UCH-L1 levels are reduced in the DLB cerebral 
cortex [245]. This provides evidence for the involvement of multiple pathways related 
to the removal or degradation of modified proteins and/or accumulations in DLB, the 
failure in these mechanisms builds the platform for LB formation.  
Collectively, when considering the pathways involved in clearance of α-synuclein and 
other aggregation - prone proteins, it is likely that multiple pathways may exist in 
parallel, those operating at basal levels and those in response to changes in the 
microenvironment. Autophagy is the major degradation pathway for nonspecific and 
bulk degradation of intracytoplasmic components and it is entirely feasible that if the 
UPS and CMA attempt of clearance of the aberrant fail, the balance tips in favour of 
the autophagy pathway.  
1.4.2.2. β-synuclein  
Mutant β-synuclein P123H and V70M has been shown to induce lysosomal with the 
production of cytoplasmic inclusions similar to those observed in lysosomal storage 
disorders, such as Gaucher’s disease, the phenotype is exacerbated in the presence 
of modified α-synuclein [168]. PD [246] and DLB [247] are linked to a lysosomal 
storage disorder, Gaucher’s disease by mutations in the glucocerebrosidase (GC) 
enzyme. The high homology between β-synuclein and α-synuclein may provide the 
basis for mutant β-synuclein that enables it to act in a similar manner to its 
counterpart and that the presence of both proteins together may act in a cumulative 
manner in α-synucleinopathies.  
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1.4.3. Autophagy and neurodegeneration 
In the event that autophagy is disrupted, the accumulation of proteins targeted for 
degradation will be seen with enlarged and increased numbers of autophagosomes 
and neurodegenerative phenotypes [248]. Defects in the autophagy pathway have 
been observed in neurodegeneration with the amassing of autophagic vacuoles in 
DLB [249] and PD  [250].  
Dysfunction at various stages of the autophagy pathway is associated with 
neurodegeneration, reduced levels of Beclin 1 has been identified in the brains of AD 
patients  [251], mTOR and LC3 are increased in the DLB temporal cortex and Atg7 is 
decreased [249]; the increase in mTOR and LC3 was more profuse in neurons 
exhibiting α-synuclein pathology with the additional presence of an increase and 
enlargement of autophagosomes.  Further neurodegenerative phenotypes are seen 
in knock down models of Atg7’s alone [252]. The absence of the E1-like activating 
enzyme Atg7 would lead to mis-localisation of Atg12 to Atg5, required for lipidation of 
LC3-I therefore, conjugation of PE to LC3-I would be disabled, resulting in the lack of 
recognition of cargo carried by p62 and the potential disruption in autophagosome 
closure and maturation. 
Finally, in the event that the fusion between the autophagosome and lysosome 
proceeds, it is crucial that the lysosome containing catalytic enzymes are in situ. The 
lysosome integral protein 2 (LIMP2) acts as a receptor and is crucial in targeting the 
GC enzyme to the lysosome [253] in addition to endosome/lysosome biogenesis  
[254]. The genetic linkage of LIMP2 has been associated with DLB [96] and 
mutations in the GC-encoding gene, GBA are associated with LB disorders, 12% of 
PD patients have the GBA mutation [247] implicating a role for both the enzyme and 
78 
 
its receptor in α-synucleinopathies. The mutations of the GBA gene and risk 
associated with α-synucleinopathies highlights the importance of this enzyme in the 
degradation of α-synuclein, the phenotype seen in these neurodegenerative 
conditions underscores the necessity for uninhibited and complete degradation of 
accumulation α-synuclein protein. 
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CHAPTER 2: Materials and Methods 
2.1: Human post-mortem tissues  
2.1.1: Tissue homogenisation 
Fresh frozen tissues (Table 2) from the frontal cortex (BA9), occipital cortex (BA18-
19) and hippocampus, were homogenized using a pestle and mortar in 10X volume 
of Tris-buffer saline (TBS) plus Triton-X (150mM NaCl, 50mM Tris-Hcl, 1% Triton & 
2mM EDTA, pH7.6) and protease inhibitor (cOmplete, EDTA free, Roche). Dounce 
homogenisation was performed in 20 slow strokes. The process was undertaken on 
ice, in a fume hood. The homogenised tissue was centrifuged at 3000rpm, at +4ºC 
for 10 minutes and the pellet discarded. The supernatant was collected and total 
protein quantification was performed by BCA analysis (Pierce TM) and known 
standards of bovine serum albumin (BSA). Absorbance assessed at 450nm on the 
FLUOstar Omega plate reader (BMG labech). Total lysate then used for WB or 
stored at -80◦C. 
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ID 
 
Clinical 
diagnosis at 
death 
Pathological 
diagnosis 
Gender Age  PMI 
Disease 
duration 
Braak 
stage 
tau  
 
Braak 
stage 
LB 
PDC016 Pneumonia 
Ageing-
related 
changes 
F 91     2 0 
PDC022 Lung cancer 
Mild age-
related 
changes 
M 75     3 0 
PDC23 N/A 
Mild age-
related 
changes 
F 78 23   2 0 
PDC24 N/A 
Mild age-
related 
changes 
F 68     2 0 
A002 N/A 
Mild age-
related 
changes 
M 90 45   1 0 
A114 
Lung 
adenocarcinoma 
Ageing-
related 
process 
M 82 24   2 0 
A261 Colon cancer 
Ageing-
related 
process 
M 63 23   1 0 
A388 Prostate cancer 
Ageing-
related 
process 
M 65 26   1 0 
914 Pneumonia 
normal aging 
changes 
M 96 21   2 0 
918 
Ischemic 
enterocolitis 
Control F 85 13.5   3 0 
927 Prostate cancer 
Control mild 
SVD   
M 78 51.5   2 0 
941 
Chronic kidney 
disease 
Control, 
moderate 
CAA 
M 92 56.5   1 0 
948 Ovarian cancer Mild AGD F 82 36   2 0 
957 COPD Control M 86 44   2 0 
986 Acute leukemia Control M 86 42   3 0 
988 
Pancreatic 
cancer 
Control, 
moderately 
severe CAA   
M 78 56   2 0 
265 AD DLBD F 80 68 4 3 3 
449 N/A DLB  M 84 12.5 2 3 3 
452 
Vascular 
dementia 
Neocortical 
DLB, possible 
AD 
M 82 4 3 3 3 
478 N/A DLB M 78 21 3 3 3 
82 
 
743 N/A 
Mild LBD with 
cortical 
involvement.   
M 86 15 4 3 4 
844 Pneumonia, DLB 
DLB, AGD, 
severe CAA 
M 93 16 8 3 4 
901 N/A 
LBD, vascular 
disease 
M 94 32   3 3 
A028 N/A 
Diffuse 
neocortical 
LBD 
M 81 57 6 3 4 
A273 N/A DLB M 86 8 5 2 4 
A375 N/A 
Diffuse 
neocortical 
LBD 
M 66 40 5 2 4 
PD060 
Dementia with 
hallucinations 
Brain stem 
LBD 
M 84   6 2 3 
PD120 PD 
Brain stem 
LBD 
M 83   4 3 2 
406 AD LBD M 66 23 8 3 6 
1014 N/A DLB/AD M 84 56   3 6 
A010 N/A 
DLB, 
moderate 
CAA 
M 67 35 4 2 6 
N1 N/A LBD M 86 33 8 1 6 
N2 N/A LBD M 73 47 11 3 6 
N3 N/A LBD M 81 26 5 3 6 
N4 N/A LBD M 80 34 10 3 6 
N5 N/A LBD M 71 22 5 3 6 
N6 N/A LBD M 84 72 10 2 6 
PD294 PDD/DLB 
Neocortical 
LBD 
M 78   6 1 6 
Table 2 - Post mortem tissue data 
Details of post-mortem tissues used for the study. AD (Alzheimer’s disease), AGD 
(argyrophilic grain disease), CAA (cerebral amyloid angiopathy), COPD (chronic obstructive 
pulmonary disease), DLB (dementia with Lewy Bodies), dLBD (diffuse Lewy body disease), PD 
(Parkinson’s disease), PDD (Parkinson’s disease with dementia), LBD (Lewy Body disease), 
MMSE (mini mental state examination). 
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2.1.2: Fluorescent Immunohistochemistry 
Formalin fixed paraffin embedded tissues were de-paraffinised in Xylene for 2X 5 
minutes and re-hydrated in a serial dilution of ethanol (100%, 95%, 70% & 50%) 
each for 2 minutes. Sections were washed briefly with H2O before tissue 
equilibration with phosphate buffer saline (PBS) (1.3MNaCl, 70mM Na2 HPO4 & 
30mM NaH2 PO4, pH 7.6) for 5 minutes. Auto fluorescence was quenched with 
Sudan black (Sigma, 4197-25-5) (0.1% Sudan black in 70% ethanol) for 10 minutes 
before washing (Figure 14- A-H). Antigen retrieval was performed by boiling in the 
microwave with 10mM citrate buffer (pH6.0) for 30 mins at 700watts. Tissue sections 
were blocked with 5% of corresponding serum for 1 hour at room temperature (RT) 
and incubated overnight with primary antibodies (table 3) or without primary 
antibodies. Incubation with Alexa Fluor conjugated secondary antibodies (Table 4) 
and nuclear stain hoerscht (New England Biolabs, UK) [1:1000] was performed for 1 
hour at RT, tissues were cover slipped and mounted with Perma Fluor (Thermo 
Scientific, TA-006-FM). All washes were performed with PBS and antibodies diluted 
with PBS + 0.03% Triton X. The fluorescent signal from the tissue sections was 
visualised using the Leica Confocal Microscope. Secondary only antibodies in the 
cortical regions, hippocampus and substantia nigra were visualised (Figure 14-I-Q). 
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Figure 14 - Sudan black quenching of auto fluorescence and double, 
secondary antibody only controls  
Quenching of auto fluorescence in the basal ganglia of the human brain using 0.1% Sudan 
black (A-D). Non-primary antibody controls in the double immunofluorescent protocol. A non-
primary antibody control to examine non-specificity of secondary antibodies following 
incubation with two secondary antibodies simultaneously. Three brain regions were examined: 
the hippocampus (I-K), cortex (L-N) and substantia nigra (I-Q). Emission/excitation wave 
lengths of each channel – DAPI: 350nm/470nmm; Alexa: 488 (FITC) 490nm/525 nm; Alexa 568 
(Tex Red): 578nm/603nm. 
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2.1.3: Manders overlap Coefficient analysis of co-localisation 
Manders coefficient (M1 and M2) was performed for quantification of co-localisation 
of two proteins. The mean coefficient value was established from the analysis of 10 
Z-stacks, per patient, using the Coloc2 plugin from Fiji freeware (FIJI - Image J 
software (NIH, USA).  Each image was split into two channels, green and red for our 
proteins and regions of interest. Background was subtracted and Costes 
randomisation was 10. 
2.1.4: DAB Immunohistochemistry 
Formalin fixed paraffin embedded tissues (6um) were de-paraffinised in Xylene for 2 
X 5 minutes and then re-hydrated in a serial dilution of ethanol (100%, 95%, 70% & 
50%) each for 2 minutes. Sections were washed briefly with H2O before tissue 
equilibration with TBS for 5 minutes. Antigen retrieval was performed by boiling in 
the microwave with 10mM citrate buffer (pH6.0) for 30 mins at 700watts unless 
otherwise described. 5G4 pre-treatment involved Tris-EDTA (198mM Tris-base & 
6.84mM EDTA) for 30 mins at RT minutes and 10% formic acid for 3 minutes. 
Endogenous peroxidase activity was quenched with a TBS buffer containing 3% 
H2O2, 20% methanol and 0.1% Triton X for 45 minutes. Tissue sections were 
blocked with 5% of corresponding serum for 1 hour at RT and incubated overnight 
with primary antibodies at +4ºC. On day 2, the Vectorstain Elite ABC system was 
used: secondary biotinylated antibodies were applied for 1 hour (Table 3) followed by 
avidin & biotin [1/200] for 1 hour, both at RT. Tissue sections were washed with TBS 
before applying the substrate, 3,3'-Diaminobenzidine (DAB). Tissue sections were 
washed with H2O before applying Mayer’s haemotoxylin (Thermo Scientific, 
TA125MH) for 1-2 minutes. Sections were again washed in H2O before air drying 
overnight and cover-slipping with DPX mountant (Sigma, 44581). 
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2.1.5: Scoring β-synuclein positive cells 
Following IHC, confocal analysis of cells positive for β-synuclein immunoreactivity 
was performed by randomly selecting ≥six areas throughout the cortical region, to 
achieve a minimum threshold of 100 neurons per patient. Cells were considered β-
synuclein-positive with the appearance of strong β-synuclein immunoreactivity. The 
number of cells that are positive for β-synuclein are presented as a percentage of the 
total number of nuclei. 
2.1.6: Pre-absorption 
DAB immunohistochemistry was performed as described. Primary antibody, β-
synuclein (0.096 mg/ml) and equivalent recombinant β-synuclein protein were co-
incubated overnight with rotation. This antibody-antigen complex was added to the 
control slide at the primary antibody stage (Figure 15-A). Brightfield microscopy 
produced virtually no visual signal of β-synuclein in the tissues where pre-absorption 
was performed. The control slide was treated with β-synuclein antibody (Figure 15-B) 
without pre-absorption. 
 
Figure 15: Pre absorption of the β-synuclein antibody 
The β-synuclein antibody was incubated with (A) or without (B) β-synuclein recombinant 
protein to validate the specificity of the antibody. 
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2.1.7: Western blotting 
Tissue homogenate proteins were separated by sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE), using a 12-14% gel, dependent on protein size. 
Electrophoresis was performed at 120V for 1 hour and transferred to a 0.2uM 
polyvinylidene difluoride (PVDF) at 15V for 1.30 hours, both at RT. Membranes were 
blocked in 5% skimmed milk and TBS-T 0.05% tween for 1 hour and then incubated 
with primary antibodies (Table 3) overnight at +4ºC with rotation. The membranes 
were washed 3 X 30mins and HRP-conjugated secondary antibodies (Table 4) were 
applied at RT for 1 hour. The membranes were exposed to detection Amersham 
Prime ECL western blotting detection reagent (Fisher, 10308449) for 1 minute. Data 
was analysed by measuring the density of the specific band on the immunoblot using 
Image J software (NIH, USA) and presented as a ratio to the corresponding β-actin 
density. Washes were performed with TBS and antibodies diluted in TBS+ 0.05% 
Tween. 
2.1.8: Synaptosomal isolation 
Synaptosomal isolation was performed using the SynPer ™ (Thermo Scientific) 
synaptic protein extraction kit (Figure 16). Samples were homogenised using a hand-
held pestle and mortar, on ice, in a fume hood with 10X the sample volume of the 
SynPer reagent and protease inhibitors. Dounce homogenisation was performed in 
10 slow strokes. The homogenate was centrifuged 1200 × g for 10 minutes at 4°C. 
The pellet was discarded and total protein quantification was performed by BCA 
analysis (Pierce TM) and known standards of bovine serum albumin (BSA). A sample 
of the supernatant was taken for the total protein fraction analysis. The supernatant 
was further centrifuged at 15,000 × g for 20 minutes at 4°C and the cytosolic fraction 
was collected for analysis. 300-500μl of SynPer was used to resuspend the 
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synaptosome pellet. Western blot analysis was performed, or the samples were 
frozen at -80◦C. 
 
Figure 16 - Synaptosomal isolation optimisation 
100mg of mouse cortical brain lysate homogenised and probed for neuronal marker NeuN and 
synaptic marker SNAP25. NeuN was barely visible in the synapse rich fraction and SNAP25 
was abundant in this fraction.  
 
2.1.9: ELISA 
2.1.9.1: Oligomeric α-synuclein (5G4): The AnalytikJena human α-synuclein patho 
ELISA kit (0104000108) was used for this enzyme immunoassay. 50ug of total brain 
homogenate per patient was assayed by ELISA for 5G4 immunoreactivity. Antibody 
and homogenate were incubated overnight at RT and shaking at 300rpm. Following 
washing the samples were incubated in the dark at RT with 3,3’,5,5’-
Tetramethylbenzidine (TMB) and peroxide. Following termination of the reaction, the 
plate was briefly shaken and absorbance was read at the FLUOstar Omega plate 
reader (BMG labech) at 450nm and 650nm reference wavelength. 
2.1.9.2: β-synuclein: The Abexxa (abx055444) human β-synuclein (SNCB) ELISA 
kit was used for quantitative detection of β-synuclein in the human brain lysates. 
30ug of total brain homogenate per patient was assayed by ELISA for β-synuclein 
immunoreactivity. Samples were added to the plate and incubated for 30 mins at 
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37◦C. Following washing HRP conjugated anti-β-synuclein secondary antibody was 
added to the samples and incubated for 30 mins at 37◦C. Subsequent washing was 
followed by the addition of the TMB substrate and the plate was shaken for 30 
seconds before being incubated at 37◦C for 15 minutes. Once the reaction was 
terminated, absorbance was read (450nm) on the FLUOstar Omega plate reader 
(BMG labech).  
2.2: In vitro work 
2.2.1: Cell culture maintenance: BE(2)-M17 cells and Hela cells 
Cells were grown in Dulbecco’s Modified Medium (DMEM) (Gibco) with 10% fetal 
bovine serum (FBS)/ 5% penicillin/streptomycin and incubated at 37ºC with 5% CO2. 
Media was changed every 48-72 hours. 
Hela cells were gratefully received from Dr. Shouqing Luo’s lab - Peninsula School of 
Medicine, University of Plymouth. 
2.2.2: Cell culture maintenance: Inducible N27 (iN27) cells 
N27 rat dopaminergic neuronal cells were grown in Roswell Park Memorial Institute 
(RPMI) media with 10% fetal bovine serum (FBS), 1% Geneticin® reagent, G418 
and 0.4% hygromycin antibiotic. The media was changed every 48 hours.  
N27 cells were gratefully received from Prof Kim Tieu’s lab - Florida International 
University (FIU) Miami, Florida. 
2.2.3: Induction of human α-synuclein in iN27 
The expression of human α-synuclein was under the regulation of two vectors: vector 
pEGSH is PonA inducible and consists of SP1 and minimal heat shock promoter. 
PERV3 is under the CMV promoter, a positive control reporter. 
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Cells were treated with 1mM PonA to induce expression of human α-synuclein (h-α-
synuclein), 24 hours post plating. Control cells were treated with the equivalent 
volume of 100% ethanol. Cells were collected at 24, 48 and 72 hours post induction 
(h.p.i) of human α-synuclein (Figure 17) for western blot or ICC. 
 
Figure 17 - Time course for human-α-synuclein expression in iN27 cells 
Time course schematic of human-α-synuclein gene expression in iN27 cells. Gene is induced 
24 hours post plating of cells and cells are harvested at 24 hpi, 48 hpi & 72 hpi. 
2.2.4: Immunocytochemistry 
Cells were plated on coverslips coated with 50ug/ml poly-L-lysine (PPL) (Sigma, 
P1399) on day 1 at a density of 7 X 104 in a 24-well plate. Upon collection of cells at 
various time points, cells were fixed with 4% paraformaldehyde for 15 minutes, 
washed with PBS and blocked with 5% of appropriate serum for 1 hour. The fixed 
cells were incubated overnight with primary antibodies at +4ºC (Table 3).  Following 
appropriate washing, the fixed cells were incubated with both Alexa Fluor conjugated 
secondary antibodies (Table 4) and hoerscht [1/1000], for nuclei staining. After 
appropriate washing, cover slips were mounted onto slides with Perma Fluor. All 
washes were performed with PBS and antibodies diluted with PBS + 0.03% Triton X. 
3 repeats were performed unless otherwise stated. 
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2.2.5: Scoring β-synuclein positive or negative cells for human-α-synuclein 
levels 
The detection of h-α-synuclein (Syn204) immunofluorescent intensity was analysed 
using FIJI - Image J software (NIH, USA). Cells that were positive and negative for β-
synuclein were examined for Syn204 immunoreactivity and the corrected total cell 
fluorescence (CTCF) was expressed in arbitrary units (AU). CTCF = integrated 
density – (area of selected cell × mean fluorescence of background readings). 
Subtraction of any background intensity was applied. In order for β-synuclein positive 
cells to be considered, a threshold of a mean-grey intensity density in excess 
of >200 AU (arbitrary units) for the region of interest (ROI) was set or the cells were 
excluded from the analysis. A minimum of 100 cells per group were analysed from 3 
experimental repeats.  
 
2.2.6: DNA transfection 
Cells were grown in Roswell Park Memorial Institute (RPMI) media with 10% fetal 
bovine serum (FBS), 1% Geneticin® reagent, G418 and 0.4% hygromycin antibiotic. 
Cells were plated on day 1 and treated with β-synuclein (N27: 0.5μg & Hela: 0.25μg) 
(jetPRIME® polyplus DNA) on day 2 and media was changed after 4 hours.  
2.2.6.1: Hela cells on day 4 cells were harvested and lysed with NP40 and a 
protease inhibitor in preparation for western blot analysis or fixed. Three repeats 
were performed. 
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2.3: Microscopy 
Human brain fluorescent imaging was performed on the Leica TCS SP8 microscope; 
in vitro imaging was conducted on the Zeiss LSM 510meta or Leica TCS SP8 
microscope and Brightfield images were taken on the Leica MC170HD microscope. 
2.4: Statistics 
Statistical analysis was performed using the analysis of variance (ANOVA) and/or 
the Student's t-test. Bonferroni posthoc test was applied where necessary. A 95% 
confidence interval was applied P< 0.05 (*), P< 0.01 (**) and P<0.001 (***). 
GraphPad Prism (version 5.01) software was used to perform statistical analysis and 
graphical representations of the data. 
2.5: Primary and secondary antibody concentrations (see table 1 & 2) 
2.6: Reagents  
All reagents and chemicals were from ThermoFisher (UK) unless otherwise stated. 
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Table 3 - Primary antibodies and technique dependent concentrations 
 
 
Technique Dilution Supplier 
Rabbit anti- β-synuclein Western blot 1/1000 Abcam (ab76444) 
 ICC 1/250  
 IHC 1/250  
Mouse anti-β-synuclein ICC 1/250 Millipore (36-009) 
Mouse anti-α-synuclein 
(Syn1) 
Western blot 1/1000 BD Biosciences (610787) 
 ICC 1/250  
Mouse anti-oligomeric 
alpha-synuclein (5G4) 
IHC 1/2000 Millipore (MABN389) 
Mouse anti-α-synuclein 
(Syn204)  
 1/500 Abcam (ab3309) 
Mouse-anti-beta actin Western blot 1/5000-10,000 Sigma, A5441 
Rabbit anti-LC3B Western blot 1/1000 Novus Biologicals (NB100-
2220) 
 ICC 1/500  
 IHC 1/500  
Rabbit anti-p62 Western blot 1/1000 MBL, PM045, 1/1000 
 IHC 1/500  
Rabbit anti-LIMP2 Western blot 1/1000 ThermoFisher (PA5-20540) 
 IHC 1/500  
Mouse-anti-synaptophysin Western blot 1/5000 Cell signaling (12270) 
Mouse anti-SNAP25 Western blot 1/2000 Abcam 
 IHC 1/500  
Rabbit anti-VAMP2 Western blot 1/500 Cell signalling (14811) 
 IHC 1/500  
Mouse anti-syntaxin IHC 1/500 Gifted by Bristol labs  
Mouse NeuN WB 1/500 Gifted by Dr Bing Hu (UoP) 
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Secondary Antibody Technique Dilution Supplier 
Alexa Flour 488 - conjugated 
to anti-mouse IgG antibody 
IHC/ICC 1/1000 Invitrogen Molecular 
Probes 
Alexa Flour 488 - conjugated 
to anti-rabbit IgG antibody 
IHC/ICC 1/1000 Invitrogen Molecular 
Probes 
Alexa Flour 568 - conjugated 
to anti-mouse IgG antibody 
IHC/ICC 1/1000 Invitrogen Molecular 
Probes 
Alexa Flour 568 - conjugated 
to anti-rabbit IgG antibody 
IHC/ICC 1/1000 Invitrogen Molecular 
Probes 
HRP - conjugated to anti 
mouse IgG 
WB 1/10,000 Amersham, ECL  
HRP - conjugated to anti rabbit 
IgG 
WB 1/10,000 Amersham, ECL 
Biotinylated Goat Anti-Mouse 
IgG 
IHC 1/200 Vector laboratories 
(BA-9200) 
Biotinylated Goat Anti-Rabbit 
IgG Antibody 
IHC 1/200 Vector laboratories 
(BA-1000) 
Table 4 - Secondary antibodies and technique dependent concentrations  
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3.1: AIMS OF THE PROJECT 
α-synuclein has been extensively examined in α-synucleinopathies, with modified 
and aggregated α-synuclein species being a primary feature of LBs and LNs. 
Moreover, aggregated α-synuclein appears to affect SNARE protein complex 
formation and function and the autophagy process of protein degradation. Family 
member, β-synuclein has been largely left unexplored. It is feasible that changes in 
β-synuclein protein levels may decrease its innate anti-fibrillisation effect on α-
synuclein. These changes may be crucial for processes underlying the pathological 
function of α-synuclein, such as synaptic failure and protein degradation defects. If β-
synuclein levels are diminished the pursuance of α-synuclein aggregation in DLB 
may proceed unabated.  
3.1.1: Aim 1 of this project is to examine levels and the distribution of β-synuclein in 
the DLB brain. The pathological spread of LBs is seen throughout the brain and in 
order to fully elucidate the role of β-synuclein, DLB pathologically relevant brain 
regions were examined for β-synuclein changes, to be correlated with any changes 
in α-synuclein species.  
3.1.2: Aim 2 is to examine key SNARE protein distribution in DLB brain tissues and 
to correlate this with changes in β-synuclein. It is possible that β-synuclein may take 
on a compensatory role in the event of loss of a monomeric α-synuclein function. 
3.1.3: Aim 3 is to study a role of β-synuclein in the autophagy-lysosomal protein 
degradation pathway. For this, I will examine autophagy-lysosomal markers in 
human DLB tissues and in vitro models of β-synuclein overexpression and a stable 
cell line expressing the mRFP-GFP-LC3 tandem construct. This data will be 
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correlated with β-synuclein. Changes in autophagy are observed in 
neurodegenerative conditions, including DLB and mutant β-synuclein has been 
shown to induce lysosomal dysfunction. Clearance of aggregates or toxic proteins is 
critical to cell survival and therefore, the examination of β-synuclein in relation to key 
autophagy related proteins is necessary in the human brain. 
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Results chapter 4: β-synuclein and α-synuclein in the human brain  
β-synuclein is an abundant pre-synaptic protein seen throughout most regions of the 
human brain. There is evidence supporting a neuroprotective role for β-synuclein 
with its ability to prevent fibrillisation of α-synuclein [124], reduce the rate of mutant 
α-synuclein fibril formation [179]  and reduce the number of α-synuclein inclusions 
and associated motor deficits in a mouse-PD model [178]. Whilst β-synuclein and α-
synuclein have a similar pattern of distribution throughout the brain, when compared 
to α-synuclein, mRNA expression levels of β-synuclein are more elevated in the 
cortex and cerebellum in the control brain [133]. In contrast, in DLB there is a 
decrease in some cortical regions of β-synuclein mRNA [98]. Due to the neuro 
protective qualities bestowed by β-synuclein, a decline in its protein levels will enable 
the pursuance of α-synuclein aggregation and the formation of LBs and LNs, 
promoting the neuropathology associated with DLB. This study aimed to identify any 
changes in the levels and distribution of the β-synuclein protein in the DLB human 
brain when compared to the control. The changes were correlated with α-synuclein 
protein levels thereby enabling the elucidation of synuclein proteins modifications in 
DLB.  
4.1: β-synuclein and α-synuclein protein levels in the human brain  
The frontal cortex (BA9), occipital cortex (BA18/19) and hippocampal regions were 
examined. These areas were selected due to the neocortical and subcortical 
degeneration observed in neurodegenerative conditions, including DLB [61, 255].  
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4.1.1: Changes in levels of total β-synuclein, α-synuclein and oligomeric α-
synuclein protein in the human brain 
The available literature relating to β-synuclein protein levels in the human brain is 
limited. It is reported that β-synuclein is reduced in the frontal cortex in pDLB and in 
the temporal cortex of DLB with concomitant AD pathology [98], no data for β-
synuclein has been reported for the occipital cortex or hippocampus in DLB. Total 
protein levels in human brain tissue lysates from cortical and paralimbic regions were 
studied by western blot or ELISA in the frontal cortex, occipital cortex and 
hippocampus of controls and DLB patients. 
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Figure 18 - β-synuclein protein is altered in the DLB brain 
Western blot analysis of β-synuclein in the frontal cortex (A): control (n= 9), DLB (n= 17); 
occipital cortex (B): control (n= 10), DLB (n= 18) and the hippocampus (C): control (n= 4), DLB 
(n= 5). In DLB β-synuclein is increased in the frontal cortex (P=0.006) and decreased in the 
occipital cortex (P=0.03). Statistical analysis was performed by the Student’s two-tailed t-test.                  
*: P=<0.05; **: P=<0.01; ***: P=<0.001. 
 
Examination of β-synuclein in the cortical regions and hippocampus shows a 
significant increase in β-synuclein levels in the frontal cortex of DLB patients (Figure 
18-A) (P=0.006) and conversely, a significant decrease observed in the occipital 
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cortex (Figure 18-B) of DLB patients (P=0.03) when compared to controls. There are 
no changes in β-synuclein in the hippocampus (Figure 18-C) although, overall the 
hippocampus appeared to have higher levels of β-synuclein when compared to the 
cortical regions. Examination of monomeric α-synuclein protein levels was next 
performed in the same regions as β-synuclein in order to correlate any changes. 
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Figure 19 - Monomeric α-synuclein is reduced in the frontal cortex of the DLB 
brain 
Western blot analysis of α-synuclein in the frontal cortex (A): control (n= 12), DLB (n= 23); 
occipital cortex (B): control (n= 10), DLB (n= 17) and the hippocampus (C): control (n= 4), DLB 
(n= 5). α-synuclein is decreased in the frontal cortex of DLB brains (P=<0.001). Statistical 
analysis was performed by the Student’s two-tailed t-test. *: P=<0.05; **: P=<0.01; ***: 
P=<0.001. 
 The examination of α-synuclein in the frontal cortex (Figure 19-A), occipital cortex 
(Figure 19-B) and hippocampus (Figure 19-C) showed a significant decrease in the 
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frontal cortex of DLB patients (A) (P<0.001) however, no changes were observed in 
the occipital cortex (B) or the hippocampus (C).  
In order to identify whether changes in β-synuclein are related to the presence of 
pathological α-synuclein species, the levels, of oligomeric α-synuclein, as detected 
by the 5G4 antibody, were quantified in these regions by ELISA. 
 
Figure 20 - Oligomeric α-synuclein is increased in the frontal and occipital 
cortex in the DLB brain 
Enzyme-linked immunosorbent assay (ELISA) of human brain lysates from fresh frozen brain 
tissue. Immuno-detection of oligomeric α-synuclein (5G4) was detected in the frontal cortex: 
control (n= 5) and DLB patients (n= 16). 5G4 immunoreactivity is increased in DLB in the 
frontal cortex (P=0.03); the occipital cortex: control (n= 6) and DLB patients (n= 20) with an 
increase of 5G4 observed in DLB (P=0.004) in DLB. Examination of the hippocampus: control 
(n= 1) and DLB (n= 9) revealed no changes in 5G4. Absorbance was measured at 450nm 
reference 620nm. Absorbance data was converted to total protein concentrations (pg/ml) by 
correlating the absorbance with a standard curve of known concentrations. Statistical analysis 
was performed by one-way-ANOVA and Bonferroni post hoc test. *: P=<0.05; **: P=<0.01; ***: 
P=<0.001. 
 
104 
 
 A significant increase in 5G4 immunoreactivity was observed in the frontal cortex of 
the DLB patients (P=0.03) and the occipital cortex of DLB patients (P=0.004) (Figure 
20). No significant difference was observed between the frontal cortex and occipital 
cortex in DLB.  Statistical analysis on the hippocampus was not performed as the 
control number was set at 1 patient. 
 
4.1.2: Correlations between β-synuclein and α-synuclein or oligomeric α-synuclein 
and β-synuclein and disease duration 
The data in this study shows an increase in β-synuclein in the frontal cortex (Figure 
18-A) that correlates with a decrease in monomeric α-synuclein (Figure 19-A) and an 
increase in oligomeric α-synuclein (Figure 20). Conversely, in the occipital cortex a 
decrease in β-synuclein (Figure 18-B) is associated with an increase in oligomeric α-
synuclein (Figure 20) but no change in monomeric α-synuclein (Figure 19-B). 
Transcriptional interplay between the synucleins is reported, decreased levels of one 
of the synucleins may lead to a transcriptional increase of the other [99]. I next 
wanted to examine the relationship between β-synuclein and α-synuclein at a protein 
level in the frontal and occipital cortex where modifications have been observed. 
Further, I aimed to explore whether the changes in β-synuclein levels may be 
associated with the duration of pathology. Regression analysis was performed using 
the western blot ROD values for Syn1 and β-synuclein and/or ROD β-synuclein in 
accordance with ELISA values for 5G4 and β-synuclein was correlated with disease 
duration as described in the patients’ ID (Table 2).               
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Figure 21 – In the frontal cortex a correlation exists between β-synuclein and 
α-synuclein and β-synuclein with disease duration.  
Linear regression analysis: α-synuclein and β-synuclein ROD values in the Controls and DLB 
frontal cortex (A & C): (n= 8 & n= 19, respectively; occipital cortex (B & D) (n= 7 & n=12, 
respectively). β-synuclein (ROD) and 5G4 (pg/ml) in the frontal cortex (E) (n= 16) and the 
occipital cortex (F) (n= 20). β-synuclein (ROD) and disease duration (years) in the frontal 
cortex (G) (n= 17) and the occipital cortex (H) (n= 16). 
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Linear regression analysis on β-synuclein and α-synuclein, as detected by Syn1, 
identified a negative correlation between β-synuclein and syn1 in the frontal cortex 
(Figure 21-A) of the controls (R2 = 0.4); this was indicative of high levels of β-
synuclein correlating with low levels of α-synuclein. Correlation analysis between β-
synuclein and 5G4 levels (Figure 21-E-F) reveal a significant positive relationship in 
the frontal cortex (R2 = 0.44) (Figure 21-E). Higher levels of oligomeric α-synuclein 
positively correlated with higher levels of β-synuclein but no other significances were 
observed. In addition, analysis of β-synuclein in relation to disease duration in the 
frontal cortex showed a low-moderate positive correlation (Figure 21, G) (R2 = 0.2), 
this effect was lost in the occipital cortex. 
 
4.2: The distribution of β-synuclein in the frontal cortex, occipital cortex and 
hippocampus of controls and DLB patients  
Following the identification of alterations in the synuclein protein levels, the β-
synuclein pattern of immunostaining was explored in the frontal cortex, occipital 
cortex and hippocampus. Despite no changes in α-synuclein or β-synuclein having 
been observed in the hippocampus, intergroup variation was seen. In addition, this 
region physiologically has high levels of β-synuclein [76] and DLB patients often 
have concomitant AD pathology, a disease that sees extensive hippocampal 
degeneration. Examination of the control brains was undertaken in the first instance 
to provide a background for comparison to the DLB brain. 
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4.2.1: β-synuclein in the normal human brain  
  
Figure 22 - β-synuclein in the frontal cortex of the control brain 
Immunoreactivity for β-synuclein in the frontal cortex of the control brain (B – F) revealed by 
DAB substrate. Diagrammatic representation of cortical layers (A) and images captured by 
Brightfield microscopy moving from layer I to deeper frontal cortical layers V/VI (B). 
Differential staining of β-synuclein demonstrated by sequential images taken through the 
frontal cortical region (C-F) from Layer I/II (C) to deeper layers V/VI (F). Lowest staining 
intensity is depicted by the area between blue dotted lines (A). Non-Primary antibody control 
(G). N=6 control brains examined for the frontal cortex. Brightfield microscopy and 
magnification X40, scale bar 20μm (C-H) magnification X20, scale bar 50μm (B). 
 
A β-synuclein immunopositive signal was detected throughout all layers (I to VI) in 
the frontal cortex of the control brains (Figure 22-B-F). Staining presented in a 
uniform manner with small granular speckles representing the neuropil. Although 
primarily homogenous, the staining was more prominent in the granular layer II 
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(Figure 22-B-C) and the deeper cortical layers V/VI (Figure 22-B & F). There 
appeared to be strong β-synuclein immunoreactivity around some neurons (Figure 
22-D & E, enlarged). 
 
 
Figure 23 - β-synuclein in the occipital cortex of the control brain  
Immunoreactivity for β-synuclein in the frontal cortex of the control brain (B – F) revealed by 
DAB substrate. Diagrammatic representation of cortical layers (A) and images captured by 
Brightfield microscopy moving from layer I to deeper occipital cortical layers V/VI (B). 
Differential staining of β-synuclein is demonstrated by sequential images taken through the 
occipital cortical region (C-F) from Layer I/II (C) to deeper layers V/VI (F). Lowest staining 
intensity is depicted by the area between blue dotted lines (A). N=6 control brains examined 
for the occipital cortex. Non-primary antibody control for DAB reactivity (G). Brightfield 
microscopy and magnification X40, scale bar 20μm (C-F) magnification X20, scale bar 50μm 
(B).  
Examination of the pattern of β-synuclein immunoreactivity in the occipital cortex of 
the control brain showed that β-synuclein was present in all layers - layer I to VI 
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(Figure 23-B-F). The intensity of staining appeared more intense in layers II-IV 
(Figure 23-C-E) when compared to the deeper cortical layers V and VI (Figure 23-F). 
Darker regions of speckled staining around some neurons were observed throughout 
all layers (Figure 23-D & E, see enlargements).The comparison between the frontal 
cortex and occipital cortex showed that the level of intensity of β-synuclein 
immunoreactivity appears to be lower in the occipital cortex of the control brain.  
 
 
Figure 24 - β-synuclein in the hippocampus of the control brain 
Immunoreactivity for β-synuclein in the hippocampus of the control brain (A – E) revealed by 
DAB substrate. Immunoreactivity was detected in the CA1 (B), CA2/3 (C), CA4 (D) and dentate 
gyrus (E). The regional depiction of β-synuclein in the hippocampus of the control brain (A) - 
CA1 (red), CA2/3 (purple), CA4 (blue) and dentate gyrus (green). β-synuclein is observed in the 
neuropil (#). Lowest staining intensity depicted by the area between blue dotted lines (A). Non-
primary antibody control for DAB reactivity (F). Brightfield microscopy and magnification X10 
(A). Magnification X40, scale bar 20μm (B-E). N=6 control brains examined for the 
hippocampus. Hippocampal region drawing – Adapted from [256]. 
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Examination of β-synuclein was undertaken in the hippocampus of a control brain, in 
CA1 (Figure 24-B), CA2/3 (Figure 24-C), CA4 (Figure 24-D) and dentate gyrus 
(Figure 24-E). Differential regional intensities of immunoreactivity were observed in 
the hippocampus, with the CA1 having the most prominent staining (Figure 24-B) 
and the dentate gyrus, the lowest level of β-synuclein immunoreactivity (Figure 24-
E).  A strong distribution pattern of β-synuclein was observed around the perimeter 
of neurons in the CA1 region (Figure 24-B, enlarged) and varying sized granules 
speckled throughout the neuropil of differing staining intensity (B, #).  
Collectively, the pattern of β-synuclein reactivity differed between the cortical regions 
and the hippocampus in the control brains; there was a unique, more granular and 
intense staining identified in the hippocampus when compared to the neocortex. 
Observations of some positively stained neuronal somata were seen in the cortex of 
the control brains. However, these were absent in the hippocampus, indicative of 
variance in β-synuclein protein distribution patterns between these regions.  
 
4.2.2: β-synuclein in the DLB brain 
Examination of the pattern of β-synuclein immunoreactivity was performed on the 
DLB patients in the frontal cortex, occipital cortex and hippocampus.  
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Figure 25 - β-synuclein is re-distributed in the frontal cortex of the DLB brain 
Immunoreactivity for β-synuclein in the frontal cortex of the DLB brain (B – F) revealed by DAB 
substrate. Diagrammatic representation of cortical layers (A) and images captured by 
Brightfield microscopy moving from layer II (B) to deeper frontal cortical layers V/VI (D). The 
Orange dotted line represents the enlarged region. The arrows depict single stained neurons. 
Differential staining of β-synuclein is demonstrated by sequential images taken through the 
occipital cortical region (E-H) from Layer I/II (E) to deeper layers V/VI (H). Lowest staining 
intensity is depicted by the area between blue dotted lines (A).   N=6 DLB brains examined for 
the frontal cortex. Pre-absorption of β-synuclein antibody was performed to validate the 
specificity of β-synuclein immunoreactivity (Figure 15). Non-primary antibody control for DAB 
reactivity (Figure 22-G). Brightfield microscopy and magnification X40, scale bar 20μm (E-H) 
magnification X20, scale bar 50μm (B-D) 
 
A β-synuclein immunopositive signal was detected throughout all layers (I to VI) of 
the DLB brain (Figure 25-B-H). The staining was not homogenous throughout the 
layers; immunoreactivity was more intense in layers II (E) and deeper layers IV/V 
(G). The neuropil was variable in immunoreactivity and there was frequently 
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neuronal soma positive for β-synuclein immunoreactivity in DLB brains (Figure 25-B-
D). 
 
Figure 26 - β-synuclein is re-distributed in the occipital cortex of the DLB brain 
Immunoreactivity for β-synuclein in the occipital cortex of the DLB brain (B – F) revealed by 
DAB substrate. Diagrammatic representation of cortical layers (A) and images captured by 
Brightfield microscopy moving from layer II (B) to deeper frontal cortical layers V/VI (D). The 
Orange dotted line represents the enlarged region. The arrows depict single stained neurons. 
Differential staining of β-synuclein is demonstrated by sequential images taken through the 
occipital cortical region (E-H) from Layer I/II (E) to deeper layers V/VI (H). Lowest staining 
intensity is depicted by the area between blue dotted lines (A).   N=6 DLB brains examined for 
the occipital cortex. Pre-absorption of β-synuclein antibody was performed to validate the 
specificity of β-synuclein immunoreactivity (Figure 15) and non-primary antibody control for 
DAB reactivity (Figure 23-G). Brightfield microscopy and magnification X40, scale bar 20μm (E-
H) magnification X20, scale bar 50μm (B-D) 
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Having examined β-synuclein in the occipital cortex of a DLB brain, it was revealed 
that β-synuclein is more intensely stained in layers II (Figure 26-E) and deeper layer 
VI (Figure 26-H). β-synuclein positive neurons are present throughout the layers 
(Figure 26-B-D, enlarged and arrows). 
 
 
Figure 27 - Large β-synuclein positive granules are present in the 
hippocampus of the DLB brain 
Immunoreactivity for β-synuclein in the hippocampus of the control brain (A – E) revealed by 
DAB substrate. Immunoreactivity was detected in the CA1 (B), CA2/3 (C), CA4 (D) and dentate 
gyrus (E). The regional depiction of β-synuclein in the hippocampus of the control brain (A) - 
CA1 (red), CA2/3 (purple), CA4 (blue) and dentate gyrus (green). β-synuclein is observed in the 
neuropil (#). Lowest staining intensity depicted by the area between blue dotted lines (A). N=6 
DLB brains examined for the hippocampus.  Pre-absorption of β-synuclein antibody was 
performed to validate the specificity of β-synuclein immunoreactivity (Figure 15) and non-
primary antibody control for DAB reactivity (Figure 24-F). Brightfield microscopy and 
magnification X10 (A). Magnification X40, scale bar 20μm (B-E) Hippocampal region drawing – 
Adapted from [256]. 
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The β-synuclein pattern of staining in the hippocampus of DLB patients (Figure 27-A-
E) showed granular, multi-sized β-synuclein-positive speckles of varying degrees of 
intensity in the neuropil, throughout all regions shown for the hippocampus (Figure 
27-B-E, #). There was frequently a clumping appearance throughout the neuropil. In 
the control brain (Figure 24), the highest level of reactivity was the CA1 (Figure 24-B) 
and the lowest observed in the dentate gyrus (Figure 24-E) however, in the DLB 
brain although, the highest immunoreactivity remained to be seen in the CA1 (Figure 
27-B), the dentate gyrus (Figure 27-E) also produced noticeable levels of staining 
(Figure 27-E & enlarged). There was intense reactivity around large pyramidal 
neurons of the CA1 (B, enlarged), the other regions showed differential patterns of 
staining around neuronal soma, however, unlike the cortex there was no appearance 
of β-synuclein positive neuronal soma reactivity. 
 
4.2.3: β-synuclein, α-synuclein or oligomeric alpha synuclein protein 
distribution in the human brain and β-synuclein positive cells. 
I have seen changed patterns of β-synuclein immunoreactivity and protein levels in 
the cortical regions of the DLB patients. Moreover, a reduction in α-synuclein is 
observed in the frontal cortex in DLB, and a moderate correlation is found between 
β-synuclein and oligomeric α-synuclein in the same region. The neuropathological 
characteristic of DLB is the widespread distribution of Lewy bodies throughout the 
paralimbic and neocortical regions. Phosphorylation of serine 129 (ps129) of α-
synuclein is extensively undertaken and well defined in α-synucleinopathies [110] 
with ps129 antibodies being commonly appropriated for Lewy body and Lewy neurite 
identification. More recently it has been established that pre-synaptic oligomers of α-
synuclein may be more detrimental to the cell and Lewy bodies may be acting in a 
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protective manner by encapsulation of toxic oligomers. I next examined the regional 
morphological and distribution pattern of oligomeric-α-synuclein using the 5G4 
antibody in the cortico-paralimbic areas of control and DLB brains. In addition, it is 
known that β-synuclein is able to prevent α-synuclein aggregation [178] but this 
protein is not observed in LBs or LNs. Therefore, examination of β-synuclein in the 
presence of monomeric or oligomeric α-synuclein was performed.  I wanted to 
identify whether these proteins show mutually exclusive localisation “in situ” by 
performing a double fluorescent IHC. Moreover, in this study, IHC analysis reveals 
that β-synuclein immunopositive neuronal soma exists in the cortical regions. The 
presence of β-synuclein positive cells has not been previously reported, therefore, 
the examination of these immunopositive cells in the vicinity of oligomeric α-
synuclein positive cells, was of particular importance, looking for any morphological 
changes or shifts in the distribution patterns of β-synuclein and oligomeric α-
synuclein and observe the pattern of β-synuclein staining in and around cells that 
were positive for oligomeric α-synuclein (5G4). Having identified β-synuclein positive 
neuronal immunoreactivity in DLB and modifications in the levels of β-synuclein, I 
have then examined the number of β-synuclein positive cells in the cortical areas.  
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Figure 28 – β-synuclein positive cells are increased in the frontal cortex of the 
DLB brain and β-synuclein does not co-localise with oligomeric α-synuclein 
Examination of β-synuclein (β-syn), α-synuclein (α-syn) and oligomeric α-synuclein (5G4) in 
control and DLB brains: double immunohistochemical examination of the frontal cortical 
regions of control (A) and DLB brains (B) detecting β-synuclein and α-synuclein (α-syn) 
reactivity. The neuropil-type pattern of the staining is marked with (*). Co-localisation is 
observed (A-B, **). Neuronal soma, positive for β-synuclein exclusive staining is observed in 
DLB (B, arrow & enlarged). Enlarged cell indicated by the arrow. N=3. Non-primary antibody 
controls performed (AB) and (Figure 14). Images A & B - Confocal microscopy, magnification 
X63. Scale bar 20μm.  
Oligomeric α-synuclein (5G4) in the control frontal cortex (Frontal Ctx-C) (n=3), DLB (Frontal 
Ctx-D), DLB occipital cortex (Occipital Ctx-E) and DLB hippocampus (F) N=≥6 for DLB brains. 
Non-primary 5G4 antibody control (G). Brightfield microscopy, magnification X60. Scale bar 
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15μm.  Double immunohistochemical examination of the frontal cortical regions of control (H) 
and DLB (I-K) and DLB occipital cortex (J-L), detecting β-synuclein and 5G4. Neuronal soma, 
positive for β-synuclein exclusive staining is observed (K & L, arrow). Multi-sized 5G4 deposits 
and filiform structures (K & L). Enlargements are shown by the arrow. N=≥3. Confocal 
microscopy, magnification X63. Scale bar 50μm (H-J) and (K-L) 10μm. β-synuclein positive 
cells were identified by confocal microscopy and expressed as a percentage of the total 
number of neurons visualised (M) ≥ 6 randomly selected regions from each control and DLB 
brain were examined to achieve a minimum total threshold of 100 neurons.  There is a 
significant increase in β-synuclein positive neurons in the frontal cortex of DLB when 
compared to the controls (P=0.4) (M). Frontal cortex: control (n=8) and DLB (n=9); Occipital 
cortex: control (n=7) and DLB (n=8).  Statistical analysis was performed by one-way-ANOVA 
and Bonferroni post hoc test. *: P=<0.05; **: P=<0.01; ***: P=<0.001. Data represents the mean 
and SEM. 
 
As expected in the control (Figure 28-A) and DLB (Figure 28-B) tissue examination, 
β-synuclein and α-synuclein was primarily homogenous throughout the neuropil with 
small-medium sized puncta, observations include exclusive representation in the 
neuropil of both proteins as seen by green (β-synuclein) and red (α-synuclein) 
puncta. Co-localisation of both synucleins was observed throughout the neuropil 
(Figure 28-A & B, enlarged, **) and both β-synuclein and α-synuclein were located at 
the perimeter of the neurons, appearing as speckled borders (A & B, #) respectively. 
In the cohort of healthy control tissue sections and DLB, neuronal α-synuclein was 
not observed in the cytoplasmic form of neuronal inclusions; however, there were 
neuronal somata that stained immuno-positive for β-synuclein, these were devoid of 
α-synuclein (Figure 28-B, arrow & enlarged). In DLB the β -synuclein staining was 
evidently more intense in most of the DLB patients and frequently took on a more 
granular effect.  
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Examination of cortical regions and the hippocampus of control and DLB patients for 
5G4 immunoreactivity (Figure 28-C-G) revealed notable distribution differences 
between regions and different morphological structures. In all regions examined the 
presence of intracytoplasmic inclusions was observed of differing shapes and sizes, 
reflecting differential distribution patterns of 5G4 stained aggregations. In the frontal 
cortex (Figure 28-D) was the appearance of typical cortical Lewy bodies, with a 
disorganised structure and dotted around were diffuse aggregates, small in size and 
with variable staining intensity. Additionally, faintly stained, Lewy neurite-like 
structures could be seen; these structures were short but may be representative of 
new Lewy neurite formations in progress. 
In the occipital cortex (Figure 28-E) small-intermediate and mostly round structures 
that varied in size and staining intensity were observed. These smaller 5G4-positive 
aggregates were more abundant in the occipital cortex than the frontal cortex. Noted 
was the presence of longer filiform Lewy neurite-like 5G4 structures (E, *) that 
differed in staining intensity along the process and between processes. These 
structures were also more prominent in the occipital cortex than the frontal cortex.  
The hippocampus (Figure 28-F) showed the greatest diversity of morphological 
immunoreactivity. There was a high burden of 5G4 immunoreactivity in this region 
with the presence of sizable Lewy bodies, irregular in shape and intensely stained. 
Surrounding and amongst the Lewy bodies were multiple structures of intermediate 
sized and smaller sized aggregates, irregular in shape (F, *) and were not diffuse 
throughout the hippocampus, rather the burden of the pathology showed few areas 
free from some form of oligomeric α-synuclein immunoreactivity. There were thick 
and longer Lewy neurites, compared to the cortex and multiple aggregates ranging in 
size. The staining intensity of the aggregates was variable, but overall the 
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hippocampus appeared to have the greatest burden of oligomeric α-synuclein 
pathology when examined by IHC.  
Some immunoreactivity was also observed in the controls in the frontal cortex 
(Figure 28-C), this staining was minimal and appeared as small fuzzy edged 
structures (C, enlarged). It is possible that this may be indicative of the early signs of 
pathology in some patients. 
When observing β-synuclein in the presence of 5G4 the DLB frontal cortex (Figure 
28-I & K) and DLB occipital cortex (Figure 28-J & L) showed 5G4 reactivity for small 
aggregates and filiform α-synuclein structures in and throughout the neuropil of both 
the frontal cortex and occipital cortex (I, K & J, L, respectively). 5G4 
immunoreactivity was absent in the control (Figure 28-H). There was no β-synuclein 
present in the cell bodies of any cells that were reactive for 5G4 although, in both 
regions, there was the presence of β-synuclein positive cells in the vicinity of 5G4 
positive cells (Figure 28-K & L, arrow). Very rarely was co-localisation seen between 
β-synuclein and 5G4 in any of the sections examined. The appearance of 5G4 
immunoreactivity was more prominent in the occipital cortex when compared to the 
frontal cortex with larger and thicker filiform structures that may be LN-type 
structures (K & L, *).  
When examining the number of cells that were positive for β-synuclein in the frontal 
cortex and occipital cortex of DLB patients. An increase was detected in the frontal 
cortex of DLB when compared to the controls (P= 0.04)(Figure 28-M). Similar 
numbers of β-synuclein-positive cells were observed between the frontal and 
occipital cortex, with some patients showing greater variability. 
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4.3: Cellular location of the increase in β-synuclein 
β-synuclein positive cells have been detected in addition to the increase in β-
synuclein, revealed by the western blot. To determine whether this change is of a 
cytosolic or synaptic origin, I have isolated synaptosomes from the control and DLB 
tissue. Levels of β-synuclein were then examined in the synaptic rich fraction and 
cytosolic fractions of total lysate and compared to β-synuclein protein levels in the 
total lysate. This was performed in the frontal cortex/occipital cortex and β-synuclein 
levels were normalised to synaptophysin, a synaptic protein that is unchanged in 
DLB [209] or actin. 
 
 
 
Figure 29 - β-synuclein protein changes may reflect changes in its cellular 
location 
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 Western blot analysis of total lysates (A & C) compared to synapse-rich fractions (B & D) from 
human brain lysates with immuno-detection of β-synuclein and synaptophysin. Comparisons 
were made been control patients (≤3) and DLB patients (≤3) for the frontal cortex (A & B) and 
occipital cortex (C & D). Immunoblot images were collected by GSystems and data was 
analysed by measuring the relative optical density of the specific band on the immunoblot 
using FIJI-Image J software (NIH, USA) and presented as a ratio to the corresponding 
synaptophysin density. The frontal cortex cytosolic fraction (E) and synapse rich fraction of 
control (n=3) and DLB (n=3) were examined in patients with high β-synuclein levels in the total 
lysate (G). A trend for increased cytosolic β-synuclein is shown (F). 
 
Analysis of the frontal cortex of DLB patients when compared to the controls, 
showed an increase in β-synuclein in the total lysate fraction (Figure 29-A & G), β-
synuclein showed a differential synaptic presence among patients from increased, 
unchanged to absent at the synapse of DLB patients (Figure 29-B & H) and there 
was a trend towards an increase in the cytosolic fraction (Figure 29-E & F).  
In the occipital cortex, total lysate levels of β-synuclein were decreased or 
unchanged (Figure 29-C) in the DLB patients when compared to the controls and 
there was an almost complete loss of β-synuclein at the synapse in this region for 
the DLB patients (Figure 29-D). 
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 Chapter 4: Results discussion  
The examination of total protein levels of α-synuclein and β-synuclein in the frontal 
cortex has shown an increase in β-synuclein (Figure 18) is associated with a parallel 
decrease in monomeric α-synuclein levels (Figure 19) but an increase in oligomeric 
α-synuclein (Figure 20). Although in the control frontal cortex, high β-synuclein 
negatively correlates with low α-synuclein (Figure 21), this effect was lost in DLB and 
replaced with a correlation between increasing levels of β-synuclein and oligomeric 
α-synuclein. The frontal cortex is variably affected in DLB with those patients with 
concomitant AD pathology, seeing greater synaptic loss [43]. In DLB fluctuating 
cognitive changes are considered a core symptom in the diagnosis of DLB. 
Therefore the cortical region is particularly important for cognitive function [257] such 
as executive decision-making planning and decision making [258].  
In the occipital cortex, a decrease was observed in β-synuclein, although, while there 
was no change in α-synuclein levels there was an increase in oligomeric α-synuclein. 
Interestingly, for this region in controls and DLB, there were no significant 
correlations between β-synuclein and α-synuclein or oligomeric α-synuclein. Even 
though α-synuclein is unchanged in the occipital cortex; the oligomeric α-synuclein is 
increased; together, this produces increased levels of α-synuclein species overall for 
the occipital cortex. The levels of oligomeric α-synuclein in the occipital cortex of 
DLB brains are similar to that seen in the frontal cortex but in this regard, when 
comparing monomeric α-synuclein levels between regions, the levels of α-synuclein 
in the controls of the occipital cortex are approximately 50% less than the frontal 
cortex control, indicating regional differences under normal conditions. Changes 
related to the occipital cortex in DLB sets it apart from other dementias, including 
AD, due to the visual cortex being particularly affected [259] although Lewy bodies 
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are not abundant in the occipital cortex [27] there is hypometabolism [260] and 
occipital thinning [261]; thus, indicating pathological demise of the region is 
underway. 
The cortical changes observed in α-synuclein and β-synuclein in DLB may reflect 
interaction on the transcriptional level, changes in protein stabilisation or protein 
turnover. If an increase in one of the synucleins occurs, there may be changes in 
relation to the stability of a family member. It is feasible that the synucleins employ 
mechanisms to re-address the synuclein protein balance. This may explain the 
increase in overall α-synuclein species levels in the occipital cortex leading to a 
decrease in β-synuclein protein levels. Moreover, although there is an increase in 
oligomeric α-synuclein levels in the frontal cortex there is a decrease in monomeric 
α-synuclein that may result in an increase in β-synuclein stability for this region that 
at some level is not affected by oligomeric α-synuclein levels. The pilot data from our 
laboratory show that mRNA levels of α-synuclein and β-synuclein are not changed in 
frontal cortex in DLB patients although, further work to progress and validate these 
findings is required. 
IHC analysis of the β-synuclein pattern of distribution shows variations in the 
dissemination of the protein throughout the DLB brains in the cortex and the 
hippocampus (Figures 25-27). The differences in the pattern of re-distribution that is 
observed in the DLB brain in the cortical regions see the presence of large granules 
of β-synuclein in both the neuropil and around the neuronal perimeter, as opposed to 
small-medium homogeneous speckles primarily seen in the control brains (Figure 
22-24). This provides evidence for changes of β-synuclein at the protein level that 
impact on its localisation status. These changes collectively may be representative of 
synaptic dysfunction or displacement in the presence of oligomeric α-synuclein at the 
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synapse. It is possible that either of these explanations see relocation as 
represented by protein “clumping.  
The hippocampus is the anatomical region responsible for the consolidation of short 
term memories to long term memories, memory impairment is observed in DLB in 
addition to hippocampal atrophy, primarily in the CA1 region but to a much lesser 
extent than that seen in AD [262]. The hippocampus, shows a distinct morphological 
distribution when compared to the cortical regions, with a larger and intense staining 
around large pyramidal neurons observed in both the control and DLB, in particular, 
the CA1 region is most intensely stained in both groups however, DG accumulations 
are seen in DLB that are not present in the control brains. Interestingly, human wild 
type α-synuclein expressed in mice has been shown to impact on neurogenesis, in a 
negative manner, by reducing the survival rate of neuronal committed progenitors in 
the olfactory bulb and dentate gyrus [140]. It is possible that the presence of β-
synuclein in this region is a neuroprotective effect; further, supported by the cell 
survival properties associated with β-synuclein under toxic conditions [180]. The 
dentate gyrus is an important location for neurogenesis; one could speculate that β-
synuclein is preserving this process in the face of degenerating neurons in the 
presence of increasing pathology.  
The hippocampus sees no modifications in β-synuclein or α-synuclein protein levels, 
a trend towards increased levels of oligomeric α-synuclein is observed in DLB for this 
region, also observed by oligomeric α-synuclein in the IHC analysis. The control also 
exhibited high levels of 5G4 and so statistical significance was not found in the 
ELISA assay. When considering this control patient, the clinical- pathological report 
indicates Braak stage 2 and ageing of this brain. Therefore, high levels of oligomeric 
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α-synuclein in the hippocampus of the control brain may be more representative of 
ageing or AD pathology.  
I have shown that both monomeric α-synuclein and β-synuclein present a similar 
pattern of immunoreactivity in the cortex of the human brain (Figure 28-A-B) due to 
their similarities and pre-synaptic location, it is unsurprising that co-localisation is 
observed. Conversely, very rarely were there observations of β-synuclein and 5G4 
co-localisation in this study. It could be speculated that β-synuclein transiently binds 
to α-synuclein in normal physiological circumstances, however, once pathological 
modifications occur that enable the oligomerisation and aggregation of α-synuclein, it 
may prevent direct contact between the two proteins due to contact sites being 
occupied or post-translational modifications preventing co-binding. This may see the 
re-localisation of either synuclein and once this neuroprotective effect is lost, 
pathological changes may proceed. 
This study also provides evidence for the previously undescribed presence of 
cytoplasmic localisation of β-synuclein in the cortical regions by IHC, an otherwise 
pre-synaptic protein. In this context, α-synuclein is also pre-synaptic with its 
presence in the neuronal cell body more specifically associated with Lewy bodies; 
regardless of whether Lewy bodies are toxic or as a result of neuroprotective 
mechanisms, the presence of Lewy bodies is a pathological indicator of an α-
synucleinopathy. The synaptosomal isolation work in this study (Figure 29) has 
shown that the total increase in β-synuclein levels in the frontal cortex is likely 
attributed to primarily cytosolic proteins although, an increase in the number of 
patients is required for validation. The examination of the cytosolic fraction saw all 
the DLB patients presenting with high levels of cytosolic β-synuclein. The findings 
were not proven signifant due to the presence of high levels of cytopsolic β-synuclein 
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in one of the controls. In contrast, the decrease in β-synuclein that has been 
observed in the cohort of DLB patients in the occipital cortex is likely related to loss 
of β-synuclein at the synapse. This is a possible indication of synaptic dysfunction 
occurring in this region which will be further explored in the examination of other pre-
synaptic proteins (Chapter 6). 
The occipital cortex sees an almost total loss of β-synuclein at the synapse in DLB 
(Figure 29), the absence of this protein may impair potential protective attributes, 
enabling α-synuclein to proceed in the direction of oligomerisation. In DLB, the α-
synuclein aggregating process may start many years before clinical presentation 
which can 10 years prior. One could speculate that in the early course of the disease 
process, modifications to α-synuclein may lead to a loss of or impaired function that 
will see β-synuclein acting as a substitute at the synapse; potentially explaining the 
lack of DLB phenotype, early in the disease course. As α-synuclein pathology 
progresses and the burden becomes too high for the neurons it may be that β-
synuclein is no longer able to act in a supporting role and the cell demise/synaptic 
dysfunction proceeds with the disease course favouring α-synuclein modification, 
oligomerisation, fibrillisation and Lewy body formation.  
The data produced in figures 22-27 are descriptive and are intended to provide an 
indication of the general observations made in these cohort of patients, for each 
region. It must be pointed out that this is a qualitative and subjective analysis made 
on a minimum number of six patients. It is recognised that this analysis is not 
necessarily representative of changes directly attributed to DLB per se. It is also 
accepted that there are limitation regarding any observations due to subjectivity and 
therefore, caution in interpretation should be made. Indeed, when discussing the 
cortical layers and hippocampal regions, as I have done, it is not possible to be 
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absolutely certain of the correct layer in the field of vision, leading to possible 
morphological misinterpretation. The use of cell-specific markers to identify true 
cortical layers produces challenges due to the homogenous cell population in the 
human brain. The expertise of a neuropathologist would be beneficial, to validate the 
observations of changes that have been described in this thesis. The descriptions 
result from my own interpretation of the differences I see in control and DLB patients, 
of specific interest was the neuropil, β-synuclein positive cells and any changes in 
immunoreactivity intensity, as images were taken down through the cortical layers. 
The analysis was performed within a reasonable time constraint in order to maximise 
interpretation consistency and microscope settings optimised to ensure the 
comparisons were as reliable as possible.  
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Results Chapter 5: Modulation of β-synuclein in the presence of human-α-
synuclein (h-α-synuclein) in vitro 
Chapter 4 provides evidence for changes in β-synuclein levels in the human brain in 
parallel to alterations in oligomeric and monomeric α-synuclein. The available 
literature suggests that expression of α-synuclein and β-synuclein follow a reciprocal 
relationship, an increase of β-synuclein protein sees a decrease of α-synuclein 
protein expression, but not SNCA mRNA [263], SNCA mRNA is increased while 
SNCB mRNA is decreased in DLB patients [133] and transcription factor ZSCAN21, 
represses SNCA and increases SNCB expression in dopaminergic neurons [99]. 
Here I employed a rat dopaminergic neuronal line (N27) stably expressing human α-
synuclein to identify whether changes in levels of α-synuclein have an impact on β-
synuclein protein expression and distribution. The dopaminergic system is typically 
affected in PD and PD with dementia. Severe degeneration of nigrostriatal 
connections producing characteristic PD, motor symptoms of bradykinesia [264]. 
Although cholinergic neurons of the basal forebrain are primarily and most 
profoundly affected in DLB, the catecholaminergic (and dopaminergic) system also 
suffers – with a significant loss of dopaminergic cells in the ventral periaqueductal 
gray matter [265] and norepinephrinergic cells in the locus coeruleus (reviewed in 
[266]). In addition, advanced DLB patients display LB pathology in the substantia 
nigra and β-synuclein is highly expressed in the substantia nigra. Collectively this 
indicates a suitable cell type for examination of β-synuclein in the presence of α-
synuclein. This cell line allows the precise temporal control of α-synuclein expression 
by ponasterone A (PonA) promoter activity induction, permitting examination of 
endogenous β-synuclein expression.    
129 
 
5.1: β-synuclein protein levels and distribution pattern of immunoreactivity in 
the presence of h-α-synuclein  
5.1.1: β-synuclein protein is unchanged in the presence of h-α-synuclein 
In order to reveal potential changes in β-synuclein levels, I examined h-α-synuclein 
over-expressing rat dopaminergic cells at 24, 48 and 72 hours post induction (hpi) of 
the transgene. 
 
Figure 30 - β-synuclein protein levels are unchanged during the time course 
induction of h-α-synuclein 
Western blot analysis of α-synuclein transgene expression (Antibody: syn1) (A). Time course 
of h-α-synuclein expression in N27 cell line (B – E). No treatment (B) and at 24, 48 & 72 hours 
h.p.i (C, D & E respectively). Pon A induction of human-alpha synuclein 24, 48 & 72 h.p.i. 
Syn204 & β-synuclein co-expression (F, *) 48 h.p.i β-synuclein (H) showed exclusive staining 
**.Higher levels of syn 204 immunoreactivity (G) was represented by low levels of β-synuclein 
(arrows, G & H). α-synuclein is detected by syn204 (green) and β-synuclein (red). Scale bar is 
20µm.  
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The western blot analysis (Figure 30-A) confirmed that α-synuclein (revealed by 
syn1) is upregulated in response to PonA treatment. β-synuclein levels were 
unchanged between treatment groups when compared to the control. 
The western blotting data was further supported by immunocytochemistry (ICC) 
(Figure 30-B-E). α-synuclein staining was consistently present following the 
transgene induction in the expressing cells, no significant overall change in β-
synuclein (red) distribution was detected - similar levels of immunoreactivity were 
observed between controls (B) and 24-72 hpi groups (C - E). When examining co-
localisation (F, *) between β-synuclein (H) and syn204-immunoreactivity (G), 
interestingly, a higher intensity of β-synuclein immunoreactivity was seen in cells that 
did not harbour high levels of α-synuclein (**) in contrast higher levels of syn204 saw 
lower levels of β-synuclein (arrows). 
 
5.1.2: The β-synuclein pattern of immunoreactivity is redistributed in the 
presence of h-α-synuclein 
There is no difference in the levels of β-synuclein in relation to α-synuclein 
expression in the N27 cells. However, it appeared that the cells that are harbouring 
higher levels of α-synuclein corresponded with lower levels of β-synuclein. 
Differential patterns of staining are also seen in the human brain with cells 
harbouring pathological α-synuclein, seemingly devoid of β-synuclein (Figure 28). 
Further, in the human brain, the β-synuclein IHC signal appears re-distributed in 
those cells that are positive for α-synuclein reactivity and enlarged granules 
immunoreactive for β-synuclein are observed in the cortex and the hippocampus of 
DLB patients (Figures 25-27). Next, the pattern of β-synuclein staining in cells 
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harbouring variable levels of h-α-synuclein was examined in rat dopaminergic cells 
from 24 – 72 h.p.i.  
 
 
 
Figure 31 - β-synuclein immunoreactivity is low or absent in cells harbouring 
h-α-synuclein 
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β-synuclein (1B & 2A) and Syn204 immunoreactivity (1 & 1A) 24 hours post induction of h-α-
synuclein. In cells, positive for syn204 (1 & 1A), β-synuclein is speckled with larger spots near 
the nucleus (*); β-synuclein is absent in areas of high syn204 staining (#) and β-synuclein 
shows a peri-nuclear localisation pattern (##). In cells, devoid of syn204 (2 & 2A), β-synuclein 
is speckled throughout the cytoplasm (**). B: β-synuclein (3B & 4A) and Syn204 
immunoreactivity (3 & 3A) 48 hours post induction of h-α-synuclein. In cells, positive for 
syn204 (3 & 3A), β-synuclein is reduced (##) and absent in some regions (#); β-synuclein is 
speckled in cells in close proximity to syn204 expressing cells (*) and in cells negative for 
syn204 β-synuclein is speckled throughout the cytoplasm (**). C: β-synuclein (5B) exclusively 
stains syn204 -ve cells (#) and is devoid (*) or very sparse (**) in highly expressing α-synuclein 
cells (**). Scale bar 20μm. Images were taken with Zeiss confocal microscope. 
 
24 hours following upregulation of h-α-synuclein, β-synuclein is present in syn204 
positive neurons (Figure 31-A); the levels of α-synuclein are consistently low in these 
cells (Figure 31-A-1 & 1A). β-synuclein appears to be both speckled (1B) and with 
larger spots appearing close to the nucleus (IB, *). β-synuclein is absent (1B, #) in 
the region of the neuron with a higher intensity of syn204 staining (1A, #) indicating 
the cytoplasmic redistribution of β-synuclein protein within individual cells; further, 
some neuronal regions show a perinuclear pattern of β-synuclein (1B, ##). In 
contrast, the neurons that show no syn204 immunoreactivity (Figure 31-2) display a 
consistent diffuse cytoplasmic pattern of β-synuclein immunoreactivity (2A, ++). 
48 hours post-treatment (Figure 31-B) syn204-positive cells, positive for β-synuclein 
immunoreactivity (B-3) was observed, in addition to β-synuclein positive cells, devoid 
133 
 
of syn204 staining (B-4). Cells expressing higher levels of α-synuclein had only low 
levels of β-synuclein immunoreactivity (3B ##) with the total absence of β-synuclein 
in some regions of the same neuron (3B, #). Cells in close proximity to an α-
synuclein expressing cell show a diffuse pattern of staining of β-synuclein in a 
predominantly mono-polar manner (3B, *) with the appearance of low levels of α-
synuclein at the opposite pole. Cells not closely associated with α-synuclein show a 
diffuse and uniformly speckled distribution throughout the cytoplasm (4A, **).  
72 hours of α-synuclein expression (Figure 31-C-5) sees diminished β-synuclein (5B, 
*) or very low levels of speckled puncta (**) in those cells expressing α-synuclein.  
5.1.3: β-synuclein positive cells do not express high levels of α-synuclein in 
iN27 cells 
There is no change in β-synuclein protein levels but I identify a differential pattern of 
immunoreactivity when examining β-synuclein co-localisation with α-synuclein: cells 
with higher levels of α-synuclein immunoreactivity appear to present with lower levels 
of β-synuclein intensity. This may be indicative of β-synuclein single-cell modulations 
occurring, that are dependent on the local level of α-synuclein. To examine this 
hypothesis, the immunofluorescent signal of β-synuclein positive cells was examined 
for each time point and then the immunofluorescent signal of α-synuclein (revealed 
by Syn204 immunoreactivity) was analysed in cells that are both positive and 
negative for β-synuclein. 
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Figure 32 - β-synuclein positive cells are associated with low levels of h-α-
synuclein 
N27 cells treated with EtOH as a control or 24, 48 & 72 hpi (hours post induction) of human-α-
synuclein gene expression. Data is expressed as the percentage of β-synuclein positive cells 
relative to the total number of cells examined in each group, nuclei ≥250 per group. A decrease 
in β-synuclein positive cells is seen at 72 hours (P = 0.02) (A). h-α-synuclein 
immunofluorescent intensity was measured in cells that were either positive (+ve) or negative 
(-ve) for β-synuclein (B). The detection of h-α-synuclein (Syn204) immunofluorescent intensity 
was analysed using FIJI - Image J software (NIH, USA). Cells that were positive and negative 
for β-synuclein were examined for Syn204 immunoreactivity and the CTCF (corrected total cell 
fluorescence) expressed in arbitrary units. β-synuclein positive cells required a mean-grey 
intensity density in excess of >200 AU (arbitrary units) for the region of interest (ROI) or were 
excluded from the analysis. A minimum of 100 cells per group were analysed from 3 
experimental repeats. At 48 hours a significant decrease in Syn204 immunoreactivity is seen in 
β-synuclein positive cells (P = 0.03). Statistical analysis was performed using ANOVA and 
Bonferroni post-hoc test. *: P=<0.05; **: P=<0.01; ***: P=<0.001. 
 
When examining the number of β-synuclein positive cells overall (Figure 32-A), there 
was a significant decrease in the 72 h.p.i group when compared to the control 
(P=0.02) and the 24 h.p.i and 72 h.p.i group (P=0.002). This data shows a decrease 
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in the number of β-synuclein positive cells 72 hours post expression of human-α-
synuclein. 
The immunofluorescent intensity of α-synuclein was examined in cells that were 
positive or negative for the presence of β-synuclein. To minimise subjectivity, a 
threshold level for grey mean intensity was set at >200AU for β-synuclein cells to be 
considered positive. A significant increase in levels of syn204 immunofluorescence 
was observed in β-synuclein negative cells at 48 hpi when compared to β-synuclein 
positive cells at 24 h.p.i. (P=0.002). Furthermore, at 48 h.p.i. there was significantly 
higher levels of syn204 immunofluorescence in cells that were β-synuclein negative 
when compared to β-synuclein positive (P=0.03). 
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Chapter 5: Results discussion  
I provide here the evidence for a redistribution of the β-synuclein staining pattern in 
the neuronal culture system (Figure 30-32). The cytosolic representation of β-
synuclein in the presence and absence of α-synuclein was distinctive and consistent. 
Single-celled differential patterns of immunoreactivity are observed: neurons 
expressing high levels of h-α-synuclein see changes in β-synuclein 
immunoreactivity, often the region positive for syn204-immunoreactivity shows low 
levels of, or is devoid of β-synuclein. In comparison, in the non-α-synuclein 
expressing cell, β-synuclein shows a diffuse cytosolic pattern of staining throughout 
the cell. This is representative of the findings in the human brain whereby the 
differential distribution of β-synuclein occurs in DLB brains and there is very little co-
localisation of oligomeric-α-synuclein and β-synuclein (Figure 28). 
I have shown that β-synuclein levels overall are unchanged in the presence of 
accumulating α-synuclein (Figure 30), in dopaminergic neurons in vitro. Whilst this 
does not mimic the findings in our human brains, where altered β-synuclein protein 
levels are seen, a significant decrease of β-synuclein positive neurons was seen at 
72 hours (Figure 32). Therefore, it is a good indicator of a potential temporal change 
in the β-synuclein protein behaviour. When comparing the in vitro model with DLB 
brains, it must be considered that the majority of neurons in the cortex are 
glutamatergic large pyramidal neurons or GABAergic interneurons. It is, therefore, 
possible that the dopaminergic neuronal phenotype of these in vitro cells leads to 
differential changes in β-synuclein behaviours that may not support the change in 
protein levels in the cortical regions of the human brain, but more representative of 
the substantia nigra. It is known that β-synuclein is highly expressed in the 
substantia nigra, a region selectively targeted in PD, further indicating potential 
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mechanisms that seek to balance or minimise damage by α-synuclein. The findings 
that β-synuclein levels are not altered in response to α-synuclein, but rather, 
distribution of the protein is altered, in this dopaminergic cell model may be indicative 
of the type of mechanisms undertaken in regions rich in catecholamines. It may be 
considered, therefore, that β-synuclein behavioural may have neurochemical-specific 
responses.  
The synucleins are known to colocalise and this study demonstrates that modified 
levels of either of the synucleins also appear to be represented by the lack of co-
localisation. It is shown here (Figure 32-B) that at 48 hours h.p.i., α-synuclein levels 
are higher in cells that are not expressing detectable levels of β-synuclein when 
compared to cells positive for β-synuclein. It is possible that a) an increase in α-
synuclein or β-synuclein leads to the loss of synuclein-synuclein interactions, b) β-
synuclein is demonstrating a pattern of redistribution that may be associated with 
neuroprotective effects in an attempt to prevent or minimise α-synuclein toxicity 
rather than loss of interaction c) it is possible that the absence of β-synuclein in 
syn204 highly immuno-positive cells may result from α-synuclein-induced toxicity 
having deleterious effects although, diminished levels of β-synuclein in this cell 
model were not identified to support this, and finally d) transcriptional regulation of 
the synucleins may be occurring; therefore, increased levels of α-synuclein in a 
single neuron may see reduced levels of β-synuclein in the same cell.  
Collectively, I have shown that in the presence of h-α-synuclein there is a temporal 
change in β-synuclein cellular localisation in rat dopaminergic neurons. But in the 
event that in vivo, β-synuclein is providing a protective function, this may present 
indications of how the protein behaves in the face of α-synuclein cellular burden. The 
observations that β-synuclein appears to be present only in cells primarily with lower 
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levels of α-synuclein may support a role that is indicative of the prevention of 
accumulations, that is at some point overwhelmed, seeing loss of β-synuclein in the 
same neurons. What is not clear is whether this redistribution is an effort to perform 
physiological roles that are typically attributed to α-synuclein, these roles include 
chaperoning SNARE complex assembly or whether this results from the toxic effects 
of α-synuclein that see trafficking of β-synuclein to different cellular locations.  
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Results Chapter 6: SNARE protein distribution changes in the DLB brain and 
in the presence of β-synuclein 
Synaptic alterations are well described in neurodegeneration, with observations of 
synaptic loss [176] [43] [267], changes in protein composition [209], modifications of 
distribution patterns [208] and alterations in SNARE protein physiological activity, 
with impairments in SNARE complex formation observed [141]. T-SNAREs SNAP25 
and syntaxin ensure the integrity of vesicle docking in association with the target 
membrane and therefore, any obstructions at the synapse will potentially lead to loss 
of functional integrity. Alterations in some SNARE protein levels have been reported 
in DLB, showing in general, a reduction of their levels [209]. Synaptic dysfunction, 
manifesting as redistribution of SNAREs, is observed in the striatum of patients with 
early-onset PD [208]. 
Although, Lewy body disease is characterised by Lewy bodies and neurites, small, 
oligomeric α-synuclein accumulations at the pre-synapse of DLB patients interfere 
with synaptic function [268] and may  contribute to development of the clinical 
phenotype with suggestions synaptic malfunction and deregulation may be 
representative of the pre-clinical and early symptoms associated with these 
conditions  (reviewed by [269]).  To evaluate the damage entrapped oligomeric α-
synuclein undertakes at the pre-synapse, it is necessary to examine other pre-
synaptic proteins to appreciate synaptic changes that occur in the course of 
pathology.  
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6.1: Immunohistochemical distribution of the major SNARE proteins in cortico-
paralimbic regions of the human brain 
To examine whether α-synuclein aggregation leads to redistribution or accumulation 
of SNARE proteins in cortical and limbic areas of DLB brains, IHC was performed 
examining key synaptic proteins in the control brains, specifically observing patterns 
of distribution around the neurons and throughout the neuropil and comparisons are 
made with pattern of immunoreactivity occurring in the DLB brains.  
 6.1.1: VAMP2 and SNAP25 in cortical and hippocampal brain regions 
α-synuclein is an essential chaperone in the process of SNARE complex formation 
[270] this role is performed by direct interaction with VAMP2, enabling an association 
of the pre-synaptic vesicle with the target membrane, facilitating the release of the 
neurotransmitter at the synapse. Moreover, SNARE-complex protein, SNAP25 is 
associated with the pre-synaptic plasma membrane having a dominant influence in 
the docking and fusion of vesicles at the synapse [185]. 
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Figure 33 – In DLB occipital cortex VAMP2 and SNAP25 immunoreactivity is 
reduced and SNAP25-positive clusters are observed  
Immunohistochemical detection of VAMP2 (A-F) and SNAP25 (H-M) proteins in the cortical and 
hippocampal regions of the human brain. VAMP and SNAP25 is observed in the control (A-C, 
H-J) and DLB (D-F, K-M) brains respectively. The neuropil-type pattern of the staining is 
marked with (*). Accumulation of immunopositive signal around the neuronal soma is marked 
with an arrow with the addition of immuno-positive clusters (#) and clumping (**). Non-primary 
control for VAMP2 and SNAP immunostaining (G & N, respectively). N = 3 per group and per 
region. Scale bar 19.5μm. 
 
VAMP2 in the frontal cortex and occipital cortex of control patients gives the 
appearance of small puncta that both surround the neuronal periphery in addition to 
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a small and speckled distribution throughout the neuropil (Figure 33- A & B, 
respectively, *). The pattern of distribution in the hippocampus (Figure 33-C), when 
compared to the cortex,  is more granular (C, *) and more immunoreactivity is seen 
surrounding some of the larger pyramidal neurons (C, arrow). Some puncta appear 
to have a more condensed pattern of staining in specific regions at the neuronal 
border (C, #) 
The pattern of VAMP2 immunoreactive staining was changed in DLB tissues when 
compared to the controls. VAMP2 in the frontal cortex of DLB showed intermediate 
sized granular puncta that were dotted throughout the neuropil (Figure 33-D, *), often 
larger than that observed in the control tissues. The signal from VAMP2 in the 
occipital cortex was evidently diminished when compared to the frontal cortex with 
significantly reduced immunoreactivity appearing around the neurons and appearing 
non-homogenously throughout the neuropil (Figure 33-E). The hippocampus had a 
relatively intense pattern of staining (Figure 33-F) it was variably distributed with 
small to intermediately sized puncta throughout the neuropil (F, *). There was 
immunoreactivity surrounding the neuronal-border (F, arrow). 
The detection of SNAP25 in the frontal and occipital cortical areas of the control 
brain presented similarly in dissemination with small puncta dotted throughout the 
neuropil (Figure 33-H-I). SNAP25 was present around the neuronal perimeter in the 
cortical regions. In the hippocampus (Figure 33-J) staining was evident around the 
border of the large neurons in the CA2/CA3 regions (J, arrow) with a speckled 
appearance throughout the neuropil (J, *).   
The frontal cortex of the DLB patients (Figure 33-K) appeared to have less 
homogenous patterns of staining in the neuropil when compared to the control. 
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There was evidence of staining around the edge of the neurons although this 
appeared re-distributed in places (K, arrow). SNAP25 immunoreactivity in the DLB 
occipital cortex (Figure 33-L) was less pronounced overall when compared to the 
frontal cortex. There were also irregularities in the pattern of staining in this region: 
some neurons had positive staining at the perimeter of the somata but it appeared 
clumped and not uniformly distributed in places (L, **). The DLB hippocampus 
(Figure 33-M) had a distribution that was more coarse and granular in places, but not 
too dissimilar to the control, with SNAP25 immunoreactivity present around the 
neurons (arrow). 
 
6.2: SNARE proteins in the cortical region of the DLB brain 
The data related to SNAREs protein levels in the DLB brain is scarce. A significant 
correlation between levels of pre-synaptic proteins and advancement of dementia 
related neuropathological disorders has been reported in DLB, PDD and AD; 
indications are that VAMP2 levels negatively correlate with the duration of dementia 
[209]. A significant decrease in SNAP 25 is observed in the DLB primary and 
association visual cortex and the neocortex of LB variants of AD patients [271]. 
Overall studies point to a reduction in the SNAREs in cortical regions indicating the 
possibility of trans-synaptic degeneration. To confirm and expand these observations 
in DLB, I examined the levels of key v-SNARE and T-SNAREs, VAMP2 and 
SNAP25, respectively in human brain tissue lysates of control and DLB. 
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Figure 34 - VAMP2 protein levels are increased in the frontal cortex of the DLB 
brain and VAMP2 and SNAP25 are decreased in the occipital cortex in DLB  
Western blot analysis of VAMP2: frontal cortex (A) (control n = 8) & (DLB n = 13) & occipital 
cortex (C) (control n = 5) & (DLB n = 14). VAMP2 is increased in DLB in the frontal cortex 
(P=0.012) and decreased in the occipital cortex (P=0.018). SNAP25: frontal cortex (B) (control n 
= 8) & (DLB n = 15) & occipital cortex (D) (control n = 7) & (DLB n = 13). SNAP25 is decreased 
in the occipital cortex of DLB brains (P=0.036). Statistics were performed using student’s two-
tailed t-test. 
 
Examination of control and DLB human brain tissue lysates (Figure 34-A-D) led to 
the identification of a significant increase in VAMP2 in the frontal cortex (Figure 34-
A) of the DLB brains (P= 0.012) and conversely, a significant decrease in the 
occipital cortex (Figure 34-C) (P= 0.018). Further, SNAP25 was reduced in the 
occipital cortex (Figure 34-D) of the DLB patients when compared to the controls (P 
= 0.036), no changes were observed in the frontal cortex for SNAP25 (Figure 34-B).  
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6.3: β-synuclein & key SNARE proteins changes in DLB 
I have provided evidence for the re-distribution of β-synuclein and altered levels of β-
synuclein protein in the cortex of the DLB brain in addition to SNARE protein 
redistribution and protein level modifications in the same regions. The increase of 
VAMP2 in the frontal cortex and decrease of VAMP2 and SNAP25 in the occipital 
cortex mimic the direction of change observed in β-synuclein. Despite the homology 
between the synucleins, and the close proximity of β-synuclein to the pre-synaptic 
vesicles [76] there is no evidence of a direct involvement of β-synuclein in SNARE 
complex formation or synaptic vesicle binding. In accordance with this, the precise 
role of β-synuclein is not entirely understood. It is, however, well established that α-
synuclein and VAMP2 are binding partners with the coordinated effort of α-synuclein 
binding directly to VAMP2 assisting in the complex formation of the SNAREs. The 
phenotype for behavioural, biochemical and physiological changes associated with 
the triple knockout models is much more pronounced than those single or double 
knock out models, with detectable changes associated predominantly with ageing; 
thus, underscoring the potential for intra-protein redundancy. However, cooperative 
redundancy effects may be regionally or neuron specific since, α-synuclein is 
required to maintain the integrity of the nigrostriatal system, with β-synuclein failing 
to offer compensatory responses [272].  VAMP2 is key for fast endocytosis of 
synaptic vesicles [203] and deceleration of the kinetics of endocytosis in the absence 
of α/β/γ- synuclein in hippocampal neurons is observed. This effect is reduced with 
re-introduction with one of the synucleins  [273]. The possibility that β-synuclein may 
act as a compensatory protein in the absence of α-synuclein or in the presence of α-
synuclein modifications is intriguing and a role mediating SNARE protein complex 
cannot be excluded.  
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In order to examine β-synuclein in relation to SNAREs, a double fluorescence 
immunohistochemistry protocol was implemented to observe the localisation of β-
synuclein in the cortical regions and hippocampus in relation to the SNARE proteins, 
paying particular attention to the SNARE protein distribution patterns in the vicinity of 
β-synuclein immunoreactivity. 
 
6.3.1: Immunohistochemical distribution of β-synuclein and SNAP25 in the 
human brain 
This study has presented evidence of redistribution of SNAP25 in DLB brains in the 
cortical regions and the hippocampus by IHC (Figure-34) and reduced levels of the 
SNAP25 protein in occipital cortex (Figure 34). Next, I examined the distribution of 
the proteins in the frontal cortex, occipital cortex and hippocampus. 
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Figure 35 - SNAP25 is re-distributed in the frontal cortex and diminished in the 
occipital cortex 
Immunohistochemical distribution of β-synuclein and SNAP 25 in the frontal cortex: control 
(A) and DLB (B) N=4; occipital cortex: control (C) and DLB (D), N = 3 and the hippocampus: 
control (E) and DLB (F) brains, N = 3. The neuropil-type pattern of the staining is marked with 
(*). Non-primary antibody, secondary antibody only controls (G). Accumulation of 
immunopositive signal around the neuronal soma and/or enlarged image insert is marked with 
an arrow. Scale bar 19.5μm. 
 
In the frontal cortex and occipital of the control brain (Figure 35-A & C, respectively), 
β-synuclein and SNAP25 display a similar pattern of staining with a distinctly similar 
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pattern of β-synuclein and SNAP25 throughout the neuropil (A & C*) revealed by 
small speckles. Co-localisation is shown by yellow puncta in addition to the exclusive 
representation of both proteins (Arrow, enlarged). 
In contrast to the control, the frontal cortex of the DLB patient (Figure 35-B) shows a 
differential pattern that often has a more granular appearance of β-synuclein and 
SNAP25 staining, with speckles of varied size and intensity of immunoreactivity. β-
synuclein positive neurons were frequently surrounded by larger sized, coarsely 
patterned β-synuclein and SNAP25 granules (B, enlarged); both were independently 
stained along with grainy yellow puncta representing possible co-localisation. 
SNAP25 immunoreactivity was more prominent in the DLB patients when compared 
to the controls with the more obvious presence of red puncta, (B, enlarged). 
In the occipital cortex of the DLB patients (Figure 35-D), overall both β-synuclein and 
SNAP25 presented with less immunoreactivity as I previously described for this 
region for both β-synuclein and SNAP25 single stains. Evidence of neuronal 
perimeter immunoreactivity of either protein is diminished when compared to control 
brains (Figure 35-D).  
The control hippocampus (Figure 35-E) showed very similar patterns of staining 
between β-synuclein and SNAP25 around the perimeter of the neurons (see 
enlarged, arrow); presentation of immuno-positive punctate of β-synuclein or 
SNAP25 as singular stains was observed (enlarged). 
As previously described for the hippocampus, the DLB brain (Figure 35-F) generally 
showed a very coarse pattern of medium sized granules that were immunopositive 
for β-synuclein. The SNAP25 pattern of distribution appeared, like the control brain, 
150 
 
as smaller speckles throughout the neuropil and around the neurons, (F, * & arrow 
respectively).  
 
6.3.2: Immunohistochemical distribution of β-synuclein and VAMP2 in the 
human brain 
Redistribution of the VAMP2 protein has been identified in the DLB patient cohort 
(Figure 33). Further, modulation of VAMP proteins has been identified (Figure 34) 
with an increase of VAMP2 seen in the frontal cortex and a decrease in the occipital 
cortex. The available literature provides no evidence of a binding association 
between VAMP2 and β-synuclein, however, by virtue of their location at the pre-
synapse, they are in close proximity to each to each other. This study sought to 
examine β-synuclein and VAMP2 protein behaviours in the presence of double 
immunofluorescence; in particular, the frontal cortex and occipital cortex are of 
interest in view of altered β-synuclein levels. 
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Figure 36 – VAMP2 and β-synuclein immunoreactivity is diminished in the 
occipital cortex 
VAMP2 and β-synuclein in the frontal cortex of the control (A) and DLB brain (B), N = 3; 
occipital cortex in the control (C) and DLB (D), N = 4 and hippocampus of the control (E) and 
DLB (F) brain, N = 3. Non primary antibody controls (G). The neuronal somata perimeter 
staining is shown (arrow) and the neuropil (*) represented for both proteins. High-intensity β-
synuclein immunoreactivity is observed (**), in addition to β-synuclein positive cells. Scale bar 
19.5μm. 
 
The frontal cortex control and occipital cortex (Figure 36-A & C, respectively) 
presented a staining pattern that was primarily uniformed for β-synuclein and VAMP2 
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throughout the neuropil (*). There was evidence of both proteins being distributed 
around neuronal cell bodies in the shape of small puncta (A & C, enlarged) and 
some yellow puncta indicating possible co-localisation. 
Examination of the DLB brain (Figure 36-B) in the frontal cortex identified multiple β-
synuclein positive cells (B & enlarged). There were regions with clustering that 
appeared to be immunopositive for both β-synuclein and VAMP2 (B, **) with both 
proteins presenting a coarser appearance in the DLB brain when compared to the 
control.  
In the occipital cortex of the DLB patient (Figure 36-D) the level of immunoreactivity 
for β-synuclein and VAMP2 were both diminished when compared to the controls. 
The distributions of the proteins both in the neuropil (D, *) and around the neuronal 
periphery (arrow & enlarged), in relation to the levels of immunoreactivity was largely 
reduced. The appearance of some yellow puncta (enlarged) was indicative that there 
might be some co-localisation between β-synuclein and VAMP 2. There were 
regions throughout the neuropil that appeared to have clusters of β-synuclein (D, **) 
immunoreactivity, these areas were devoid of VAMP2 (E, **) staining. 
The hippocampus control brain (Figure 36-E) pattern of staining was that of small-
medium speckles for β-synuclein and small puncta for Vamp2. Both β-synuclein and 
VAMP appeared throughout the neuropil (E, *) and the pattern of staining was largely 
that of small-medium speckles for β-synuclein and small puncta for Vamp2. These 
puncta were clearly observed around the periphery of the large neurons in the 
hippocampus CA2/3 region (E, arrow).  
As previously described for this region, the hippocampal DLB brain (Figure 36-F) 
showed a distinctively different pattern of staining for both β-synuclein and VAMP2 
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when compared to the control, both were displayed throughout the neuropil (F, *) 
and around the neuronal perimeter (arrow, enlarged) presenting with a grainy 
appearance of differential sized granules and the appearance of clumping (F, **).  
 
6.4: β-synuclein colocalisation with SNAP 25 and VAMP2 in control and DLB 
brains 
Super-imposing fluorescent images following IHC is a widely-used technique to 
evaluate co-localisation. Co-localisation is observed when the staining of two 
antigens in the same tissue section are labelled with differing excitation spectra and 
produce an overlap in colour; in this study, the overlap produces a yellow signal that 
occurs when the two different antigens are labelled independently with either a red or 
green fluorophore. This can provide evidence that the molecules are in close 
proximity to each other but it does not provide a rigorous proof of interaction. The 
quantification of two fluorescent probes is required in order to establish the validity of 
co-localisation meticulously; this is as opposed to the more subjective approach via 
visual interpretation [274]. This study provides evidence of yellow puncta following 
the IHC examinations of β-synuclein and the SNAREs, indicating the potential for co-
localisation between these proteins. Evidence for these interactions has not been 
previously reported and could provide valuable evidence for inter-relationship 
between pre-synaptic proteins. To this end, I employed quantitative co-localisation 
analysis (QCA) [275] using the Manders coefficient [276] in order to estimate the 
level of antigenic co-localisation in multiple, confocal microscopy, immunofluorescent 
images. The examination focused on colocalisation between the β-synuclein 
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immunopositive signal with that of SNAP25 or VAMP2; thus, enabling a more 
accurate and objective predictor of co-localisation.  
 
 
6.4.1 β-synuclein colocalises with VAMP2 and SNAP25 in control and DLB 
brains 
 
Figure 37  – A moderate level of co-localisation between β-synuclein and 
Vamp2 or SNAP25 is observed in the cortex and hippocampus of control and 
DLB patients.  
Manders coefficient for co-localisation between β-synuclein and VAMP2 (A) or SNAP25 (B) in 
control and DLB patients. N= 3 per group and per region; 10 z-stacks. Manders M1 indicates 
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the proportion of the green signal, β-synuclein, that coincides with a signal in the red channel, 
VAMP2 or SNAP25, in relation to the total intensity of the green channel.  Tabulated results of 
M1, M2 and Pearsons correlation coefficient (PCC) above the Costes Threshold (C).  
 
In order to validate an apparent co-localisation between β-synuclein and the 
SNAREs, Manders overlap coefficient of co-localisation has been applied. Manders 
calculates the proportion of overlap between the green (β-synuclein) and red channel 
(VAMP2 or SNAP25) in the stack of images for each patient  [277]. The Manders 
coefficient value produced is between 0 and 1, ‘0’ represents no co-localisation and 
‘1’ signifies100% co-localisation. In this study, a moderate index of co-localisation 
between β-synuclein and both VAMP2 (Figure 37-A) and SNAP25 (Figure 37-B) is 
observed in the cortical and hippocampal regions (M1 = 0.6 - 0.7).  There was no 
discrimination in the co-localisation data when comparing control and DLB. The PCC 
index showed low-moderate level of co-localisation based on the relationship 
between the intensity of the pixels of the two fluorophores. PCC (R values) above 
the Costes threshold. R ≥ 0.5  [278] describe strong co-localisation of two 
fluorophores [274]. 
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Chapter 6: Results discussion 
This study provided evidence for an increase in VAMP2 in the frontal cortex and in 
parallel, a reduction in the occipital cortex of the DLB patients (Figure 34). In 
conjunction with this, a reduction of SNAP25 in the occipital cortex was seen but not 
the frontal cortex (Figure 34). SNARE proteins underpin effective neurotransmitter 
exocytosis, with modifications of levels indicating potential dysfunction occurring at 
the pre-synapse. Changes in the synaptic proteins may be indicative of the level of 
α-synuclein pathology present in the region. It has been reported that reductions in 
SNAREs correlate with LB pathology and a decrease in ChAT levels [271]. It is 
possible to speculate that increasing α-synuclein pathology in DLB causes synaptic 
dysfunction, whether this results in synapse loss is unclear although, this is a feature 
in other dementias such as AD [279] and FTD [280]. The relationship between α-
synuclein and VAMP2 is critical and the loss of α-synuclein in the frontal cortex of 
these DLB brains (Figure 19) is not reflected in VAMP2 levels with an increase 
observed (Figure 34). It is suggested that VAMP2 is important for the replenishment 
of the readily available pool of vesicles [203] a role described for α-synuclein, 
providing a possible protective role for VAMP2 in supporting the synapse in the face 
of declining levels of monomeric α-synuclein. In AD the synaptic protein loss is 
indicative of later stages of dementia with SNAP25 and syntaxin levels unchanged or 
increased in the frontal and temporal cortex early in dementia with a subsequent 
reduction with moderate to severe dementia [281]. If this holds true in DLB, the 
changes observed in the frontal cortex may indicate early cognitive decline and the 
occipital cortex may reflect greater synaptic dysfunction. Moreover, VAMP2 
increases in the frontal cortex may be suggestive of possible attempts of synaptic 
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transmission reparation following α-synuclein toxicity; the loss of VAMP2 is able to 
induce neurodegeneration and autophagy defects in photoreceptor neurons [282]. 
In the cortex, the direction of change of either increasing or decreasing β-synuclein 
(Figure 19) is mimicked by the direction of change in important SNARE proteins for 
the same region (Figure 34). IHC analysis provides evidence for re-distribution in β-
synuclein and the SNAREs in the frontal cortex, occipital cortex and the 
hippocampus (Figure 35 & 36).  
When examining VAMP2 and SNAP25 in the presence or absence of β-synuclein, 
the data provided is descriptive and therefore, subjective. Whilst 
immunohistochemistry is a widely used tool, there are limitations when using this 
method to describe changes occurring in the human brain that may or may not be 
associated with DLB. In this regard, descriptive data is not suitable to correlate 
variables, perform statistical analysis or identify the cause or effect and should be 
interpreted cautiously. Misinterpretation of both positive and negative results are 
possible potentially leading to an incorrect morphological perspective. 
Descriptions have focused on the intensity of immunoreactivity of the proteins of 
interest and the pattern of staining throughout the neuropil or around β-synuclein 
positive cells. Interpretation consistency was employed, I ensured that I was familiar 
with the specific observations I wished to make. From the beginning of the protocol 
to the image acquisition stage, all tissues were treated with the same level of 
consistency.  
An increase in the number of patients per group examined would enable a greater 
appreciation of whether the changes observed in the study may be relevant to the 
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disease course. In addition, to ensure the exclusion of any bias in this method of 
analysis, it would be necessary for an additional examination to be undertaken 
independently, for each group and each region, by a neuropathologist; the 
observations would then be collated and compared.  
In order to observe two proteins in tandem, the double immunofluorescent protocol 
was employed. In view of the implementation of fluorescent microscopy, it is more 
challenging to approximate the layer of the cortex/hippocampus and therefore, it is 
possible that different regions of the brain tissue have been compared between 
patients and groups. I attempted to be as consistent as possible to minimise such 
variation. 
Potentially, damaged tissue, due to the disease process or human error during the 
tissue processing – from fixing to cover-slipping - may allow for accumulations of the 
antibody leading to a false-positive signal. In all cases of IHC processing, the brains 
were treated with the same protocol that was adhered to as strictly as possible and 
microscope settings optimised in order to enable comparable descriptions between 
groups and regions. In order to minimise the possibility of subjective bias, imaging 
was performed without the knowledge of whether the patient was a control or DLB, 
analysis was performed by myself only and within a reasonable period of time. Whilst 
one accepts that disease duration and other pathological considerations may 
interfere with the observations, where possible, patients and controls were age-
matched to provide a relative and comparable discussion.  
The IHC analysis indicated colocalisation that is supported by Manders 
colocalisation analysis (Figure 37). Surprisingly, the co-localisation analysis did not 
discriminate between controls and DLB indicating that these relationships are not 
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pathologically driven but rather represent previously unreported physiological roles. 
In this regard, one may assume that homology between the synucleins will dictate 
these potential interactions indicating a possible function for β-synuclein with regard 
to SNARE protein complex formation that cannot yet be excluded. Therefore, it is 
possible that β-synuclein acts in a supporting role at the pre-synapse attempting to 
modulate SNARE protein behaviour and ensure ongoing synaptic transmission and 
loss of β-synuclein at the pre-synapse will see the demise of any functional 
relationship.  
One could speculate, that loss of SNARE complex formation would disrupt the 
neurochemical balance in relation to neurotransmitter release which could impact 
cognitive function. Furthermore, loss of the SNAREs may have a wider reaching 
impact, loss of VAMP2 is associated with impairment of protein degradation and 
slow neurodegeneration, that is not linked to its role in neurotransmitter release 
[282]. The yeast homolog of SNAP-25 is required for autophagosome and yeast 
vacuole fusion, the equivalent of the mammalian lysosome fusion [283]. It must, 
therefore, be considered that loss of /increases in SNARE proteins may disrupt 
processes such as autophagy, dysfunction of which is observed in DLB. 
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Results chapter 7: Autophagy in the cortical regions of the DLB brains and in 
vitro 
Failure in the lysosomal-proteolytic degradation pathway has been implicated in 
neurodegeneration with the accumulation of enlarged and morphologically impaired 
autophagosomes/lysosomal-like organelles observed in DLB [249] and high levels of 
lysosomal-like vacuoles in PD [250]. Variations in some autophagy proteins are 
observed in Lewy body disease [284] and upregulation of autophagic factors leads to 
a recovery of neurodegenerative phenotypes [285]. β-synuclein has been shown to 
promote neuronal survival [178] and prevent neurotoxic cell death [180]. Conversely, 
increased levels of mutated β-synuclein lead to enhanced lysosomal dysfunction 
[168], is associated with autophagosome-like swellings [177]  and in an AD mouse 
model, β-synuclein  levels are increased and localised with enlarged lysosomes 
[286].This study has identified increased levels of β-synuclein protein in the frontal 
cortex of the DLB brain with increased cytosolic representation. The next step was to 
examine key autophagy factors in these regions to identify any autophagy-related 
changes that may be occurring. 
 
7.1: Examination of p62, LC3, Beclin and LIMP2 protein levels in the cortical 
regions of the human brain 
In order to identify whether potential alterations in the autophagy process occurs in 
regions with altered β-synuclein protein levels, I examined some key lysosomal and 
autophagosome-associated proteins in the cortical regions of human brain lysates by 
western blotting. 
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7.1.1: P62 protein levels in the human brain  
Autophagy receptor p62 binds to ubiquitinated cargo destined for autophagy [287] 
and is a component of Lewy bodies [288], with loss of p62 seeing an increase α-
synuclein fibrillisation properties [289]. P62 is degraded with the cargo by lysosomal 
enzymes, following the fusion of the lysosome and the autophagosome. 
 
Figure 38 - p62 is increased in the DLB frontal cortex 
Western blot analysis of levels of p62 in the frontal cortex (A) of controls (n= 8) and DLB (n= 
15) and p62 in the occipital cortex (B) of controls (n= 7) and DLB patients (n= 13). P62 is 
increased in the frontal cortex in DLB (P=0.04). Statistics were revealed by Student's two-tailed 
t-test. 
 
The examination of p62 in the frontal cortex (Figure 38-A) identified a significant 
increase in levels of the protein in the DLB patients when compared to the controls 
(P=0.04). In contrast, no changes were observed in the occipital cortex (Figure 38-B) 
between the groups.  
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7.1.2: LC3 protein levels and distribution in the human brain 
The increase of p62 in the frontal cortex of the DLB brains led to the examination of 
the levels of LC3-II in the cortical regions. LC3-II serves as an anchor for P62 [284] 
and the reciprocal binding, between these two proteins, ensures the efficient delivery 
of the cargo to the autophagosome for degradation; further, LC3-II  is required for 
elongation of the phagophore to an autophagosome [234]. An increase in LC3 in the 
temporal cortex [249] and the entorhinal cortex and amygdala [290] of DLB brains is 
reported. The frontal and occipital cortex was next examined. 
 
      
Figure 39 - LC3-II protein is increased in the DLB frontal cortex 
Levels of LC3-II in the frontal cortex (A) of controls (n= 4) and DLB (n = 8) and LC3-II in the 
occipital cortex (B) of controls (n= 6) and DLB patients (n=7). LC3-II is increased in the frontal 
cortex of the DLB brain (P=0.02). As detected by western blot analysis. Statists revealed by 
Students two-tailed t-test. 
Analysis of LC3-II in the cortical regions shows that LC3-II is significantly increased 
in the frontal cortex of the DLB patients when compared to the control (Figure 39) 
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(P= 0.02); however, no changes are observed in the occipital cortex. These changes 
mimic the changes that are observed when examining p62 in these regions.  
 
7.1.3: LC3-I protein in the human brain 
Under physiological conditions, LC3B is expressed as a full-length protein and 
stimulation of autophagy leads the proteolytic cleavage of its CTD to form LC3-I 
[232] the precursor to LC3-II  [248]. Having identified changes in the frontal cortex of 
LC3-II next I sought to examine LC3-I in this region. 
 
 
Figure 40 - LC3-I is increased in the frontal cortex of the DLB brain 
Levels of LC3-I in the frontal cortex of controls (n= 4) and DLB (n= 7) as detected by western 
blot analysis. LC3-I is increased in the frontal cortex of the DLB brain (P=0.04). Statistics 
revealed by student’s two-tailed t-test. 
 
Examination of LC3-I in the frontal cortex identified a significant increase in LC3-I 
protein levels in the DLB brains when compared to the controls (Figure 40)            
(P= 0.04).  
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7.1.3: Beclin 1 protein in the human brain 
The finding that the un-lipidated form of LC3, LC3-I, is increased in DLB patients in 
the frontal cortex indicates that there may be early events in the autophagy process 
that are involved in dysfunctional clearance functions. Beclin 1 is a major factor in 
the initiation of autophagosome formation and early in PD a significant reduction of 
beclin 1 is observed [291], indicating potential time-course events in protein levels 
under pathological conditions.   
 
Figure 41 - Beclin levels are unchanged in the frontal cortex of the DLB brain 
when compared to the control and there is a negative correlation between 
protein levels of Beclin 1 and the disease duration 
Levels of beclin 1 in the frontal cortex of controls (n= 7) and DLB (n = 12) as detected by 
western blot analysis. Statistics revealed by Students t-test. Regression analysis shows a 
negation correlation (R2) between levels of beclin 1 and the duration of disease (2 – 5 years) in 
the frontal cortex (n=7). R2 analysis performed by Excel. 
 
There is no change in the levels of beclin 1 when comparing DLB patients to the 
controls in the frontal cortex (Figure 41); although large inter-group variations seen. I 
then examined the correlation between beclin levels and the disease duration by 
regression analysis. DLB patients with a disease duration spanning 2-5 years in the 
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frontal cortex, identified a strong relationship between a decline in beclin 1 levels as 
the pathology progressed (Figure 41), (R2 0.9); indicating that levels of beclin 1 are 
higher earlier in the disease course in the frontal cortex of the DLB patient and 
significantly reduce over a period of 5 years of α-synuclein-induced pathology.  
 
7.1.4: Lysosomal marker (LIMP2) protein levels in the human brain 
DLB has been associated with lysosomal pathology, in particular, the SCARB2 gene 
(LIMP2) has been identified as a risk factor [96]. LIMP2 is a transmembrane 
lysosomal associated protein and a binding receptor for enzyme glucocerebrosidase 
(GC), ensuring the efficient delivery of the enzyme to the lysosome [292]. 
Importantly, GC may be involved in the degradation of α-synuclein, with mutations in 
the GBA gene increasing the risk of PD [293]. LIMP2 in the frontal cortex and 
occipital cortex of control and DLB patients were explored to identify whether protein 
levels of this protein are altered in our DLB brains, in the regions that we have 
identified as having modified β-synuclein levels. 
 
 
              
Figure 42 - LIMP2 is unchanged in the DLB brain when compared to the control 
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Levels of LIMP2 in the frontal cortex of controls (n= 7) and DLB (n = 15) and LIMP2 in the 
occipital cortex of controls (n= 7) and DLB patients (n=10). Statistical analysis was performed 
by one-way ANOVA and Bonferroni post hoc test. 
 
There were no discernible differences of Limp2 in the DLB brain when compared to 
the controls in either the frontal cortex or occipital cortex (Figure 42). The frontal 
cortex showed large inter-group variation in both the controls and DLB patients that 
may be corrected by higher patient numbers.  
 
7.2: β-synuclein and autophagy markers in vitro  
This study has shown that p62 and LC3-II are increased in the frontal cortex of the 
DLB brain and strong evidence is provided for an increase in β-synuclein in the same 
region of the DLB brain. There is evidence to support a role for mutated β-synuclein 
in lysosomal dysfunction [168] and the observed changes in β-synuclein, may 
potentially have a direct or indirect relationship with the autophagy related changes 
that are occurring in the DLB patients. In the human brain, it is not possible to 
establish whether β-synuclein induces the autophagy-related changes that are 
observed in DLB patients. In order to examine this potential relationship, examination 
of autophagy related proteins was undertaken in Hela cells and BE(2)-M17, 
neuroblastoma cells in the presence or absence of β-synuclein.  
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7.2.1: β-synuclein and autophagy markers in Hela cells 
In order to explore the relationship between β-synuclein and autophagy related 
components, the use of a mRFP-GFP-LC3-II quenching assay was employed. This 
assay enabled the autophagy flux to be examined in Hela cells expressing a human-
β-synuclein construct. The mRFP-GFP-LC3 vesicle quenching assay is widely used 
to monitor autophagosome synthesis and autophagosome-lysosome fusion devised 
to label the autophagic compartments prior to and subsequent to lysosomal fusion 
and cargo degradation  [294].  
The labelling of the autophagosome with LC3-II in GFP (green) and mRFP re results 
in co-localisation of the channels producing a yellow signal. During the lysosomal 
acidic degradation process, the GFP-LC3 signal is quenched but mRFP is 
maintained. Thus, providing an assay that enables the monitoring of the 
autophagosome prior to and following fusion events with the mRFP signal being an 
indication that the autophagy flux has proceeded to completion. The presence of a 
red signal represents autophagosomes and autolysosomes, in contrast, a green 
signal is indicative of autophagosomes only. Therefore, the examination of the 
number of autophagosomes vs. autolysosomes, as quantified by puncta number, 
enables the autophagy flux to be more accurately observed [295]. Furthermore, 
investigation of the levels of autophagy related proteins in neuroblastoma cells was 
examined in the presence of human β-synuclein by western blot analysis. Enabling 
the characterisation of autophagy changes in relation to increased levels of β-
synuclein. 
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 Figure 43 - LC3-II and p62 are increased in Hela cells in the presence of β-
synuclein and autophagosomes and autolysosomes are depleted 
Hela cells were transfected with or without human β-synuclein (A & B, respectively) in the 
presence of the LC3-GFP construct. There is an increase of LC3-GFP puncta (B) in β-synuclein 
containing cells (stained in red). mRFP-GFP-LC3 vesicle quenching assay (C & D) shows an 
increase in yellow puncta after overexpressing β-synuclein (D) versus control (C). LAMP2 in 
cyan blue (E) is associated with the large yellow structures (F). An increase of LC3-II (P=0.012) 
(G) and p62 (P=0.02) (H) levels are detected by western blotting in Hela cells. Autophagosomes 
are reduced in β-synuclein expressing cells (P=<0.0001) (I) and autophagy flux is decreased 
(P=0.003) (J). N = 3 experimental repeats. Statistical analysis performed by Student t-test. 
Scale bar 25µm.  
 
In the presence of β-synuclein (Figure 43-B) there is a significant presence of LC3-II 
accumulations (B, arrow) in the cytoplasm of the Hela cells when compared to the 
cells not expressing the β-synuclein construct (Figure 43-A). The LC3-II labelling of 
the autophagosome (Figure 43-C & D) enabled the observation of the autophagy flux 
170 
 
in the presence (D) and absence (C) of human β-synuclein. In Hela cells over 
expressing human β-synuclein the presence of large yellow puncta was seen (D, 
enlarged, *) indicating a decrease in GFP-LC3-II quenching in cells overexpressing 
β-synuclein. Conversely, the controls (C) presented with small speckles that were 
labelled both green and red (C, enlarged, #). LAMP2 (cyan blue) (Figure 43-E) was 
associated with the large yellow structures (Figure 43-F). Furthermore, western blot 
analysis identified an increase in LC3-II (P = 0.012) (G) and p62 (P = 0.02) (H) in 
those cells expressing β-synuclein when compared to the control. The quantification 
of GFP and RFP structures demonstrated that in β-synuclein over expressing cell, 
autophagosome number (Figure 43-I) (P=<0.0001) and autolysosomes (Figure 43-J) 
(0.0033) are depleted. 
 
7.2.2: β-synuclein and autophagy in neuroblastoma cells 
The data I present (Figure 43) is indicative of a decrease in the autophagy flux in the 
presence of β-synuclein with the increase of LC3-II demonstrating that lysosomal 
degradation is not taking place. This is suggestive of β-synuclein interfering in 
upstream autophagy events. To validate these findings, the impact of β-synuclein on 
autophagy is addressed using neuronal cell lines. This ensures that the changes 
identified can be used to translate the changes presented in the human brain. 
Neuroblastoma cell line, BE(2)-M17 was used utilised with transient overexpression 
of β-synuclein or the control vector in the presence of a LC3-II construct in order to 
examine the behaviour of LC3-II in the presence and absence of β-synuclein. 
Furthermore, BE(2)-M17 cells were also treated with chloroquine, an inhibitor of 
autophagosome and lysosome fusion, in the presence and absence of β-synuclein in 
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an attempt to identify whether β-synuclein is preventing fusion and therefore, 
providing an explanation for the decrease in the autophagy flux. 
  
 
Figure 44 - β-synuclein impairment of the autophagy flux is comparable to 
chloroquine treatment indicating a reduction in autophagosome and lysosome 
fusion 
 An increase in p62 is revealed in β-synuclein stable expressers (P=0.03) (A). An increase in 
LC3-II levels is detected by western blotting in BE(2)-M17  (P=<0.0001) (B) after β-synuclein 
expression (FL Beta-syn) however, this dramatic increase was less pronounced in the 
presence of chloroquine (Cq). Autophagy flux (C) was calculated as the difference between the 
LC3-II levels in the cells treated with Cq and the vehicle. Statistics revealed by student’s two-
tailed t-test. N=3 experimental repeats. 
 
In correlation with the data presented in the Hela cells (Figure 43), there is a 
significant increase in p62 in cells that stably express β-synuclein (Figure 44-A) 
(P=0.03). There is also an observed increase in LC3-II protein in the presence of β-
synuclein when compared to the controls (P = < 0.0001), in the absence of 
chloroquine (Figure 44-B, Cq -). Whilst there is a trend for an increase, there is no 
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difference between the controls and β-synuclein expressing cells in the presence of 
chloroquine (Figure 44-B, Cq +). When performing quantification of the levels of LC3-
II between chloroquine treated cells and non-treated, in the control group and β-
synuclein expressing cells, the difference between the treatment and non-treatment 
is lower in the β-synuclein expressing cells when compared to the control (Figure 44-
C). 
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Chapter 7: Results discussion 
This study indicates that autophagy related proteins p62 (Figure 38), LC3-II (Figure 
39) and LC3-I (Figure 40) are increased in the human brain lysates in the frontal 
cortex. These are essential autophagy markers that are critical for ensuring that the 
autophagy flux proceeds to completion. The increase in LC3-I may be a 
consequence of autophagy upregulation; alternatively, it may indicate that lipidation 
is not progressing at the rate required for protein removal.  The presence of LC3-II 
shows that lipidation is occurring at some level, although, potentially if the insult is 
great, the cell may not be in a position to maintain the levels of autophagy required 
for clearance marked by the presence of LC3-II.  
P62 and LC3-II are degraded with the cargo by lysosomal enzymes if the cargo does 
not reach the lysosome or a fusion event does not occur, these protein aggregates 
will accumulate in the cytoplasm leading to a backlog of multi-complex formations 
destined for removal. When considering the point at which the autophagy flux is 
impaired, it is possible that a) the autophagosome is not engulfing the p62 bound 
cargo and/or b) the autophagosome engulfed cargo is not being delivered to/fusing 
with the lysosome for degradation.  
The increase in autophagy-related proteins is occurring only in the frontal cortex of 
the DLB patients, the region that sees an increase in β-synuclein protein levels in 
these patients. In correlation with the findings in the DLB human brain, the in vitro 
observations show an increase in β-synuclein is associated with an increase in LC3-
II and p62. It is possible that this increase is related to the failure in the autophagy 
flux to move towards completion, as identified by large yellow structures. These may 
be autophagosome accumulations, indicating that there is a block in the early stages 
of the pathway and this is possibly being mediated by the presence of β-synuclein. 
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Furthermore, a reduction in the presence of autolysosomal fusion with 
autophagosomes is seen (Figure 43) however, surprisingly a decrease in 
autophagosomes is also seen despite an increase in LC3-II levels. In this regard, it is 
feasible that the large structures are indeed accumulations of autophagosomes or 
autophagosomes and lysosomes that are prevented from fusing. The traffic light 
cells are well reported in the literature. The quantification enables only the counting 
of single puncta; therefore, in reality, autophagosome number may not be reduced 
but rather backing up and accumulating in different regions of the cell leading to 
these large yellow structures that are observed (Figure 43). In neuroblastoma cells, 
LC3-II levels and P62 levels are also increased in the presence of β-synuclein and 
but there is no change when the cells were treated with chloroquine (Cq) (Figure 44). 
Cq is used to prevent autophagosome and lysosomal fusion indicating a similar role 
for β-synuclein that is not accentuated in the presence of chloroquine; in this regard, 
the difference between the Cq treatment and non-treatment ROD in the presence of 
β-synuclein sees lower levels of LC3-II indicating a potential threshold has been 
reached. Examination of LIMP2 levels by western blot analysis (Figure 42) show that 
in the frontal cortex and occipital cortex of the DLB patients when compared to 
controls there are no changes; however, LIMP2 levels are lower in the occipital 
cortex than the frontal cortex for both the control and DLB groups. This may suggest 
that the functional requirement for LIMP2 in the occipital cortex may be reduced and 
in this regard, it is also possible that in pathological conditions, lower expression of 
this protein leads to less trafficking of GC to the lysosome. In this situation, less 
lysosomal degradation of α-synuclein would occur in the occipital cortex when 
compared to the frontal cortex; therefore, an increase in deposits would be expected. 
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It is possible that regional differences in LIMP2 may lead to selective vulnerability in 
the clearance of protein aggregates. 
Collectively, I show in the human brain, that autophagy dysfunction at different 
phases of the autophagy process may be implicated in the mechanisms that drive 
the neuropathology observed in DLB and potentially, other α-synucleinopathies. It is 
likely that various components of the autophagy pathway are implicated at different 
phases of the disease course. It is also possible that as the cellular system is over-
powered by protein accumulations, its clearance capabilities become fatigued and 
less-efficient. Importantly, β-synuclein, like α-synuclein, has membrane binding 
properties, whilst under physiological conditions, this behaviour may not represent a 
threat, under the influence of pathology and increased levels of the β-synuclein 
protein, it is feasible that β-synuclein protein crowding can bind to the 
autophagosome or lysosome, leading to impairment of the autophagy process. 
Whether this is independent of α-synuclein or whether it accentuates α-synuclein-led 
pathology remains to be explored. These observations of an increase in β-synuclein 
in the frontal cortex, the abnormal granule deposits of the proteins in DLB patients, in 
addition to alterations in the autophagy pathway in this same region, give credence 
to the possibility that an increase in β-synuclein may present itself as playing a role 
in the pathological process.  
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Chapter 8: Final discussion and future work 
8.1: Final discussion 
Regional changes in the protein levels of the synucleins, key SNAREs and 
components of the autophagy pathway have been revealed in the cortical regions of 
the DLB human brain (Figure 45). 
 
Figure 45 - An overview of protein changes identified in this study in the 
cortical regions of the DLB brain  
 
The synucleins represent approximately 1% of the proteins in the cytosolic fraction of 
the human brain [25] indicating an important functional role for this family that for the 
most part remains elusive. β-synuclein and α-synuclein are binding partners with this 
relationship being described in relation to β-synuclein’s attenuation capacity in α-
synuclein pathology. This creates an important function for β-synuclein with the 
potential to inhibit the pursuance of α-synuclein aggregation and pathological 
behaviour in α-synucleinopathies. A role for β-synuclein has been explored in this 
study: (1) with examination of the levels of β-synuclein in the cortical-paralimbic 
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regions enabling the elucidation of whether β-synuclein levels are modified in relation 
to α-synuclein levels in the DLB brain; (2) in relation to key pre-synaptic SNARE 
proteins and (3) β-synuclein and the protein degradation pathway, autophagy. 
I provide evidence for region-specific changes of β-synuclein protein levels in the 
DLB brain (Figure 18) in addition to its re-distribution and re-localisation into the 
neuronal soma. Modifications in the levels of β-synuclein are only observed in the 
cortical regions: an increase in the frontal cortex in parallel with a decrease in the 
occipital cortex. Despite the difference in the directional change in β-synuclein, both 
regions present with similar levels of pathological oligomeric α-synuclein (Figure 20) 
although, the frontal cortex sees a decrease in monomeric α-synuclein (Figure 19).  
When comparing the synuclein proteins in the control brain, twice the level of α-
synuclein in the frontal cortex is seen when compared to the occipital cortex (Figure 
20), although α-synuclein is known to be highly expressed in the cortical regions, this 
indicates regional physiological preferences. In the DLB brains examined, the α-
synuclein balance in the frontal cortex is reversed with an almost 50% depletion 
compared to the controls but a similar increase in β-synuclein is seen in the DLB 
patients (Figure 18). In the occipital cortex, α-synuclein remains unaltered in DLB 
with a decrease in β-synuclein levels; providing evidence for attempts in these 
regions to maintain levels of the synucleins overall. 
The mechanisms behind these alterations in protein levels of β-synuclein is not clear. 
It was considered that protein level modifications might reflect changes in 
transcriptional activity by the synucleins, supported by previous studies that report a 
decrease in mRNA transcripts in the cortex of pDLB patients [98]. β-synuclein 
transcription in the frontal cortex has not been previously examined in isolation in the 
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DLB brain and pilot data indicate that β-synuclein mRNA is not significantly 
increased in the frontal cortex although future work will require an increase in 
patients to validate these findings and expansion into other regions. Therefore, 
based on the current evidence it is possible to surmise, that the increase in β-
synuclein protein in the frontal cortex is attributed to protein stabilisation or 
impairment of protein degradation pathways, maintaining elevated levels of the β-
synuclein protein in this region. In contrast, the decrease of β-synuclein in the 
occipital cortex may be explained by increased protein turnover or synaptic loss.  
It is conceivable that an increase in β-synuclein protein levels and observed re-
distribution of β-synuclein that I have identified in the frontal cortex of the DLB brain 
may be driven by a protein redundancy effect. Despite the lack of evidence for a role 
for β-synuclein at the pre-synapse, by virtue of its localisation properties it is likely to 
have a similar role that will see loss of α-synuclein being compensated for by β-
synuclein. Evidence of synuclein family protein redundancy is provided by triple 
knockout models [146], a model that sees alterations in synaptic architecture and 
transmission deficits in addition to age-related neuronal dysfunction that does not 
appear with a single synuclein knockout. β-synuclein is specifically important in the 
cortex during the normal ageing process that sees cortical increases in β-synuclein 
mRNA and a decline in α-synuclein mRNA [296], prior to ageing similar levels of 
cortical synuclein expression is observed. This suggests that β-synuclein, under 
physiological conditions, is an important factor to consider in the ageing brain and 
changes in levels may lead to aberrant synaptic behaviours. 
The significant loss of monomeric α-synuclein seen in the frontal cortex of the DLB 
brains may lead to an increase in the stability of the β-synuclein protein, resulting in 
a subsequent increase in β-synuclein protein levels. This may indicate an attempt by 
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β-synuclein in the frontal cortex to rescue any deficit in a physiological role resulting 
from declining monomeric α-synuclein levels or the increasing pathological behaviour 
of α-synuclein. This proposed role for β-synuclein is lost in the occipital cortex that 
sees the demise of β-synuclein. In the occipital cortex although monomeric α-
synuclein is unchanged there is the additional burden of oligomeric α-synuclein. It is 
possible, therefore that these regional differences in β-synuclein may be more 
directly driven by the changes in total levels of the α-synuclein protein present in the 
region.  
The appearance of β-synuclein, an otherwise pre-synaptic protein, in the cytosol of 
cortical neurons is novel and intriguing. The number of β-synuclein positive cells in 
DLB do not differ significantly between both cortical regions (Figure  28). This 
indicates that the reduced β-synuclein levels observed in the occipital cortex may be 
primarily associated with the cytosolic fractions of these brains with almost total loss 
of the protein in the synaptosomes. β-synuclein positive neurons are also present in 
the control brains, although at a reduced level. It is possible that the cytosolic 
presence of β-synuclein is a physiological effect. This effect may be accelerated in 
the wake of neurodegeneration, as identified by the increased number of β-synuclein 
positive cells in DLB patients when compared to the controls in the frontal cortex. 
Furthermore, β-synuclein has been shown to promote cell survival in the presence of 
cellular toxicity and inhibit apoptosis [101]; this may predispose a role for β-synuclein 
that involves re-localisation and upregulation of cell survival pathways to prevent 
cellular demise. Finally, it cannot be discounted that the cytosolic presence of β-
synuclein may result from impaired trafficking events of the protein to or from the 
synapse. α-synuclein is associated with axonal trafficking defects [297] and it is 
thought that axonal dysfunction may also contribute to a “dying back” process that 
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leads to loss of neuronal function and loss of neurons from disease-specific neuronal 
populations [298]. In support of impaired trafficking, I observed 5G4-immunoreactive 
filiform structures in the cortical regions that appear more pronounced in the occipital 
cortex when compared to the frontal cortex (Figure 28). These structures may be 
regarded as LNs in differing phases of maturity, LNs are a predominant feature of 
DLB; although, it was not determined whether this immunoreactivity I observe is 
associated with axons or dendrites. In each case, the presence of oligomeric α-
synuclein in neuronal extensions most likely will interfere with trafficking events and 
normal cellular functioning.  
 
 
Figure 46 - An increase in the pathological presence of α-synuclein may lead 
to re-distribution of β-synuclein 
 (A) a cytosolic presence of β-synuclein in the absence of pathological α-synuclein in the cell 
body of local neurons or neurons with synaptic α-synuclein pathology (B) or β-synuclein may 
be increase in the pre-synapse and/or cytosol of neighbouring neurons (C) in an effort to 
modulate local neuronal activity or mediate the physiological function of α-synuclein with loss 
of α-synuclein. 
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In addition to modifications in the levels of β-synuclein, I identify alterations in 
SNARE proteins in the DLB brain with an increase in VAMP shown in the frontal 
cortex (Figure 34). The increase of VAMP2 that I observe in the DLB frontal cortex 
may also be driven by mechanisms attempting to rescue impending synaptic 
dysfunction in the face of increasing oligomeric α-synuclein and loss of monomeric 
α-synuclein in this region. α-synuclein assists in the cis-SNARE complex formation 
[141] but oligomers of α-synuclein have been shown to prevent SNARE complex 
formation and inhibit neurotransmitter release [299]. In ageing mice with triple 
synuclein knockout, an increase in VAMP2 is observed and VAMP2 levels have 
been shown to be increased in SNAP25 knockout mice [300], it is suggested that 
SNAREs such as VAMP2 may increase early in the pathology of α-synucleinopathies 
in an attempt to compensate for failing synapses [209],  implying that changes in 
levels of key synaptic proteins may occur when others are lost in an effort to 
restore/maintain homeostasis at the synapse. 
In contrast to the frontal cortex, VAMP2 and SNAP25 protein levels are reduced in 
the occipital cortex (Figure 34) supporting the idea that pre-synaptic loss or 
dysfunction is occurring in this region with a significant loss of pre-synaptic proteins. 
There is evidence that overexpression of α-synuclein leads to “vacant synaptic 
boutons” leading to the almost total loss of endogenous pre-synaptic proteins, 
including VAMP 2 [301]. This reinforces the idea that α-synuclein at the synapse may 
induce synaptic pathology that precedes neuronal cell death. The lack of SNARE 
proteins in the occipital cortex will see reduced neurotransmitter release resulting in 
a breakdown in the signalling circuitry. The concept that β-synuclein is acting in a 
compensatory manner to protect the synapse in the frontal cortex is supported by the 
evidence I provide for β-synuclein and SNARE protein co-localisation (Figure 37), 
182 
 
further, the changes I observed in β-synuclein protein levels are altered in the same 
direction as the SNARE protein level changes. This leads to the reasonable 
conclusion that β-synuclein may independently assist in the formation of the SNARE 
complex, like its family member α-synuclein. Although, co-localisation between β-
synuclein and SNAREs is not changed between controls and DLB brains in the 
cortex it presents an important task for β-synuclein at the pre-synapse that is not 
primarily driven by pathological events but rather a physiological role. Under normal 
physiological conditions the primary driver may be α-synuclein and β-synuclein may 
act as a bystander until required. In this event, the loss of β-synuclein in the DLB 
brains will prevent any compensatory assistance that will potentially lead to 
enhancement of signalling dysfunction and synaptic demise (Figure 47); this may be 
representative of changes occurring in the occipital cortex of the DLB patients. 
 
 
Figure 47 - Synaptic dysfunction in the absence of β-synuclein 
Loss of β-synuclein and increasing α-synuclein levels see loss of pre-synaptic SNAREs 
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I have suggested that total α-synuclein regional levels may be the leading factor for 
the changes observed in β-synuclein protein levels and the consequential loss of 
other pre-synaptic proteins. In DLB the greatest burden of LBs is seen in the 
temporal lobe and limbic regions with lower levels seen in the frontal and the 
occipital cortex [27]. Indications are that the pathogenesis of α-synucleinopathies 
originates at pre-synapses with 90% of α-synuclein aggregates localised to the 
synapse [176].This study has provided evidence for high levels of oligomeric α-
synuclein in the frontal and occipital cortex (Figure  20), that are likely causing pre-
synaptic damage prior to sequestration of α-synuclein into LBs. It would be tempting 
to speculate that whilst LB pathology is considered to be low in the frontal cortex and 
occipital cortex of the DLB brain, the levels of oligomeric species of α-synuclein I 
observe in the DLB brain are undoubtedly producing a toxic effect. In both cases, 
this could explain the fluctuating cognitive impairment, an early sign of DLB that is 
associated with the frontal cortex in addition to the plethora of symptoms associated 
with the occipital cortex that include: visual hallucinations; poor responses to visuo-
perceptive tasks, a severe deficit in neurotransmitters, involving the cholinergic 
system [259] and hypometabolism that is more severe than in other 
neurodegenerative conditions [302].  
It is suggested that impaired synaptic activity, rather than neuronal loss, may fortify 
the symptoms associated with cortical neurodegeneration  [303] & [304], it is likely 
that that the loss of SNAREs and increasing levels of α-synuclein in the occipital 
cortex would precede dysfunctional synaptic activity. Therefore, I propose that loss 
of the SNAREs and β-synuclein in the occipital cortex may contribute to the 
extensive cognitive dysfunction associated with the occipital cortex.  
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In the frontal cortex, increased β-synuclein correlates with disease duration (Figure 
21), it is possible that loss of α-synuclein into oligomeric species, sees an increase in 
β-synuclein to balance the monomeric synucleins present in the frontal cortex. It 
needs to be established why this correlation does not occur in the occipital cortex. A 
potential explanation could be that an increase in β-synuclein is a disease-specific 
temporal event with the changes observed in the occipital cortex being more 
resonant of this region becoming overwhelmed by α-synuclein pathology prior to the 
frontal cortex. Therefore, it needs to be established whether these changes I observe 
are related to a temporal spread of pathology with the possible demise of one 
cortical region preceding another during the disease course. Alternatively, it cannot 
be ignored that the occipital cortex may be more susceptible to changes in the face 
of increasing pathology; clarification of β-synuclein levels in other cortical regions will 
help establish whether this is a stand-alone effect or whether there are region-
specific changes that occur in tandem leading to the symptoms produced in the DLB 
patient. 
 When considering the direct interaction between the synucleins that may bestow 
protection against α-synuclein aggregation, co-localisation by IHC has shown that 
the pathological species of α-synuclein very infrequently co-localises with β-
synuclein in the human brain (Figure 28), unlike monomeric α-synuclein (Figure 28). 
β-synuclein is not associated with LBs or LNs [49] reinforcing the theory that β-
synuclein is not involved in the pathological process but may be an innocent 
bystander. It may be promoted that the interaction between β-synuclein and α-
synuclein arises from non-modified forms of the protein and PTMs may prevent this 
association. It is likely that under physiological conditions when a balance in the 
synuclein proteins is present, transient interactions may occur but if the environment 
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sees an increase in α-synuclein or modified α-synuclein, then β-synuclein levels may 
not be sufficient to prevent oligomerisation and a pathological environment may 
ensue.  
I speculate as to whether the changes observed in the frontal cortex and occipital 
cortex in respect of β-synuclein levels may be representative of temporal changes 
occurring that relates to the pathological spread. To address the temporal aspect of 
α-synuclein pathology, in relation to changes in β-synuclein, a dopaminergic in vitro 
model overexpressing human α-synuclein was employed. Surprisingly, β-synuclein 
levels were unchanged in this model at the different time points assessed during 
increasing α-synuclein levels. In contrast, there was clear evidence of β-synuclein 
cellular localisation changes - those cells that have high levels of β-synuclein display 
low α-synuclein and vice versa. This is fitting with the human IHC brain data with re-
distribution of β-synuclein observed and its absence in oligomeric α-synuclein 
containing cells. The re-distribution and unchanged levels of β-synuclein may 
indicate that cellular modulations occur that see an overall balance in synuclein 
availability in the culture. This is demonstrative of either the potential cross-talk 
between synucleins that is performed at an inter-cellular level or the passage of the 
synucleins between cells. α-synuclein has been shown to have prion-like properties 
and in vitro has been shown to transfer between cells [305]. It is entirely feasible that 
β-synuclein may display similar properties and is an avenue to be explored further. 
An alternative explanation in the in vitro model I employed is more specifically 
related to the neuronal phenotype and the lack of changes in β-synuclein proteins 
levels may be explained by the use of dopaminergic neurons alone, the human brain 
is not homogeneous in cell types and models involving other neuronal phenotypes 
needs to explored, of particular interest would be cortical neurons.   
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Collectively, changes in key pre-synaptic proteins are observed in the frontal cortex 
and occipital cortex of the DLB brain in the presence of increasing levels of 
oligomeric α-synuclein. In order to prevent protein accumulations, it is essential for 
degradation pathways to remove any toxic threat to the cell. This requires efficient 
cellular homeostatic mechanisms that are able to address cellular dysfunction. 
Ageing is a risk factor for neurodegeneration as proofreading mechanisms and 
detection systems decline with age. It may be that any age-related decline in 
performance may further contribute to the failure of the cells to remove aggregating 
proteins. Furthermore, an increase in protein levels and aberrant behaviours 
produces additional stress in the cell, leading to interference in these pathways that 
augments the pathological process.  
I have also provided evidence for changes in key autophagy-related proteins in the 
frontal cortex of the DLB brain, leading to the hypothesis that these changes in 
autophagy may be related to the increase in β-synuclein. These results were not 
mimicked in the occipital cortex where β-synuclein is diminished. Aggregating α-
synuclein has been shown to interfere with the UPS and autophagy pathways, due to 
the similarities in synuclein properties it is intriguing that β-synuclein may also 
interfere with pathways associated with degradation processes in the DLB brain. In 
the frontal cortex LC3 protein (Figures 39 & 40) and p62 (Figure 38) are increased 
and the increased presence of these proteins demonstrates an early block in the 
autophagy pathway that is prevented from proceeding to completion. 
In vitro methods were employed to validate the block in autophagy in the presence of 
β-synuclein. I present data that supports a role for β-synuclein-positive cells 
displaying dysfunctional autophagy-related behaviours with the presence of 
increased levels of β-synuclein appearing to prevent the autophagy flux, resulting in 
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increased levels of LC3-II and p62 (Figure 43). Further, transient expression of β-
synuclein reveals large autophagosome-lysosome accumulations in Hela cells and 
BE-2-M17 cells, in parallel to increases in LC3 and p62 (Figure 44). The inherent 
membrane binding capabilities of the synucleins by their NTD cannot exclude the 
possibility that β-synuclein is able to bind to the autophagosome/lysosome directly 
and impair fusion events (Figure 48). A role for β-synuclein in the accumulation of 
large autophagosome-lysosomal structures has already been described. β-synuclein 
mutants P123H and V70M produce a phenotype that sees these large 
accumulations of abnormal structures that predisposes a toxic gain of function for β-
synuclein in impairment of autophagy [168]. Moreover, lysosomal storage disorders 
are associated with α-synucleinopathies. Both cortical regions see similar levels of 
oligomeric α-synuclein therefore, it is proposed that the observed changes in the 
autophagy proteins is directly related to the levels of β-synuclein; providing strong 
evidence for β-synuclein autonomously inducing dysfunction. The use of a lysosomal 
fusion inhibitor, chloroquine, showed β-synuclein produced levels of p62 and LC3-II 
that were not dissimilar with or without treatment (Figure 44), indicating that a 
threshold had been reached.  
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Figure 48 - β-synuclein prevents autophagosome and lysosomal fusion 
β-synuclein prevents fusion of the lysosome and autophagosome (A) leading to inhibition of 
protein degradation. 
 
An alternative explanation for the modifications occurring in the autophagy process 
may be as a direct result of the increase in β-synuclein, leading to upregulation of 
autophagy in order to enhance protein turnover of this protein. However, the 
increase in β-synuclein may contribute to protein crowding that then sees β-
synuclein obstructing the process in the frontal cortex.  α-synuclein is unable to be 
transitioned into the lysosomal lumen, in this regard the association of β-synuclein 
with the lysosome may be responsible for impairment of the fusion process. Whilst 
not intended to be pathological, the increase as a physiological response to pre-
synaptic dysfunction may indirectly contribute to the failure of the autophagy system. 
Potentially, the finding that β-synuclein interferes with the autophagy flux in addition 
to the toxic effects of α-synuclein in the same region indicates two independent 
mechanisms that obstruct protein clearance strategies, resulting in the cellular 
accumulation of protein aggregates and autophagosome/lysosomes.  
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The role of α-synuclein in α-synucleinopathies is uncontested, but there are variable 
reports of the viability of α-synuclein as a biomarker in DLB. Increases in CSF-α-
synuclein has been shown [306] in addition to decreases [307] and no changes 
[308]. Recently, β-synuclein in the CSF was shown to be consistently higher in the 
dementias when compared to α-synuclein, the β-synuclein to α-synuclein ratio was 
higher in PDD when compared to controls and PD further, β-synuclein highly 
correlates with tau levels in the CSF of AD patients [313]. This presents an important 
role for β-synuclein as a biomarker candidate in AD and PDD that requires further 
examination in relation to dementia. This study provides evidence for a positive 
correlation between increasing β-synuclein levels and disease duration in DLB in the 
frontal cortex only, an effect that is lost in the occipital cortex, a region that is 
relatively spared in the most common form of dementia, AD [309]. Therefore, further 
investigations into the regional levels of β-synuclein in other types of dementia, 
including AD, is necessary.  
To surmise, the role of β-synuclein, previously considered a passive bystander, may 
be dependent on its cellular localisation status. Pre-synaptically, β-synuclein may act 
to maintain the integrity of the synapse in the absence of α-synuclein, in contrast, its 
cytosolic presence may represent a physiological or pathological response to α-
synuclein toxicity that appears to directly impair essential protein clearance 
mechanisms in some brain regions.  
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8.2: Concluding remarks and future work 
This study provides correlative evidence for a role for β-synuclein in the frontal cortex 
of the human brain, providing an interesting candidate for further exploration in the 
context of DLB and other dementias.  
Evidence for a compensatory role of β-synuclein in the frontal cortex that may act to 
support the pre-synapse in the presence of increasing α-synuclein pathology and 
absence of monomeric α-synuclein requires further examination. Functional assays 
including the monitoring of neurotransmitter release in the presence of β-synuclein 
and absence of α-synuclein is required to clarify whether this protein is acting to 
preserve the integrity of the pre-synapse. In this regard, β-synuclein could be 
considered a valid therapeutic when considering its role at the pre-synaptic terminal. 
Single cell transcriptomics from cells in the cortical regions that are positive for β-
synuclein may identify whether α-synuclein mRNA is downregulated in these 
neurons and conversely, the level of β-synuclein mRNA in cells harbouring 
oligomeric alpha synuclein would also be useful to elucidate whether transcriptional 
changes are occurring in single cells. Investigations undertaken in this study have 
analysed the protein levels of whole tissue sections from a heterogenous cell 
population that needs to be narrowed down to single cell levels to reveal whether the 
changes in β-synuclein is restricted to specific cell populations. 
In contrast to the protective role I propose for β-synuclein, a potentially detrimental 
role is observed with β-synuclein appearing to be directly or indirectly involved in the 
discontinuation of the autophagy flux. It is possible that the role of β-synuclein is to 
inhibit the process of one degradation pathway thereby, upregulating another. Future 
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work should also focus on β-synuclein in relation to the UPS and CMA pathways 
both in the presence and absence of α-synuclein.  
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